ANNUAL REPORT 2014–2015 Stein Eye Institute ANNUAL REPORT

July 1, 2014–June 30, 2015

Director Bartly J. Mondino, MD

Faculty Advisor Debora B. Farber, PhD, DPhhc

Managing Editor Tina-Marie Gauthier c/o Stein Eye Institute 100 Stein Plaza, UCLA Los Angeles, California 90095–7000 Email: [email protected]

Editors Teresa Closson Susan Ito Rosalie Licht Peter J. López Ellen Pascual Debbie Sato M. Gail Summer

Guest Writer Dan Gordon

Photography Reed Hutchinson J. Charles Martin Robin Weisz

Design Robin Weisz/Graphic Design

Printing Colornet Press

Send questions, comments, and updates to: [email protected].

To view the Annual Report online, visit: jsei.org/annual_report.htm.

For more information about the Institute, see: www.jsei.org.

On the cover: Signature eyewear worn by philanthropists Edie and Lew Wasserman dominate the lobby of the Edie & Lew Wasserman Building, paying homage to the couple’s infinite vision and long- standing commitment to preventing blindness and restoring eyesight. A Year in Review 1

Stein Eye Institute 2 Transitions 6 Alumni News 6 Honors and Awards 8 Research 11 Education 13 Community Outreach 15 Philanthropy 17 Thank You 19 Jules and Doris Stein 24 Board of Trustees and Executive Committee 26

Faculty 29

Programs 87

Patient Care Services 88 Research and Treatment Centers 90 Clinical Laboratories 95 Training Programs 97

Appendices 101

Volunteer and Consulting Faculty 102 Residents and Fellows 104 Educational Offerings 105 Research Contracts and Grants 107 Clinical Research Studies 116 Publications of the Full-Time Faculty 123 Giving Opportunities 130 Dear Friends, The 2014–2015 academic term stands as a banner year for the Stein Eye Institute. A ceremonial ribbon cutting marked the moment our vision-science campus became fully realized. On October 28, 2014, we officially opened the doors of the Edie & Lew Wasserman Building, a spectacular example of green architecture that houses a state-of-the-art, outpatient surgical center, and expands the Institute’s Oculoplastics and Orbital Division and the Cataract and Refractive Surgery Division. Patients now have the convenience of “one- stop-shopping,” with exams, testing, and surgery all in the same facility. We now focus on the final phase in the transformation of Stein Plaza, with renovation of the Jules Stein Building underway to modernize the infrastructure and reconfigure the interior space to further our knowledge of specific vision processes and eye diseases. This academic year, we welcomed Doheny Eye Institute researchers and clinicians to the faculty roster of the David Geffen School of Medicine at UCLA, and formed a single, integrated UCLA Department of Ophthalmology––and the synergistic power of this historic Stein/Doheny affiliation was felt immediately. At the 2015 meeting of the American Glaucoma Society, everyone in the UCLA Department of Ophthalmology glaucoma service played an important role––from lecturing at the podium or in poster sessions, to serving on the program committee and chairing sessions. Our combined glaucoma service is active, thriving, and having a major impact on the present and future of glaucoma research and patient care. Access to excellent eye care has never been easier with Stein and Doheny Eye Center UCLA locations open from the westside to the eastside and south to Orange County. But our dedication to community outreach goes far beyond our region. Anthony J. Aldave, MD, exemplifies the Stein Eye Institute’s mission to preserve and restore vision. His non-profit organization Visionaries International is striving to eliminate corneal blindness in the developing world by “training the trainers.” I hope you enjoy the 2014–2015 Annual Report and learning about our activities this academic year. Thank you to our tremendous faculty and staff, and to our exceptional donors and friends, who share our mission and who contribute to our current and future accomplishments. Sincerely,

Bartly J. Mondino, MD Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology Director, Stein Eye Institute Chairman, Department of Ophthalmology David Geffen School of Medicine at UCLA A Year in Review

JULY 1, 2014–JUNE 30, 2015

his 2014–2015 academic year was highlighted by the opening of the Edie & Lew TWasserman Building and welcoming of new UCLA Department of Ophthalmology faculty. UCLA Department of Ophthalmology researchers made further inroads in vision-science investigations, increasing our knowledge of vision processes and eye diseases, and faculty members were recognized for their contributions to ophthalmology. Utilizing multidisciplinary, integrative education, faculty members mentored, counseled, lectured, and demonstrated new medical and sci- “Movements to advance science and entific approaches to the next generation of oph- medicine need the thalmologists, further contributing to the preser- time, the effort, and vation and restoration of vision around the world. the ability of those men and women And recognizing that private funding is critical to who have learned to the advancement of science and medicine, gen- move the immovable erous donors provided needed support for the mountain.”

sight-saving endeavors of the Stein Eye Institute. Jules Stein, MD

A Year in Review | Stein Eye Institute 1 Stein Eye Institute

Edie & Lew Wasserman Building New Gateway to UCLA

ampus officials dedicated the Edie & Lew Wasserman Building at a ceremonial “The Stein Eye ribbon cutting on October 28, 2014, and in their remarks, described the landmark Institute’s research and patient-care facility as “the new gateway to UCLA.” Dedicated to ophthalmology and synergistic programs between the Stein Eye Institute and physical CRonald Reagan UCLA Medical Center, the building’s name honors late philanthropists transformation Edie and Lew Wasserman. to a vision- “With the opening of this third facility, the Stein Eye Institute’s physical transformation science campus to a vision-science campus is complete,” said UCLA Chancellor Gene Block. “We’re here to celebrate the completion of a magnificent new building. Forged of steel, glass, is complete.” and concrete, the Edie & Lew Wasserman Building reflects a generous couple’s 50-year UCLA Chancellor commitment to vision sciences at UCLA, and will further enable physicians and scientists Gene Block to advance critical research and treatment aimed at restoring and preserving eyesight.

At the podium, Bartly J. Mondino, MD, director of the Stein Eye Institute and chairman of the UCLA Department of Ophthalmology, remarked, “The added space this magnificent building offers will have an enormous impact on Stein Eye, enhancing the Institute’s continued evolution into the leading eye care, vision research, and educational center of the 21st century. The Edie & Lew Wasserman Building allows us to expand our existing facilities and faculty and enables us to create revolutionary new programs that will dramatically change the way we treat patients with eye diseases.”

2 Stein Eye Institute | A Year in Review Echoing the sentiments of UCLA leadership, Dr. Mondino expressed gratitude for the hard work and dedication of everyone involved, and he thanked Casey Wasserman for spearheading the planning and construction of the new building, as well as being the driving force in seeing the project through to fruition. “The new Edie & Lew Wasserman Building is an architectural mas- terpiece and a fitting legacy to In developing the new facility dedicated to preserving and restoring sight, Dr. Bartly the Wasserman family,” said Dr. Mondino (right) found a crucial ally in Casey Wasserman (left), who spearheaded efforts to construct the building honoring his grandparents, Edie and Lew Wasserman. Mondino. “All of us at UCLA and the Stein Eye Institute are deeply grateful It is a stunning example of modern Edie and Lew Wasserman were for the Wassermans’ extraordinary architecture dominated by clean married for nearly 66 years when vision and devoted friendship, and lines, white terracotta, and pale oak. Mr. Wasserman passed away in Casey Wasserman’s commitment to The facility features floor-to-ceiling 2002. And on October 14, 2010, construct a facility in his grandpar- windows that flood the spacious with her grandson Casey by her side, ents’ name.” rooms with natural light and reveal Edie Wasserman symbolically broke Casey was a UCLA senior in dramatic views of the campus. ground on the building bearing her 1996 when he attended his first name. Edie died in 2011 at the age Although contemporary in design, the architectural meeting about the Edie of 95, following the latest chapter building features a whimsical touch: & Lew Wasserman Building with in the legacy of her family’s support inspired by the signature eyewear his grandfather, and on October 14, for the Institute. worn by Edie and Lew Wasserman, 2010, he stood at his grandmother’s a sculpture of two oversized pairs of Now a trio of buildings stand together side as she broke ground on the spectacles commands the spotlight in perpetuity—reflecting their name new building. Poised to cut the in the building’s main lobby and pays sakes’ decades-long friendship and ceremonial ribbon with his wife homage to the couple’s infinite vision shared dedication to one vision: and children present, Casey said, and long-standing commitment to restoring and preserving eyesight. “My grandparents were focused on preventing blindness and restoring making a measurable difference in eyesight. the world. This building, along with its programs and promise, will carry their vision far into the future.” A Shared Friendship and Vision Colleagues and friends, Doris and A Work of Art Jules Stein and Edie and Lew Wasserman, revolutionized educa- The Edie & Lew Wasserman Building tional, cultural, and health care insti- has received three architectural tutions across Los Angeles, and the awards, and it is a beautiful symbol of Stein Eye Institute’s vision-science UCLA’s collaborative spirit and global campus is a testament to their impact. shared purpose. The Jules Stein Eye Designed by Richard Meier and Institute opened its doors in 1966, Partners Architects, the $115.6 and in 1989, Stein Plaza expanded million project is a LEED gold- with the creation of the Doris Stein certified “green,” six-story building Eye Research Center, named after encompassing 100,000 square feet. Jules Stein’s wife.

A Year in Review | Stein Eye Institute 3 Jules Stein Building Renovation With the opening of the Edie & Lew Wasserman Building, the Institute shifts to the final phase of construction in Stein Plaza, as renovation of the Jules Stein Building begins. Built in 1966, the interior space of the Jules Stein Building is being reconfigured to meet twenty- first century needs. In addition to new examination rooms and renovation of two floors as modern wet labs for vision-science research, windows will be introduced into the west façade to bring in natural light. A three-story atrium lobby will provide a dramatic centerpiece that visually connects the B-Level entrance at Stein Plaza with the ophthalmology check-in lobby and clinic on the first floor. The flagship building’s internal plumbing, cooling, heating, and electrical systems are also being modernized, and the facility is being upgraded seismically and made ADA compliant to meet accessibility guidelines. With the temporary closure of the Jules Stein Building, all patient services have been moved to the Doris Stein Building and the Edie & Lew Wasserman Building. University Ophthalmology Associates and the Institute’s Urgent Care Clinic have been relocated to the second floor of the Doris Stein Building. The renovation is expected to be complete in 2017.

Established in 1966, the Stein Eye Institute represents the culmination of a dream shared by ophthalmologist, businessman, and philanthropist Dr. Jules Stein and his wife Doris, of creating a world-renowned center dedicated to the preservation of vision and the prevention of blindness.

Patient-care services are being conducted in the Doris Stein Building and the Edie & Lew Wasserman Building during the temporary closure of the Jules Stein Building.

4 Stein Eye Institute | A Year in Review American Glaucoma Society Meeting Showcases Power of Stein/Doheny Affiliation The UCLA Department of Ophthalmology newly doubled glaucoma service—forged by the 2013 affiliation of UCLA’s Stein Eye Institute and the The true power of the Stein/ Doheny Eye Institute—was on full display at the American Glaucoma Society’s 25th Annual Meeting, February 26–March 1, 2015, in Coronado, Doheny affiliation lies in the California. synergy created by the Highlights of the meeting included physician-scientists from UCLA Stein merging of two leading Eye Institute and Doheny Eye Center UCLA discussing topics such as groups—with wide-ranging emerging surgical techniques, enhancing outcomes with traditional glau- expertise and the ability to coma-filtering surgery, and new basic-science imaging techniques that enhance the understanding of patients’ glaucoma anatomy and assist in collaborate and benefit from developing more individually targeted medical and surgical treatment. each other’s knowledge. Showcasing the influence of the newly expanded glaucoma service, Doheny Eye Center UCLA ophthalmologist Alex A. Huang, MD, PhD, received the prestigious Young Physician Scientist Grant, while Stein Eye’s Kouros Nouri-Mahdavi, MD, MSc, received a Mid-Career Physician Scientist Award—an unheard of dual achievement for a single department in the same year. Joseph Caprioli, MD, chief of the Stein Eye Institute’s Glaucoma Division, and Brian A. Francis, MD, MS, Glaucoma Division chief at Doheny, agree that while the meeting illustrated the many important current activities of the UCLA Department of Ophthalmology’s glaucoma faculty, the true power of the affiliation lies in the synergy created by the merging of two leading groups—with wide-ranging expertise and the ability to collaborate and benefit from each other’s knowledge. The combined service now boasts leaders in areas ranging from basic-science research, diagnostic testing, traditional surgical methods, emerging techniques in minimally invasive glaucoma surgery; as well as epidemiology, outcome studies, and health-care policy issues pertaining to glaucoma. Dr. Brian Francis presents a poster at the 2015 meeting of the American Glaucoma Drs. Caprioli and Francis point out that, rather than individuals working on Society. an island, the affiliation creates a vertically integrated research approach in which all the bases are covered—from basic science to diagnosis to clinical research to surgery—and everyone is sharing experiences. Through the affiliation, the UCLA Department of Ophthalmology glaucoma service is now exponentially stronger and better able to advance glaucoma care through wide-ranging expertise and the ability to collaborate and benefit from each other’s knowledge.

A Year in Review | Stein Eye Institute 5 Transitions Alumni News

IN REMEMBRANCE UCLA Stein Eye Institute and Andrea L. Rich, PhD Doheny Eye Institute Hold Board of Trustees, Stein Eye Institute Joint Reception in Chicago The UCLA Department of Ophthal- Andrea L. Rich, PhD, a member of the Stein Eye mology held its annual alumni recep- Institute’s Board of Trustees since 2007, died from tion on October 19, 2014, at the acute myeloid leukemia at the Ronald Reagan UCLA American Academy of Ophthalmology Medical Center on July 28, 2014. She was 71. meeting in Chicago, Illinois. Chairman of the UCLA Department of This year the occasion was all the Ophthalmology and Director of the Stein Eye more celebratory, as it marked the Institute, Bartly J. Mondino, MD, noted that first time that the Stein and Doheny Andrea was a wonderful colleague whose wisdom, Eye Institutes co-hosted the event. advice, and support were greatly valued and Under terms of the historic alliance appreciated. between the two Institutes, Doheny The Stein Eye Institute Board of Trustees is respon- Eye Institute physicians and scien- sible for the leadership and preservation of the tists are UCLA Department of Institute, and Dr. Rich provided her counsel to Ophthalmology faculty. ensure the Institute’s orderly growth and development. Her invaluable contribu- Faculty members, residents, and fel- tions included participating in the fiscal planning for the Institute, adoption of low alumni from both Institutes measures to facilitate recruitment of the world’s finest vision scientists, alloca- attended the reception, renewing tion of funds for the purchase of vision research equipment, and recommenda- acquaintances, reconnecting with tions for facilities expansion programs. classmates, and interacting with col- Dr. Rich was a scholar of intercultural and interracial communications. In her leagues from throughout the world. nearly 30 years of service to UCLA, Dr. Rich rose from an assistant professorship to become UCLA’s first female executive vice chancellor. Known for being a charismatic leader, Dr. Rich went on to become president and chief executive officer of the Los Angeles County Museum of Art.

New Faculty

John D. Bartlett, MD, health sciences assistant clinical professor of ophthalmology, was recruited to full-time faculty on November 1, 2014. Dr. Bartlett has an ongoing clinical interest in cataract surgery, particularly refractive cataract surgery, and he is involved with teaching these surgical techniques to Stein Eye residents. Dr. Bartlett is also one of UCLA’s physician informaticists, participating in the ongoing implementation and optimization of electronic health records (EHRs). Dr. Bartlett is interested in using EHRs to reach the “Triple Aim” of improved patient care and satisfaction, improved population health, and decreased cost of health care. Medical Director of the Doheny Eye Center Jie J. Zheng, PhD, was appointed professor-in-residence of ophthalmology on UCLA Dr. John Irvine (left), Chairman of the January 5, 2015. Dr. Zheng’s research is at the interface of biochemistry, compu- UCLA Department of Ophthalmology Dr. Bartly Mondino (center), and Vice tational biology, systems pharmacology, and drug discovery with an emphasis on Chairman of the Doheny Eye Center UCLA therapeutic development in ophthalmology. Dr. Alfredo Sadun. Aiming to establish new translational research within the vision research community at UCLA, the goal of Dr. Zheng’s research is to develop novel therapies for retinal degenerative diseases, glaucoma, and corneal disorders.

6 Stein Eye Institute | A Year in Review Alumni News

Stein Eye Alumnus Identifies Critical Gene as Cause of Blinding Eye Disease The Stein Eye Institute’s EyeSTAR (Specialty Training and Advanced Research) program, which combines an ophthalmology residency program with a PhD or postdoctoral fellowship in vision science research, began in 1995 with the purpose of training physician-scientists as future leaders in ophthalmology. Now, thanks to the skilled efforts of Stein Eye Institute alumnus and EyeSTAR training program graduate, Vinit B. Mahajan, MD, PhD, multiple generations of an Iowa family who were blind, are blind, or who are going blind have new hope. Members of the Jackson family have a rare genetic eye disease called autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). Patients with ADNIV are normally sighted until their second decade when chronic autoimmune uveitis (damage to the eye’s middle layer) begins and cataracts develop. Over the next five decades, angiogenesis, photoreceptor degeneration, retinal neovascularization, intraocular fibrosis, and retinal detachment occur, ending in loss of vision. “Seven generations of the Jackson family had gone blind from inherited uveitis and vitreoretinopathy; half of the family was affected by a genetic disease of unknown cause,” explains Dr. Mahajan. “I took care of them in clinic, and I took care of them in the operating room. Clearly, to optimize the families’ treatment and save their sight, we had to take it into the lab.” Thankfully, because of Dr. Mahajan’s EyeSTAR training, he had the unique ability to do just that. Dr. Mahajan and his research team recently identified that mutations in a gene A new reason for hope: known as CAPN5 are the cause of ADNIV. His team’s published results are the first time theCAPN5 gene was implicated in eye disease, and it is the first gene Stein Eye Institute alumnus to directly cause nonsyndromic uveitis and a new gene to cause retinitis and EyeSTAR graduate pigmentosa. Dr. Vinit Mahajan isolated the Successful discovery of the CAPN5 gene gave Dr. Mahajan and his team a key gene responsible for causing molecular target to understand and treat inflammatory eye diseases. And with generations of blindness in that goal, Dr. Mahajan is working in close partnership with fellow EyeSTAR graduate Stephen H. Tsang, MD, PhD. “EYEStar has made a huge difference in an Iowa family. allowing us to integrate laboratory science, clinical care, and surgical care for difficult-to-treat patients,” says Dr. Mahajan, noting that the best hope for many patients is at an academic center where lab work conducted by physician- scientists can have immediate and long-lasting effects on rescuing vision. Dr. Mahajan stresses the need for physician-scientists who are as comfortable in the laboratory as they are in the operating room. “Because of EyeSTAR,” Dr. Mahajan affirms, “each week I am in the clinic, in the operating room, and in my own laboratory. I am thankful to all the Stein Eye faculty members who trained me; my accomplishments are a direct result of their dedication and excellence.” For the Jackson family, the invaluable work of trained physician-scientists like Dr. Mahajan has special urgency—protecting their grandchildren and future generations from experiencing a similar and heartbreaking loss of sight.

A Year in Review | Stein Eye Institute 7 Honors and Awards

Symposium Honors Dr. Dean Bok The UCLA Department of Neurobiology held a symposium to honor Stein Eye Institute Emeritus Faculty Member Dean Bok, PhD, Distinguished Professor, Departments of Neurobiology and Ophthalmology. The October 8, 2014, vision-science symposium, “The Neurobiology of Vision,” and the reception that followed, commemorated Dr. Bok’s 46 years of service as a faculty member of the Department of Neurobiology. Symposium speakers included Dr. Bok and Stein Eye Institute faculty members David S. Williams, PhD, and Alapakkam P. Sampath, PhD, as well as other UCLA faculty members, who presented talks on their latest research, which encompassed both the retina and the brain. Dr. Bok noted that this was the first symposium in the Neurobiology Department’s history to feature his chosen field of research and added that it was gratifying to participate with a group of young, dynamic vision scientists who work at the Dr. Dean Bok (left) and Neurobiology cutting edge of their discipline. Department Chair, Dr. Thomas Otis

Faculty Honors

ffAnthony J. Aldave, MD, Walton Li Chair in Cornea and Uveitis, received an American Academy of Ophthalmology Senior Achievement Award at the October 2014 American Academy of Ophthalmology annual meeting in Chicago, Illinois. In addition, Dr. Aldave delivered the Dr. Diego Cuevas Cancino Lecture at the 52nd Actualization Course in Ophthalmology, organized by the Asociación para Evitar la Ceguera en México, on February 19, 2015, in Mexico City, Mexico. Dr. Aldave also presented the Erin K. Jacobson Memorial Lecture at the Loma Linda University Medical Center Department of Ophthalmology Resident Research Symposium on May 22, 2015, in Loma Linda, California. ffAnthony C. Arnold, MD, Jerome and Joan Snyder Chair in Ophthalmology, was awarded the 2015 Parker J. Palmer Courage to Teach Award at the Accreditation Council for Graduate Medical Education (ACGME) Annual Educational Conference on February 27, 2015, in San Diego, California. ffJoseph Caprioli, MD, David May II Endowed Chair in Ophthalmology, received an American Academy of Ophthalmology Secretariat Award at the October 2014 American Academy of Ophthalmology annual meeting in Chicago, Illinois. ffAnne L. Coleman, MD, PhD, The Fran and Ray Stark Foundation Chair in Ophthalmology, received an American Academy of Ophthalmology Life Achievement Honor Award at the October 2014 American Academy of Ophthalmology annual meeting in Chicago, Illinois. ffJoseph L. Demer, MD, PhD, Leonard Apt Endowed Chair in Pediatric Ophthalmology, presented the William Gillies Lectureship at the Australia and New Zealand Strabismus Society, March 6–7, 2015, in Brisbane, Australia. Dr. Demer also gave the Keynote Address at the Congress of the European Society of Ophthalmology, June 6–9, 2015, in Vienna, Austria.

8 Stein Eye Institute | A Year in Review ffRobert Alan Goldberg, MD, Karen and Frank Dabby Endowed Chair in Ophthalmology, delivered the Plana Lecture at the XIX International Course on Plastic and Aesthetic Surgery on June 16, 2015, in Barcelona, Spain. ffLynn K. Gordon, MD, PhD, Vernon O. Underwood Family Chair in Ophthalmology, received an American Academy of Ophthalmology Senior Achievement Award at the October 2014 American Academy of Ophthalmology annual meeting in Chicago, Illinois. ffGary N. Holland, MD, Jack H. Skirball Chair in Ocular Inflammatory Diseases, was the recipient of the Golden Apple Award for Excellence in Teaching at the Class of 2017 Second Year Banquet, David Geffen School of Medicine at UCLA, on April 23, 2015, in Westwood, California. As the Golden Apple Award recipient, Dr. Holland also received special honors at the David Geffen School of Medicine at UCLA Hippocratic Oath Ceremony, June 5, 2015, in Westwood, California. Dr. Holland was also a featured speaker before the United States Congress at the first-ever Congressional Briefing on Uveitis on June 3, 2015, in Washington, DC. ffKevin M. Miller, MD, Kolokotrones Chair in Ophthalmology, presented the Om Prakash Oration at the Delhi Ophthalmological Society meeting on April 12, 2015, in New Delhi, India. ffBartly J. Mondino, MD, Bradley R. Straatsma, MD Endowed Chair in Ophthalmology, was honored for ten years of service as Executive Vice President of the Association of University Professors of Ophthalmology at their January 2015 annual meeting in Tucson, Arizona. ffKouros Nouri-Mahdavi, MD, MSc, Assistant Professor of Ophthalmology, Dr. Gary Holland met with Representative Ted Lieu (D–33rd District, received an American Academy of Ophthalmology Achievement Award at California) in his Washington office, the October 2014 American Academy of Ophthalmology annual meeting in following Dr. Holland’s Congressional Chicago, Illinois. Briefing on Inflammatory Eye Diseases. ffNatik Piri, PhD, Associate Professor of Ophthalmology, was recipient of the 2015 Spitzer Grant Research Program award for support of groundbreaking medical research at UCLA. ffDavid Sarraf, MD, Health Sciences Associate Clinical Professor of Ophthalmology, was awarded membership in the American Ophthalmological Society in May 2015 for his thesis, “Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).” ffSteven D. Schwartz, MD, holder of The Ahmanson Chair in Ophthalmology, was recognized by the American Society of Retina Specialists in 2014 for outstanding service to the Society’s scientific and educational programs, original papers, panel discussions, and instructional courses. ffDavid S. Williams, PhD, Jules and Doris Stein Research to Prevent Blindness Professor of Ophthalmology, was presented with a Distinguished Service Award by the International Society for Eye Research on July 23, 2014, in San Francisco, California.

A Year in Review | Stein Eye Institute 9 Institute Honors Stein and Doheny Eye Institutes Best in the West for EYE Care The recently affiliated Stein and Doheny Eye Institutes were honored as being among the top five eye care centers in the United States and the best in the Western United States, according to a ranking in U.S. News & World Report’s “Best Hospitals 2014–2015.” UCLA’s hospitals in Westwood and Santa Monica have again earned a place on the magazine’s Honor Roll. UCLA Health is ranked No. 5 in the country and No. 1 in both California and the Los Angeles metropolitan area, and is among only 17 hospitals out of nearly 5,000 nationwide named to the Honor Roll.

Edie & Lew Wasserman Building Celebrated for Excellence in Design The American Institute of Architects (AIA) presented Richard Meier & Partners Architects LLP an Honor Award for Architecture for their design of the Edie & Lew Wasserman Building. This honor is the Edie & Lew Wasserman Building’s third award for excellence in architecture and design: the building was named Best Medical Project at the Los Angeles Business Journal’s 2013 Commercial Real Estate Awards, and a Community Impact Award was bestowed in 2011 at the Los Angeles Business Council’s Los Angeles Architectural Awards. In addition, the Edie & Lew Wasserman Building has been awarded LEED (Leadership in Energy and Environment Design) Gold certification in recognition of the structure’s environ- mental and health performance.

10 Stein Eye Institute | A Year in Review Research

Stein Eye Institute Group Leads Fundamental Change in Research is a key pillar of the Muscle-Strengthening Strabismus Surgery in North America Institute’s mission and a high pri- ority for faculty who often devote Surgery to tighten and strengthen eye muscles is one of the bread-and-butter their life’s work to furthering our operations to correct misaligned eyes in patients with strabismus. Now a UCLA knowledge of specific vision pro- Stein Eye Institute group headed by Joseph L. Demer, MD, PhD, Leonard Apt cesses and eye diseases. In this ac- Endowed Chair in Pediatric Ophthalmology and chief of Stein Eye’s Pediatric ademic year, Stein Eye researchers Ophthalmology and Strabismus Division, is pioneering the North American intro- duction of an alternative muscle-strengthening approach and popularizing a fun- have made important discoveries damental change in the way strabismus surgery is performed. and have continued to take leadership roles in defining how diseases The alternative method, known as plication, offers numerous advantages and are managed. virtually no disadvantages compared to the approach taught for many decades in the United States, says Dr. Demer. At UCLA Stein Eye Institute, plication is now the approach being taught to trainees, and Stein Eye surgeons have almost uniformly moved to its use for tightening muscles to treat strabismus. One objective of strabismus surgery is to shorten an eye muscle so that it pulls harder— analogous to shortening the length of a rubber band so that the elastic material, stretched over the same distance, exerts more tension. Eye muscle tightening has traditionally been accomplished through resection—cutting out the tendon and a portion of the front of the muscle, then sewing it back into the eye, with the shortened muscle pulling tighter along the same path as a result. Plication takes an alternative approach—placing sutures through the tendon or muscle an equivalent distance from the attachment point and farther back along the length of the muscle, then sewing those sutures to the wall of the eye at the original insertion point. “The muscle is tightened as much as in resection,” says Dr. Demer, “but instead of amputating the front part of the eye muscle and tendon, in plication the redundant front part is simply folded underneath and left in place.” “This operation is less traumatic and more Dr. Demer (left) and his team perform strabismus surgery. potentially reversible,” Dr. Demer explains. “It spares blood vessels, causes less inflammation and bleeding, and is technically easier to perform than resection. We are constantly looking for ways to optimize surgery and make it less invasive. The technical innovation of plication does that, while expanding the options surgeons have for treating strabismus.” Plication is one innovative Much of the research done on eye movements at Stein Eye involves fundamen- improvement that can be tal discoveries and complex technological applications that broadly but slowly adopted overnight by any improve the field worldwide,” Dr. Demer says. “But, we do not neglect smaller ophthalmologist who has practical improvements that can quickly enhance the practice of ophthalmology. Plication is one innovative improvement that can be adopted overnight by any ever learned to operate on ophthalmologist who has ever learned to operate on the eye muscles.” the eye muscles.

A Year in Review | Stein Eye Institute 11 Orbital Vascular Disease Center

Establishing New Standards of Care for Challenging Disorders Orbital vascular diseases—rare disorders of the eye socket characterized by picture of the vascular anomalies. abnormal blood vessel growth—can be devastating to patients, leading to both The Center has developed medical disfigurement and vision loss. They are also extremely challenging to treat. treatments based on this information, including sclerosing agents that The Stein Eye Institute’s Orbital Vascular Disease Center, part of the UCLA effectively kill the inside of the abnor- Orbital Disease Center, has emerged as a leader in managing these complex mal vessels, causing them to col- cases. Using a multidisciplinary-team approach, the Center has adopted and lapse; and glues to seal off the inside developed innovative treatments that have become the standard of care at of the lesion—often facilitating sur- UCLA and other specialized centers—including surgical approaches to the orbital gery to remove the rest of the lesion. vasculature that enable direct access to the lesions for endovascular treatment, “This is work that we started 15 as well as nonsurgical interventions, such as the use of sclerosing injections years ago, and it has become stan- and glues. dard treatment,” Dr. Goldberg says. Researchers at the Center are currently investigating glues that would treat the lesions without the need for surgery, as well as sclerosing agents that are more specific to different types of vessels, as strategies for reducing side effects of the treatment. Recognizing that the field is evolving toward nonsurgical, specific kinds of therapy, the Orbital Vascular Disease Center researchers are also exploring the potential use of biologic agents that could initially augment the current therapies and eventually replace the existing ones. The Center brings together expert clinical faculty to make headway against this extremely complex group The Center’s clinical faculty was recently bolstered by the recruitment of Dr. Jack of disorders. The team features inter- Rootman (right), a world-renowned authority in orbital vascular diseases, shown ventional radiologists known for inno- teaching at the Stein Eye Institute’s annual Aesthetic Eyelid and Facial Rejuvenation Course. vative approaches to vascular lesions; head and neck surgeons and neurosurgeons who participate in the sur- “Treatment of ocular vascular diseases has been challenging for several reasons, gical management; basic scientists including that the majority of these processes don’t respond well to traditional who are unraveling the molecular bio- surgical treatment,” says Robert Alan Goldberg, MD, Karen and Frank Dabby logic features of orbital vascular dis- Endowed Chair in Ophthalmology, chief of the Orbital and Ophthalmic Plastic eases; and pediatricians, neurologists, Surgery Division, and director of the UCLA Orbital Disease Center. “Standard dermatologists, and other specialists surgical techniques can be hampered by concerns about intraoperative bleeding. who are brought in as needed. In addition, the lesions are often spread throughout the normal tissues making them difficult to surgically remove. Finally, for reasons that are not entirely clear, The Center is also training the next the lesions often return even after surgery appears successful.” generation of leaders through a two- year fellowship program in orbital Through its research and clinical efforts, the UCLA Orbital Disease Center has and ophthalmic plastic surgery that developed new surgical and nonsurgical approaches. From the surgical stand- provides trainees with a unique point, the Center has long featured advanced instrumentation and techniques to experience in the multidisciplinary perform the delicate types of surgeries required to remove orbital vascular environment. lesions. The program has pioneered minimally invasive, small-incision techniques that take advantage of advanced endoscopy and microsurgery to operate on the lesions through less-invasive approaches, often under local anesthesia. To develop nonsurgical techniques, the Orbital Vascular Disease Center takes advantage of its multidisciplinary team. Interventional radiologists map the orbital vascular disorders using advanced techniques to provide a detailed

12 Stein Eye Institute | A Year in Review Education

Annual Clinical and Research Seminar 20th Annual Vision Science Conference Ophthalmologists gathered at the Stein Eye Institute on June 12, 2015, for the Institute’s most prestigious annual academic event, the Clinical and Research The 20th annual Vision Science Seminar. Sponsored by the UCLA Department of Ophthalmology Association, Conference, co-sponsored by the the Seminar provides an opportunity for discussion of emerging vision research National Institutes of Health/National and celebrates teaching and faculty volunteerism. Eye Institute Vision Science Training Grant and the Stein Eye Institute, At this year’s Seminar, , visiting clinical professor, Department Stuart L. Fine, MD was held October 10–12, 2014. More of Ophthalmology, University of Colorado School of Medicine in Aurora, Colorado, than 70 basic scientists and clinical presented the 46th Jules Stein Lecture; , RRF David M. Gamm, MD, PhD researchers gathered at UCLA’s Lake Emmett A. Humble Distinguished Director, McPherson Eye Research Institute, Arrowhead Conference Center to and associate professor, Department of Ophthalmology and Visual Science, participate in scientific discussions University of Wisconsin School of Medicine and Public Health in Madison, and memorable networking events. Wisconsin, gave the 13th Bradley R. Straatsma Lecture; and Robert K. Maloney, MD, director, Maloney Vision Institute, and clinical professor, Department of The Conference keynote address, Ophthalmology, David Geffen School of Medicine at UCLA in Los Angeles, “Origin Story: How (and When) the California, delivered the 13th Thomas H. Pettit Lecture. Animal Got its Eye,” was given by Todd Oakley, PhD, professor and In acknowledgment of their service, selected volunteer and clinical faculty vice chairman of the Department received awards of distinction at the Clinical and Research Seminar. The S. of Ecology, Evolution and Marine Rodman Irvine Prize recognizing excellence in the Department of Ophthalmology Biology at the University of California, faculty was given to . Senior Honor Awards were Thomas A. Hanscom, MD Santa Barbara. presented to Calvin T. Eng, MD, David R. Fett, MD, Michael J. Groth, MD, Joan E. McFarland, MD, Michael Reynard, MD, and William C. Stivelman, The retreat culminated with a pre- MD, distinguished volunteer faculty who have been members of the UCLA sentation by Founding Director of Department of Ophthalmology for at least 25 years. the Stein Eye Institute and Found- ing Chairman of UCLA Department The Faculty Teaching Award, honoring contributions to residency education, was of Ophthalmology, Bradley R. presented to Pradeep S. Prasad, MD. Straatsma, MD, JD, who reflected on the 20th Anniversary of the Stein Eye Institute Vision Science Conference and its future directions. Attendees at the Stein Eye Institute 2014 Vision Science Conference

A Year in Review | Stein Eye Institute 13 Education at the Stein Eye Institute is multifaceted––ranging from teaching medical students, residents, and fellows––to leading national conferences. In the course of their educational duties, faculty members mentor, counsel, lecture, and demonstrate. They are responsible for hundreds of clinical and scientific publications each year and are entrusted with developing and sharing new approaches to science and medicine that will ultimately result in improved patient care.

Comprehensive Ophthalmology Review Course The Stein Eye Institute and the Doheny Eye Institute teamed up to sponsor the 10th Comprehensive Ophthalmology Review course February 19–22, 2015. The course co-directors, Sherwin J. Isenberg, MD, Laraine and David Gerber Chair in Ophthalmology at the Stein Eye Institute, and John A. Irvine, MD, medical director of the Doheny Eye Center UCLA, organized a program concentrating on the epidemiology, clinical presentation, diagnosis, and management of ophthalmological disease.

Aesthetic Eyelid and Facial Rejuvenation Course The Orbital and Ophthalmic Plastic Surgery Division conducted its annual Aesthetic Periorbital and Facial Rejuvenation course August 1–2, 2014, at the Stein Eye Institute. The course, now in its 25th year, featured fast-paced, high- level, and interactive continuing medical education activities that combined cadaver dissection with didactic lectures. Catherine J. Hwang, MD, assistant clinical professor of ophthalmology, was the program director, and the founding course directors, Henry I. Baylis, MD, and Norman Shorr, MD, along with Robert Alan Goldberg, MD, and Jonathan A. Hoenig, MD, headed up a team of instructors that drew heavily from UCLA volunteer faculty. The Robert Axelrod, MD, Memorial Lecture was delivered by John A. Long, MD, who has practiced oculoplastic surgery in Birmingham, Alabama, since 1988. Dr. Long conducted both his residency and fellowship in orbital facial plastic and reconstructive surgery at the Stein Eye Institute.

(L to R) Drs. Henry I. Baylis, Robert Alan Goldberg, John A. Long, Catherine J. Hwang, and Norman Shorr.

14 Stein Eye Institute | A Year in Review Community Outreach

Much of the Stein Eye Institute’s reputation springs from its first-class patient care, which includes care of those in underserved communities. The Institute is dedicated to the preservation and restoration of vision through its global programs and innovative research, quality patient care, and multidisciplinary, and integrative education, all with community outreach.

Training the Trainers in the Developing World Grounded in the belief that everyone has a right to sight, Anthony J. Aldave, MD, professor of ophthalmology and chief of the Stein Eye Institute’s Cornea and Uveitis Division, established the non-profit organization Visionaries International (VI), which is dedicated to elimi- nating corneal blindness worldwide. A staggering 90% of individuals with corneal blindness live in the developing world. Two of the main barriers to treating corneal blindness are an inadequate number of trained corneal transplant surgeons and a lack of trans- plantable corneal tissue. To combat these impediments, Dr. Aldave and colleagues, including UCLA Department of Ophthalmology faculty Sophie X. Deng, MD, PhD, and Olivia L. Lee, MD, have employed a model of surgical skills-transfer courses that focus on “training the trainers.” VI’s internationally recognized corneal specialists donate their time and expertise Drs. Anthony Aldave and Rosalind to train local surgeons in the latest forms of corneal transplant surgery. These Vo examine a child with corneal opacification at the Vietnam National trained local surgeons then teach their colleagues the same innovative proce- Institute of Ophthalmology in Hanoi, dures they have learned from VI specialists. Since its inception in 2008, VI has Vietnam. conducted over 30 training programs in 15 countries. In September 2014, members of the VI team visited the eye bank at the Vietnam National Institute of Ophthalmology (VNIO) in Hanoi, Vietnam, which is the only domestic source of corneal tissue for 90 million people. Despite this great need for donor corneas, only around 150 corneal transplants are performed annually in Vietnam, compared to approximately 50,000 in the United States. To address the lack of donor corneas, and the resultant inexperience of Vietnamese corneal transplant surgeons, VI partnered with VNIO to develop a program to increase donor cornea recoveries and to expand the surgical skills of the Institute’s corneal specialists. A primary factor in the limited number of corneas recovered by VNIO was determined to be a lack of trained grief counselors who could approach families about donation. After identifying this problem, VI Dr. Anthony Aldave instructs corneal was awarded a grant to support the training of two VNIO eye bank technicians at specialists at the Vietnam National Aravind Eye Hospital in Madurai, India. The subsequent grief training the VNIO Institute of Ophthalmology in Hanoi, eye bank technicians received in India represents the first step to building a suc- Vietnam, on the performance of deep cessful hospital-based tissue recovery program in Hanoi. anterior lamellar keratoplasty during a skills-transfer course in September 2014.

A Year in Review | Stein Eye Institute 15 Jules Stein Eye Institute Affiliates: Helping our Community and Raising Awareness

Make Surgery Bearable Program Two successful sponsorship drives were held this year for the JSEI Affiliates’Make Surgery Bearable program, an initiative that provides Dr. Teddy bears to each pediatric patient undergoing eye surgery at the Stein Eye Institute. The cuddly bears dressed in green scrubs and tagged with the name of the donor, help children feel comfort- ed and secure during what could otherwise be a frightening time. The Affiliates, in collaboration with the Pediatric Ophthalmology and Strabismus Division, introduced a Spanish version of their children’s book Making Eye Surgery Bearable, which helps pediatric patients feel more comfortable with the surgical experience by providing age-appropriate information about what they can expect when they come to the Stein Eye Institute.

MagniVision Program The Affiliates MagniVision program provides financial and volunteer support for the UCLA Vision Rehabilitation Center (VRC). Volunteers train low-vision patients on the use of magnifiers and various vision aids, and financial assistance from the Affiliates enables purchase of low-vision tools for the VRC lending library.

Preschool Vision Screening The Affiliates Preschool Vision Screening program began 15 years ago with the inspiration and support of Mrs. Glorya Kaufman and under the supervision of the late Dr. Leonard Apt, founding chief of the Division of Pediatric Ophthalmology and Strabismus. During the 2014–2015 school year, 38 Affiliates volunteers, under the supervision of four retired optometrists, visited 29 preschools to screen 742 children between three and five years of age.

Shared Vision Program The Institute’s volunteer arm, the The Affiliates Shared Vision program collected and recycled approximately 3,200 Jules Stein Eye Institute (JSEI) donated eyeglasses for those in need this year. Recycled eyeglasses were Affiliates, is a broad-based net- cleaned, tagged with the vision correction, and distributed to clinic missions work of volunteers, donors, staff, conducted by nonprofit groups in Africa, Central America, and other developing faculty, fellows, and residents nations. who participate in vision education and patient-care programs Vision Education throughout Los Angeles. Informa- Vision IN-School (VIS) is a vision education program offered free of charge to tion about the JSEI Affiliates can fourth- through seventh-grade public school students in Los Angeles. The curric- be found at: www.jseiaffiliates. ulum is fun and interactive, covering the anatomy of the eye, the developing eye com; on Facebook: www.face- and possible eye problems, eye care and eye safety tips, and optical illusions. book.com/JSEIAffiliates; via email: One of the presentation highlights is the dissection of a cow eye. VIS volunteers [email protected]; or by call- visited 26 classrooms this past year, presenting the curriculum to over 915 ele- ing 310-825-4148. mentary students. The program’s goal is to create a greater awareness of vision and the eyes, thus inspiring the children to protect their precious gift of sight for a lifetime of good vision.

Vision Walk On November 1, 2015, the Affiliates participated in the eighth annual Los Angeles Foundation Fighting Blindness Vision Walk, which was held at Woodley Park in the San Fernando Valley. The Stein Eye Team, “Volunteers with Vision,” walked the five-kilometer route with approximately 400 other participants to raise awareness and more than $100,000 to advance retinal eye disease research.

16 Stein Eye Institute | A Year in Review Philanthropy

Endowed Chair Pays Tribute to Both Donor and Holder

The commitment to the mission of the Stein Eye Institute is elevated when represented through a gift of an endowment. Such gifts allow the University to hold the fund in perpetuity. By investing the fund principal for growth over time, the “The Stein Eye Institute earnings are used to underwrite significant programs. An endowment, wheth- has flourished from the er established during a lifetime or through a planned gift, provides a constant generosity of many friends, financial source and helps secure a program’s future and continued success. Endowments may be named and serve as a lasting tribute to the donor. An en- grateful patients, and dowed chair is one of the most important gifts to higher education. supporters. We are most indebted and humbled In ancient times, chairs were rare and highly coveted pieces of furniture reserved for the exclusive use of royalty or religious leaders. The chair itself symbolized by their tremendous that its owner was an individual of high rank and prominence. Today, endowed commitment to and belief chairs are reserved for those who have reached the pinnacle of academic in Stein Eye and the work achievement. They honor and recognize the distinction of superior faculty, while we do in research, patient providing invaluable financial support, for use in research, teaching, and/or service activities. An endowed chair, which is the highest honor UCLA accords to care, education, and scholarship, pays tribute to both the holder who has earned the distinction and outreach activities.” the donor who has embraced the vision. It can memorialize or honor beloved Bartly J. Mondino, MD family members, recognize the achievements of admired colleagues, and de- clare one’s personal commitment to the excellence of, in this instance, UCLA’s Stein Eye Institute. The establishment of a permanent endowed chair is a special incentive to attract a scholar of distinction to Stein Eye or to retain gifted faculty whose teaching and research best exemplify UCLA’s mission. Each is established with a $2-million minimum gift, with the income supporting the scholar’s research and teaching, as well as freedom to explore opportunities. The continuity of funding provided by a permanent-appointment chair, including an administrative chair, gives the in- cumbent financial flexibility in planning long-term research, more independence from outside agencies, and freedom to explore promising new areas. The activities supported by a chair will attract other distinguished faculty members, as well as the best and brightest fellows and students. A term chair supports the teaching and research activities of a faculty member by underwriting graduate students and postdoctoral fellows, staff and services, and special projects. Moreover, a term chair is limited to a set period and supports the work of members of the faculty who show much promise in their field. A term chair is established with a $1-million minimum gift. The endowed-chair tradition started under the tenure of Founding Director of the Stein Eye Institute and Founding Chairman of the Department of Ophthalmology, Bradley R. Straatsma, MD, JD. The Stein Eye Institute continued to be the ben- The bronze sculpture commemorates eficiary of additional endowed chairs whenBartly J. Mondino, MD, assumed the establishment of a named endowed the leadership role as Stein Eye Director and Department Chairman in 1994. chair and is given to both the donor and Dr. Mondino was involved in establishing 15 endowed chairs and converting five the newly appointed chair holder. term chairs to permanent-appointment chairs.

A Year in Review | Stein Eye Institute 17 2013 Walton Li, MD, Chair in Cornea and Uveitis 2012 Joan and Jerome Snyder Chair in Cornea Diseases 2012 Mary Oakley Foundation Chair in Neurodegenerative Diseases 2008 Jerome and Joan Snyder Chair in Ophthalmology 2008 Jack H. Skirball Chair in Ophthalmology 2008 Ernest G. Herman Chair in Ophthalmology 2007 Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology (previously the Brindell and Milton Gottlieb Chair in Pediatric Ophthalmology) 2007 Karen and Frank Dabby Endowed Chair in Ophthalmology 2006 Ahmanson Chair in Ophthalmology 2004 Kolokotrones Chair in Ophthalmology 2003 Leonard Apt Endowed Chair in Pediatric Ophthalmology 2002 Oppenheimer Brothers Chair 2001 Karl Kirchgessner Foundation Chair in Vision Science 2000 Harold and Pauline Price Chair in Ophthalmology (converted to permanent chair in 2006) 1998 David May II Endowed Chair in Ophthalmology (converted to permanent chair in 2005) 1998 Laraine and David Gerber Chair in Ophthalmology (converted to permanent chair in 2006) 1995 Vernon O. Underwood Family Chair in Ophthalmology 1994 Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology 1992 The Fran and Ray Stark Foundation Chair in Ophthalmology (converted to permanent chair in 2007) 1991 Grace and Walter Lantz Endowed Chair in Ophthalmology (converted to permanent chair in 2010) 1982 Jules Stein Chair in Ophthalmology 1982 Charles Kenneth Feldman Chair in Ophthalmology 1980 Dolly Green Chair of Ophthalmology 1977 Edith and Lew Wasserman Professor of Ophthalmology

18 Stein Eye Institute | A Year in Review Thank You

e are grateful for the generous and steadfast support the Stein Eye Institute receives for research, education, patient care, and outreach activities. This Winvestment has a positive impact on ophthalmology, related disciplines at UCLA, and throughout the broader vision community. Thank you for your commitment to advancing eye research and treatment for the preservation and restoration of vision throughout the world.

Major Gifts over $25K:

The Allergan Foundation Randi Levine American Glaucoma Society Bert O. Levy Arnold and Mabel Beckman Foundation Macula Vision Research Foundation Andrea Bocelli Foundation Wilbur May Foundation Anonymous Ruth and George E. Moss Leonard Apt Trust The Nicholas Endowment Bruce Ford and Anne Smith Bundy Foundation The Mary Oakley Foundation The Carl and Roberta Deutsch Foundation Gerald Oppenheimer Family Foundation Drabkin Family Foundation, Inc. Arlene E. Pinkerton David R. Fett, MD The Louis and Harold Price Foundation, Inc. Carol and Timothy W. Hanneman Reichert Technologies HCP, Inc. Research to Prevent Blindness, Inc. John and Susan Hess Albert Sarnoff Katrina vanden Heuvel Mark Schulman and Esther Schulman Foundation The Frank D. Hintze Trust The Gerald Schwartz & Heather Reisman William & Margaret Fern Holmes Family Foundation Foundation The Simms/Mann Family Foundation The Karl Kirchgessner Foundation The Skirball Foundation Knights Templar Eye Foundation, Inc. The Smotrich Family Wendy and Theo Kolokotrones Marvin and Mehry Smotrich Jule D. Lamm, OD Thomas and Iris Smotrich Lavery Foundation Jerome and Joan Snyder Lewis Robert Leis and Phyllis G. Leis Dr. and Mrs. Bradley R. Straatsma Revocable Trust Vision of Children Foundation, David and Susan Leveton, Sam and Vivian Hardage, Co-Founders Ann C. Rosenfield Fund

A Year in Review | Stein Eye Institute 19 The following individuals were Laraine and David Gerber Chair in Endowed Chairs and honored with a tribute gift this Ophthalmology Fellowships past year: Established in 1998 as a term ENDOWED CHAIRS chair by Mr. and Mrs. Gerber and In Honor of: converted to a permanent chair in Richard Irwin Berg, CPA The Ahmanson Chair in 2007 with an additional pledge Ophthalmology Sandi Lyn Black Established in 2005 by The Joseph L. Demer, MD, PhD Mazie Bonfiglio Ahmanson Foundation as an 2000–2004 Teri Brown administrative chair for the Retina Sherwin J. Isenberg, MD Division Chief to further research, Joseph Caprioli, MD 2004–Present education, and clinical care programs Joseph L. Demer, MD, PhD Steven D. Schwartz, MD Dolly Green Chair of Ophthalmology Scott Feiler, MD 2007–Present Established in 1980 by Ms. Dorothy Lynn Kathryn Gordon, MD Leonard Apt Endowed Chair in (Dolly) Green Michael B. Gorin, MD, PhD Pediatric Ophthalmology Dean Bok, PhD Theresa Kruger Established in 2003 by Professor 1984–Present Antoinette Kruger Emeritus of Ophthalmology and Founding Director of the Division Ernest G. Herman Chair in Rosalie Amber Licht of Pediatric Ophthalmology and Ophthalmology Kevin M. Miller, MD Strabismus, Dr. Leonard Apt, with Initiated in 2007 by Mr. Ernest G. Faye Oelrich a gift from the trust of Frederic G. Herman to support a vision scientist Rappaport, Dr. Apt’s nephew or a clinician-investigator Grant Palmer Joseph L. Demer, MD, PhD Xian-Jie Yang, PhD Jack Rootman, MD 2005–Present 2012–Present Bradley R. Straatsma, MD, JD Karen and Frank Dabby Endowed Karl Kirchgessner Foundation Chair in Ophthalmology In Memory of: Chair in Vision Science Established in 2007 by Dr. and Mrs. Established in 2001 as a term chair Paul Sholem Amber Dabby as a term chair to support by a colleague of Dr. Jules Stein Sylvia Weider Amber the activities of a distinguished to promote basic-science research Robert S. Blees faculty member in the area of initiatives orbital disease William L. Carter Debora B. Farber, PhD, DPhhc Robert Alan Goldberg, MD 2001–Present Alwyn Duffy 2008–Present Charles B. Fiscus Kolokotrones Chair in Charles Kenneth Feldman Chair in Athena Kostas Kalpaxis Ophthalmology Ophthalmology Established in 2004 by Wendy and Reverend George E. Kalpaxis Established in 1982 by various Theo Kolokotrones to support the Mary B. Larson donors in memory of Charles teaching and research of a cataract Oscar Leidenfrost Kenneth Feldman, an entertainment surgeon and scientist industry executive Allen Mann Kevin M. Miller, MD Robert D. Yee, MD 2005–Present Ethel O’Hara Professor 1984–1987 Paul Hugo Orlopp Hillel Lewis, MD Leonard Rabinovitz Scholar 1989–1993 Maurine Reedy Ruzek Gabriel H. Travis, MD Stanley K. Rothstein 2001–Present Kay Shimizu

20 Stein Eye Institute | A Year in Review Grace and Walter Lantz Endowed Harold and Pauline Price Chair in The Fran and Ray Stark Chair in Ophthalmology Ophthalmology Foundation Chair in Established in 1991 as a term chair Established in 2000 by the Louis Ophthalmology by Mr. and Mrs. Lantz and converted and Harold Price Foundation and Established in 1992 as a term to a permanent chair in 2010 with an converted to a permanent chair in chair by the Fran and Ray Stark additional pledge 2006 with an additional pledge Foundation and converted to a permanent chair in 2007 with an J. Bronwyn Bateman, MD Michael B. Gorin, MD, PhD additional commitment Grace and Walter Lantz Scholar 2006–Present 1993–1995 Joseph Caprioli, MD Arthur L. Rosenbaum, MD Chair in 1997–2004 Sherwin J. Isenberg, MD Pediatric Ophthalmology Grace and Walter Lantz Scholar Established in 2005 by Mr. and Anne L. Coleman, MD, PhD 1993–1995 Mrs. Gottlieb as an administrative 2004–Present Professor 1996–2004 chair for the Division of Pediatric Jules Stein Chair in Joseph L. Demer, MD, PhD Ophthalmology and Strabismus Ophthalmology in honor of the late Dr. Arthur L. Professor 2004–2005 Established in 1982 as a memorial Rosenbaum tribute to Dr. Jules Stein by his Walton Li Chair in Cornea Arthur L. Rosenbaum, MD many friends, with the leadership of and Uveitis 2008–June 2010 Mr. Samuel Goldwyn, Jr Established in 2013 by Walton W. Li, MD, as an administrative chair for Jack H. Skirball Chair in Ocular Wayne L. Hubbell, PhD the Cornea and Uveitis Division chief Inflammatory Diseases 1983–Present to further research and teaching Initiated in 2007 by The Skirball Bradley R. Straatsma, MD, activities Foundation in honor of Jack H. Endowed Chair in Ophthalmology Skirball’s long-standing friendship Anthony J. Aldave, MD Established in 1994 to honor Founding with Dr. Jules Stein and Lew 2014–Present Director of the Stein Eye Institute, Wasserman Bradley R. Straatsma, MD, JD David May II Endowed Chair in Gary N. Holland, MD Bartly J. Mondino, MD Ophthalmology 2009–Present Established in 1998 as a term chair 2000–Present by the family of Mr. David May II, a Jerome and Joan Snyder Chair in Vernon O. Underwood Family founding member of the Institute’s Ophthalmology Chair in Ophthalmology Board of Trustees, to perpetuate, in Established in 2007 by Mr. and Mrs. Established in 1995 as a term chair memoriam, Mr. May’s association Snyder to support the activities of by Mrs. Adrienne Underwood with the Stein Eye Institute and a distinguished faculty member Pingree in memory of her late converted to a permanent chair with who directs the Ophthalmology husband, Mr. Vernon O. Underwood an additional pledge from the Wilbur Residency Program, ensuring May Foundation that UCLA’s accredited program John R. Heckenlively, MD 1997–2004 Gary N. Holland, MD continues to offer rigorous and comprehensive instruction for 1999–2004 Gary N. Holland, MD individuals of the highest caliber 2004–2009 Joseph Caprioli, MD Anthony C. Arnold, MD 2004–Present 2008–Present Lynn K. Gordon, MD, PhD 2012–Present Oppenheimer Brothers Chair Joan and Jerome Snyder Chair in Established in 2002 as a term chair Cornea Diseases by the Oppenheimer Brothers Established in 2012 by Mr. and Mrs. Foundation Snyder to support the activities of Joseph Horwitz, PhD a distinguished faculty member in 2003–Present the area of corneal diseases and research

A Year in Review | Stein Eye Institute 21 Edith and Lew Wasserman David and Randi Fett Orbital John and Theiline McCone Professor of Ophthalmology and Ophthalmic Plastic Surgery Fellowship Established in 1977 by Edie and Lew Fellowship Endowment Established in 1989 by the McCones Wasserman to honor Dr. Jules Stein Established in 2013 by Dr. David to support and enhance education R. Fett and Ms. Randi Levine to Manfred Spitznas, MD programs and fellowship training in support fellows in the Orbital and 1979–1981 macular disease Ophthalmic Plastic Surgery Division David Cupp, MD Bartly J. Mondino, MD Klara Spinks Fleming Fellowship 2013–2014 Scholar 1984–1988 Fund Professor 1988–2000 Sujit Itty, MD Established in 1985 by Klara Spinks 2013–2014 Ben J. Glasgow, MD Fleming to support cataract research 2003–Present Rosalind Vo, MD Abe Meyer Memorial 2013–2014 Fellowship Fund ENDOWED FELLOWSHIPS Established in 1969 by various Frances Howard Goldwyn donors to support clinical fellows at Rosalind W. Alcott Fellowship Fellowship the Institute Established in 1978 by the Rosalind Established in 1977 by Mr. Samuel W. Alcott Charitable Remainder Saradha Iragavarapu, MD Goldwyn, Jr., with gifts from Mrs. 2013–2014 Trust for the training of outstanding Goldwyn’s estate and Dr. and Mrs. postdoctoral fellows Jules Stein Adelaide Stein Miller Research Ryan St. Clair, MD Alena Reznik, MD Fellowship 2013–2014 2013–2014 Established in 1977 by Mr. Charles Miller as a tribute to Dr. Jules Stein’s Leonard Apt Endowed Fellowship Elsa and Louis Kelton Fellowship sister in Pediatric Ophthalmology Endowed by the Keltons in 1982 to Established in 2002 by Founding Erica Oltra, MD support postdoctoral research and 2013–2014 Chief of the Pediatric Ophthalmology training and Strabismus Division, Leonard Payam Morgan, MD Harold and Pauline Price Apt, MD, to support outstanding Fellowship clinical fellows in the field of 2013–2014 Established in 1986 by the Louis pediatric ophthalmology and Bert Levy Research and Harold Price Foundation to strabismus Fellowship Fund support research and education in Anika Tandon, MD Established in 1995 by Mr. Bert ophthalmology and vision care 2013–2014 Levy to enhance the educational Anika Tandon, MD opportunities of vision science 2013–2014 Thelma and William Brand scholars and advance research in Director’s Fund neuro-ophthalmology Frederic G. Rappaport Fellowship Established in 2004 with a trust in Retina/Oncology from Mr. William F. Brand to benefit Wilbur D. May Fellowship Established in 2004 by Mrs. Jeanne worthy students at the Stein Eye Established in 2013 by the May A. Rappaport as a memorial to her Institute family as a tribute to Mr. Wilbur D. son Frederic Joshua Udoetuk, MD May, the beloved uncle of Mr. David Sujit Itty, MD 2013–2014 May II. 2013–2014 David May II Fellowship Fund Cooperman Fellowship Fund Established in 1992 by the family Dr. Jack Rubin Memorial Established in 1988 by the of Mr. David May II to support Fellowship Coopermans to support eye advanced study and research in Established by the family of Dr. research and education, with ophthalmology and vision science Jack Rubin to support postdoctoral emphasis on clinical ophthalmology fellows Renu Jivrajka, MD Joshua Udoetuk, MD 2013–2014 2013–2014

22 Stein Eye Institute | A Year in Review Herb Ritts, Jr., Memorial Vision Fund Endowments for Research, Education, and Patient Care Arna Saphier Macular Degeneration Fund The Annenberg Foundation Fund Albert Sarnoff Endowed Cataract J. Richard Armstrong and Fund Ardis Armstrong Fund Richard B. Shapiro Vision Fund Elsie B. Ballantyne Regents Fund The Skirball Foundation Fund Elsie B. Ballantyne UCLA Foundation Fund Arthur Spitzer Fund Virginia Burns Oppenheimer Dr. William F. Stein and Esther Endowment Fund Elizabeth Stein Memorial Fund Card Family Research Fund Raymond and Ruth Stotter Vision Science Research Fund Edward and Hannah Carter Fund Bradley R. Straatsma Research Fund Anthony Eannelli Fund Barbara P. Taylor Fund Katherine L. Gardner Research Fund UCLA Center for Eye Epidemiology Emma B. Gillespie Fund Paul J. Vicari Endowed Cataract Audrey Hayden-Gradle Trust Research Fund Marie and Jerry Hornstein Family Uncle Claude Fund Endowed Macular Degeneration Sanford and Erna Schulhofer Research Fund Anne H. West Estate Fund Fellowship Fund Established in 1986 by Mr. Sanford Michael Huffington Ophthalmology Daniel B. Whipple Fund Schulhofer to support postdoctoral Scholarship Fund Pat and Joe Yzurdiaga Endowed research and training in vision Stella F. Joseph Fund Cataract Fund science Ryan Wong, MD JSEI Maintenance Fund 2013–2014 Herman King Fund Lee and Mae Sherman The Karl Kirchgessner Foundation Fellowship Fund Ophthalmology Endowment Fund Established in 1981 by the Sherman family to support postdoctoral Sara Kolb Memorial Fund fellows John and Theiline McCone Daniel Rootman, MD Macular Disease Research Fund 2013–2014 William, Richard, and Roger Meyer Fund Audrey and Jack Skirball Ocular Inflammatory Disease Fellowship Chesley Jack Mills Trust Established in 2011 by The Skirball Foundation to support the training Patricia Pearl Morrison Research of fellows specializing in ocular Fund inflammatory disease William R. Payden Fund for Ryan St. Clair, MD Glaucoma Research 2013–2014 Gerald Oppenheimer Family Jules Stein Research Fellowship Foundation Center for the Prevention of Eye Disease Established in 1982 by various Endowment Fund donors to honor the memory of Charles Kenneth Feldman Jerome T. Pearlman, MD, Fund Ryan Wong, MD Emily G. Plumb Estate and Trust 2013–2014

A Year in Review | Stein Eye Institute 23 The legacy of Dr. and Mrs. Jules Stein arises from their role in the 20th century as visionaries. Through brilliance and beneficence, they created a multitude of programs aimed specifically at one goal: preserving and restoring eyesight. They approached this task dauntlessly, integrating the worlds of business, medicine, and philanthropy in such a way as to enhance each and leave in trust the promise of limitless accomplishment in the advancement of eye research and treatment. The Stein Eye Institute was established as a result of their philanthropy.

24 Stein Eye Institute | A Year in Review related to vision, ophthalmic education, and the care of pa- Jules Stein tients with eye disease. Jules Stein died in 1981, leaving a Jules Stein is the fore- legacy of hope to the world. Through his accomplishments most benefactor in the and philanthropy, he created ever-replenishing resources world history of vision for eye research and the means to preserve and restore science and blind- sight for future generations. ness prevention. He combined his love for music and medicine Doris Stein with a unique talent Doris Stein’s purposeful, yet richly varied life, earned the for analysis and orga- respect and affection of the many people who benefited nization to produce a from her humanitarianism. Inspiring partner of her husband lifetime of celebrat- for more than half a century, Doris Stein shared with him ed achievements as the accomplishments of his philanthropic endeavors and musician, physician, guided his interests in ophthalmology, beginning with a business leader, and visit to the New York Lighthouse for the Blind in the late humanitarian. 1950s. Deeply moved, Doris Stein urged her husband to Born in South Bend, Indiana, in 1896, Jules Stein received “do something!” From that passionate beginning came a a bachelor of philosophy degree from the University of broad base of programs that catalyzed eye research. Chicago at age 18 followed by a medical degree from Rush Doris Stein was a major force in this vision renaissance. She Medical College. After completing postgraduate studies served as an officer and director of Research to Prevent at the University of Vienna and Chicago’s Cook County Blindness, personally leading the Hospital, he began medical practice and was certified by appeal to establish more resourc- the American Board of Ophthalmology. es for investigations into eye dis- A musician from an early age, he financed his education by eases. She suggested that Jules playing in and leading his own band. As his reputation in- Stein assume the principal role in creased, he began booking other musicians for profession- the creation of an eye institute al engagements, and in 1924, founded Music Corporation at UCLA, and her unflagging en- of America (MCA). Shortly thereafter, he gave up the prac- thusiasm nurtured the Institute’s tice of medicine to concentrate on this enterprise. Within development as a unique pro- 10 years, MCA represented most of the great name bands vider of every facet of vision re- and corporate activities began to extend to representa- search and patient care. Serving tion of film stars, directors, writers, and musical artists. as Trustee, she focused special MCA entered the promising new field of television at its attention on Institute initiatives inception, eventually acquiring the Universal City property, to combat blindness throughout Universal Pictures, and other enterprises to become pre- the world. She devoted her last eminent in the entertainment industry. days, until her death in 1984, to the development of an expansion Throughout his phenomenally successful career, Jules and companion building for eye Stein maintained a strong interest and emotional invest- research. In 1989, dedication ceremonies were held for the ment in medicine, particularly his own field of ophthalmol- Doris Stein Eye Research Center. ogy. In the late 1950s, urged by his wife, Doris, he chose to direct his considerable talents to blindness prevention. With grace, vision, and meaningful action, Doris Stein en- The result was a concert of ideas and achievements that hanced the lives of all privileged to know her, stimulated encompassed philanthropy, government, and academic a cascade of progress in eye research, co-founded the medicine. Institute with its boundless scientific potential, and extend- ed the miracle of sight to untold numbers of people. By his efforts, Research to Prevent Blindness was created, now recognized as the world’s leading voluntary organization in support of studies of the eye and its diseases. Jules Stein was largely responsible for the passage of legisla- tion to establish the National Eye Institute as a separate entity in the National Institutes of Health. Under his leadership, the Stein Eye Institute was founded as a multidisciplinary center for vision science. Since its establishment, the Institute has become internationally identified as the focus for coordinated programs of research in the sciences

A Year in Review | Stein Eye Institute 25 Board of Trustees The Stein Eye Institute Board of Trustees was established in 1977 to ensure the Institute’s orderly growth and development. The Board meets regularly during the year, with each Trustee providing his/her unique counsel. Collectively, their invaluable contributions have included fiscal planning for the Institute, adoption of measures to facilitate recruitment of the world’s finest vision scientists, allocation of funds for the purchase of vision research equipment, and recommendations for facilities expansion programs.

Current Members

Nelson C. Rising, Esq. Bartly J. Mondino, MD Chairman and Director Chief Executive Officer Stein Eye Institute Rising Realty Partners 1994–present 2011–present

Ronald L. Olson, Esq. Katrina vanden Heuvel Partner Publisher and Editor Munger, Tolles, and Olson The Nation Magazine 1995–present 1984–present

Gerald H. Oppenheimer President Gerald Oppenheimer Casey Wasserman Family Foundation President and President Chief Executive Officer Systems Design Associates The Wasserman Foundation 1992–present 1998–present

Andrea L. Rich, PhD Retired President, Chief Executive Officer, and Director Los Angeles County Museum of Art Executive Vice Chancellor Emerita UCLA 2007–present* *Dr. Rich passed away July 28, 2014

26 Stein Eye Institute | A Year in Review The Executive Committee The Executive Committee of the Stein Eye Institute and Department of Ophthalmology meets regularly during the year, with each member providing their unique expertise. The Executive Committee ensures the orderly growth and development of the Institute and Department. It is involved in fiscal planning for the Institute, space, recruitments, program development, and resolution of interdivisional issues.

Executive Committee Director, Stein Eye Institute Chairman, UCLA Department of Ophthalmology Bartly J. Mondino, MD Associate Directors, Stein Eye Institute Wayne L. Hubbell, PhD Gabriel H. Travis, MD Vice-Chair, UCLA Department of Ophthalmology Anne L. Coleman, MD, PhD Chief Administrative Officer, Stein Eye Institute Jonathan D. Smith

A Year in Review | Stein Eye Institute 27 The Stein Eye Institute at UCLA is a vision-science campus dedicated to the preservation and restoration of vision through its global programs and innovative research, quality patient care, and multidisciplinary, integrative education, all with community outreach.

28 Stein Eye Institute | A Year in Review Faculty Honors Honors Anthony J. Aldave, MD Received an American Academy of Anthony C. Arnold, MD Awarded the 2015 Parker J. Palmer Ophthalmology Senior Achievement Courage to Teach Award at the Award at the October 2014 American Accreditation Council for Graduate Walton Li Chair in Cornea and Uveitis Academy of Ophthalmology annual Jerome and Joan Snyder Chair in Ophthalmology Medical Education (ACGME) Annual meeting in Chicago, Illinois. Educational Conference on February Professor of Ophthalmology Professor of Clinical Ophthalmology 27, 2015, in San Diego, California. Delivered the Dr. Diego Cuevas Chief of the Cornea and Uveitis Division Cancino Lecture at the 52nd Chief of the Neuro-Ophthalmology Division Public Service Member of the Stein Eye Institute Actualization Course in Ophthalmology, Director of the UCLA Optic Neuropathy Center organized by the Asociación para Evitar Faculty, Stanford/Bay Area la Ceguera en México, on February 19, Member of the Stein Eye Institute Basic Science Course in 2015, in Mexico City, Mexico. Neuro‑Ophthalmology

RESEARCH SUMMARY Presented the Erin K. Jacobson Faculty, Lancaster Course in Memorial Lecture at the Loma Linda Ophthalmology, Colby College Discovering the Genetic Basis of the Corneal Dystrophies University Medical Center Department of Ophthalmology Resident Research RESEARCH SUMMARY Board Director, American Symposium on May 22, 2015, in Loma Board of Ophthalmology The Cornea Genetics Laboratory, under Dr. Aldave’s direction, is involved in Linda, California. Ischemic and Inflammatory Diseases of the Optic Nerve identifying and elucidating the genetic basis of inherited corneal disorders, Chair, ACGME Residency Review Committee for Ophthalmology such as posterior polymorphous and Lisch corneal dystrophies. Public Service Dr. Arnold directs a neuro-ophthalmol- Ongoing additional research studies Chair, American Academy of Chair, ACGME Milestones Committee ogy research program concerned with include clinical characteristics of is for Ophthalmology Ophthalmology Knowledge Base diseases of the optic nerve. The overall chemic optic neuropathy in young pa- Development Project, Cornea and Reviewer for many scientific journals External Disease Panel goals of the program are the develop- tients; improved differentiation of arte ment of new techniques for imaging ritic from nonarteritic anterior ischemic Vice Chair, American Academy of Ophthalmology Ethics Committee the optic nerve and its blood supply; optic neuropathy; identification of is an improved understanding and classi- chemic aspects of other rare optic Associate Examiner, American Board fication of ischemic and inflammatory neuropathies, such as diabetic papil- of Ophthalmology optic nerve diseases; and the develop- lopathy, uremic optic neuropathy, and Member, Cornea Society ment and evaluation of new therapeu- chemotherapy-induced optic neuropa- Board of Directors tic modalities for these diseases. thy after bone marrow transplantation; Reviewer for many scientific journals and classification of unusual optic neu- Dr. Arnold was a principal investigator ropathies, such as ethambutol-induced in the National Eye Institute-sponsored Research Grants optic neuropathy and focal congenital clinical study of optic nerve sheath de- National Eye Institute: Identification optic nerve hypoplasia. A study of dif- and Characterization of the Genetic compression surgery for nonarteritic ferentiation of optic disc drusen from Basis of PPCD, 12/1/12–11/30/17 anterior ischemic optic neuropathy, papilledema has recently been com- and he was on the study’s Visual Field JAEB Center for Health Research: pleted. A major thesis entitled, The Effect of the Corneal Preservation Data Analysis Committee. He is a pri- Spectrum of Optic Disc Ischemia, has Time on Long-Term Graft Success mary advisor for an international multi- been submitted to the American Oph- (CPTS), 3/6/12–8/31/16 center study of risk factors for nonarte- thalmological Society. ritic anterior ischemic optic neuropathy.

30 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 31 Public Service Public Service Richard S. Baker, MD Board Member, John D. Bartlett, MD Ambulatory Practice Care Associate, California Medical Association UCLA Health, Faculty Practice Group

Associate Professor of Ophthalmology Chairman, Council for Health Sciences Assistant Clinical Professor of Ophthalmology Member, CareConnect Scientific and Clinical Affairs, Ambulatory Operations Advisory Group, Executive Director, Urban Health Institute California Medical Association UCLA Health Chairman, Department of Ophthalmology Chairman, African American Physician Quality Officer, Stein Eye Institute, Charles R. Drew University of Medicine and Science Advisory Committee, Los Angeles RESEARCH SUMMARY UCLA County Medical Association Member of the Stein Eye Institute Cataract and Refractive Surgery Interim Medical Director, Board Member, Latino Physicians University Ophthalmology Associates, of California Stein Eye Institute Dr. Bartlett has an ongoing clinical in- Board Member, Hispanic-Serving RESEARCH SUMMARY Health Professions Schools terest in cataract surgery, particularly refractive cataract surgery where Ophthalmic Epidemiology and Co-Founder and Board Member, Los Angeles Eye Institute the goal is to improve the focusing Health Services Research of the eyes and reduce dependence Member, South Los Angeles on glasses, while restoring vision po- Health Care Leadership Roundtable Dr. Baker’s primary areas of research tential. He is involved with teaching Reviewer for multiple National interest are in the fields of ophthal- these surgical techniques to the Stein Institutes of Health and Agency for Eye residents, training the next gen- mic epidemiology, health services Healthcare Research and Quality research, and health information tech- Special Emphasis Panels eration of eye surgeons to deal with challenging cases. nology including telemedicine. Current Reviewer for many scientific journals projects in ophthalmic epidemiology Clinical Informatics include statistical analysis of national Research Grants and statewide databases to produce As one of UCLA’s physician informat- National Institutes of Health: icists, Dr. Bartlett is involved in the definitive population-based estimates NIH Diversity Program Consortium of the distribution and the determi- Coordination and Evaluation Center ongoing implementation and optimi- nants of major ophthalmic diseases at UCLA, 09/26/14–06/30/15 zation of electronic health records and their treatments. (EHRs). UCLA physician informaticists engage in all aspects of understand- As director of the Charles Drew Cen- ing and promoting effective organiza- ter for Health Services Research, tion, analysis, management, and use Dr. Baker works closely with collab- of clinical information. Dr. Bartlett is orators at the Stein Eye Institute and interested in using EHRs to reach across UCLA on multiple projects re- the “Triple Aim” of improved patient lated to improving access to care, op- care and satisfaction, improved pop- timizing the quality of care, and elim- ulation health, and decreased cost of inating health disparities in diverse health care. and underserved populations.

32 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 33 Public Service Honors Suraj P. Bhat, PhD Member, Joint Working Group Joseph Caprioli, MD Received an American Academy of INDO-US Collaboration in Ophthalmology Secretariat Award at Vision Research the October 2014 American Academy Associate Professor of Ophthalmology David May II Endowed Chair in Ophthalmology of Ophthalmology annual meeting in Assessor, National Health and Chicago, Illinois. Member of the Molecular Biology Institute Medical Research Council, Australia Professor of Ophthalmology Member of the Stein Eye Institute Editor, Molecular Vision Chief of the Glaucoma Division Public Service Editorial Board Member, Member of the Stein Eye Institute Chair, American Academy of Developmental Neuroscience Ophthalmology, Committee on Practice Improvement RESEARCH SUMMARY Editorial Board Member, International Journal of Biochemistry Clinical Volunteer, Venice Family Clinic RESEARCH SUMMARY Molecular Biology of Vision and Molecular Biology Editorial Board Member, Reviewer for many scientific journals American Journal of Ophthalmology, Causes and New Treatments for Glaucoma Investigative Ophthalmology and Visual Dr. Bhat’s laboratory studies the regu- generated mouse models of this cata- Science, and Journal of Glaucoma lation of gene activity during differen- ract, thus enabling first-time investiga- Research Grants Dr. Caprioli’s long-term objective in Molecular Mechanisms of Reviewer for many scientific journals tiation and development of the verte- tion of this childhood pathology. National Eye Institute: Childhood his clinical and basic research is to Retinal Ganglion Cell Damage Cataractogenesis: Heterogeneity of brate eye. This involves isolation and and Neuroprotective Approaches Studies on the function of the aB- Gene Expression, 1/1/15–12/31/18 identify those individuals at greatest Research Grants characterization of genes and gene risk for visual loss and to implement to Treatment products, identification of the regula- crystallin protein in the lens and the Allergan Pharmaceutical Corp: new treatment strategies to prevent Basic science research under Dr. Cap- The Efficacy and Safety of tory elements and factors, and eluci- RPE (in particular its relation to AMD) are focused on elucidating its “non- blindness. Currently, the only tool that rioli’s direction involves the mecha- Bimatoprost Sr in Patients with dation of their mechanisms employ- Open-Angle Glaucoma or Ocular physicians have to treat glaucoma nisms of glaucomatous optic nerve ing both in vivo and in vitro paradigms crystallin” function, which is relevant Hypertension, 4/22/15–1/31/2019 is reduction of intraocular pressure. damage. The stress protein response with manipulated gene sequences. both in the transparent and nontrans- parent physiology. These investiga- This treatment does not prevent visu- in a glaucoma model is being inten- Heidelberg, Engineering: Multicenter al loss in a substantial proportion of Study for Normal Database of Optic Two areas of research currently under tions have led Dr. Bhat’s laboratory sively studied. An important goal in Nerve Head, Retinal Nerve Fiber Layer, investigation are focused on gaining to the discovery of the secretion of patients whose damage progresses this research is to identify neuropro- and Macula Parameters, with the deeper insight into molecular mech- aB-crystallin from the RPE in lipo quickly. The development of effective tective drugs that prevent the death Heidelberg Spectralis OCT, 9/25/13–9/24/15 anisms that developmentally predis- protein vesicles known as exosomes, neuroprotective avenues of treatment of retinal ganglion cells in mammali- pose the eye to visual impairment and to initiate studies on elucidation will be a hallmark advance to elimi- an models of glaucoma, and to apply Simms-Mann Family Foundation: through ocular lens pathologies such of intercellular communication (via nate blindness from this disease. these findings to clinical trials of hu- Clinical Research Program in Glaucoma, 7/1/14–6/30/16 as cataracts, and through retinal dis- exosomes) in the RPE, in health, and man glaucoma. Evaluation of Methods to eases including age-related macular in disease. Measure Rates of Glaucomatous degeneration (AMD). Optic Nerve Damage One area of attention is the study of Accurate assessment of optic nerve the developmental and tissue-specific and nerve fiber layer is important to control of the aB-crystallin gene and the early detection and timely treat- its involvement in cataractogenesis. ment of glaucoma. Studies are under- Another is the elucidation of the phys- way to develop novel structural mea- iological function of the aB-crystallin sures of the optic nerve and nerve protein in the ocular lens, in the neuro fiber layer, which are sensitive and retina and retinal pigment epithelium specific for early and progressive glau- (RPE), and in the brain. Technically this comatous optic nerve damage. The work involves gene manipulations and goals of this work include identifying the study of their consequences on the clinically implementable techniques to phenotype, both in vitro (cultured cells) measure the rate of progressive dam- as well as in vivo (transgenic animals). age. It is unlikely that a single structural or functional technique will be best Studies on the regulation of the ex- throughout the course of the disease, pression of the small heat-shock pro- and different methods will need to tein gene, aB-crystallin, are focused be applied at different stages to best on heat-shock transcription factor 4 measure disease progression. (HSF4), which Dr. Bhat’s laboratory has reported to be the predominant heat-shock transcription factor of the developing lens, and its post-natal expression correlating with the most prevalent form of early childhood la mellar cataracts. Dr. Bhat’s group has

34 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 35 Public Service Honors Richard Casey, MD Lead Physician, Martin Luther King, Jr. Anne L. Coleman, MD, PhD Received an American Academy of Multi-Service Ambulatory Care Center Ophthalmology Life Achievement Honor Award at the October 2014 Health Sciences Clinical Professor of Ophthalmology President, Los Angeles Ophthalmology The Fran and Ray Stark Foundation Chair in Ophthalmology American Academy of Ophthalmology Medical Group, Inc. annual meeting in Chicago, Illinois. Associate Member of the Stein Eye Institute Professor of Ophthalmology Professor of Epidemiology Public Service Director of the Stein Eye Institute Centers for Community Outreach and Policy, Director/Trustee, St. John Jerusalem Eye Hospital Group RESEARCH SUMMARY Eye Epidemiology, and the UCLA Mobile Eye Clinic Vice Chair of Academic Affairs, Department of Ophthalmology Member, Awards Committee, Cornea External Disease Association for Research in Vision Member of the Stein Eye Institute and Ophthalmology Dr. Casey’s research is focused on Public Health Services/ Chair, Planning Committee, understanding the causes of corneal Health Access National Eye Health Education RESEARCH SUMMARY Program, National Eye Institute disease and developing or improving Dr. Casey has elected to dedicate a treatments for patients with these significant portion of his professional Glaucoma, Cataract, and Secretary for Quality Care, American Academy of Ophthalmology disorders. He is collaborating with career to improving access to health Age-Related Macular Degeneration the Glaucoma and Ophthalmic Pa- care in specific underserved commu- Director, H. Dunbar Hoskins Jr., MD thology Divisions on clinical research nities of Los Angeles. He has focused Center for Quality of Eye Care Dr. Coleman’s research is directed projects to understand the nature of on assessing unmet needs in vision toward the diagnosis, treatment, and Member, Board of Trustees, comorbid conditions, such as glauco- health and developing innovative strat- Helen Keller International societal impact of glaucoma, cataracts, ma and dry eye disease. For dry eye egies to meet these deficits. He has and age-related macular degeneration, Executive Editor, American Journal disease, Dr. Casey is engaged in re- established the Los Angeles Ophthal- of Ophthalmology including the study of lifestyle limita- search to evaluate the ocular surface mology Medical Group, a comprehen- tions imposed on patients with these of patients undergoing corneal trans- sive eye care service entity, which is Research Grants kinds of eye diseases. Clinical projects plantation surgery to establish previ- currently engaged in a partnership to include studies that analyze the genet- Andrea Bocelli Foundation: ously undescribed clinical-pathologic provide eye care services to facilities UCLA Mobile Clinic Project and ic markers in the trabecular meshwork correlation with tear insufficiency and of the Los Angeles County, Depart- UCLA Mobile Eye Clinic, of patients undergoing glaucoma sur- 2/6/14–12/31/15 corneal epithelial abnormalities. The ment of Health Services in South gery, the prevention of visual impair- goal of these investigations is to im- Los Angeles. LA County Children and Families First prove the success of corneal trans- ment and blindness in school-age (First 5 LA): UCLA Mobile Eye Clinic plantation in high-risk patients with children, comparative effectiveness re- Child Vision Program, 7/1/13–6/30/16 the comorbid conditions of glaucoma, search, and glaucomatous visual field The Nicholas Endowment: Center for and separately, tear insufficiency. and optic nerve progression. Community Outreach and Policy, Jules Stein Eye Institute at UCLA 2013–2014, 1/1/15–12/31/15

36 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 37 Honors Public Service Joseph L. Demer, MD, PhD Presented the William Gillies Sophie X. Deng, MD, PhD Member, American Academy of Lectureship at the Australia and Ophthalmology Ophthalmic Technology New Zealand Strabismus Society, Assessment Committee, Cornea, and Leonard Apt Endowed Chair in Pediatric Ophthalmology March 6–7, 2015, in Brisbane, Associate Professor of Ophthalmology Anterior Segment Disorders Panel Australia. Professor of Ophthalmology Member of the UCLA Jonsson Member, Association for Research in Gave the Keynote Address at the Comprehensive Cancer Center Vision and Ophthalmology Program Professor of Neurology Congress of the European Society Committee (Cornea Section) Member of the UCLA Broad Stem Cell Research Center Chief of the Pediatric Ophthalmology and Strabismus Division of Ophthalmology, June 6–9, 2015, in Vienna, Austria. Member of the Stein Eye Institute Research Grants Member of the Stein Eye Institute California Institute for Regenerative Public Service Medicine (CIRM): Regeneration of Editorial Board Member, Investigative Functional Human Corneal Epithelial Ophthalmology and Visual Science RESEARCH SUMMARY Progenitor Cells, 3/1/11– 4/30/15 RESEARCH SUMMARY Editorial Board Member, Journal of the Dompe Pharmaceutical: An 8-week Motility and Vision American Association for Pediatric Limbal Stem Cell Deficiency Phase II, Multicenter, Randomized, Ophthalmology and Strabismus Double-Masked, Vehicle Controlled Dr. Deng’s research is focused on developed xenobiotic-free and feed er- Parallel Group Study with a 24 or Dr. Demer studies the role of the brain and extraocular muscles in the control of Associate Editor, Strabismus 32 Week Follow-Up Period to eye movements and visual perception. He is directing a National Eye Institute re- improving the current diagnosis and free culture methods to expand autol- Evaluate the Efficacy of a Formulation Grant Reviewer, United States treatments for patients with limbal ogous limbal stem cells in culture. Pre- Containing Antioxidant of Recombinant search project aimed at developing an understanding of the role of orbital connec- Public Health Service stem cell deficiency. One of her on- clinical studies are ongoing to bring Human Nerve Growth Factor, tive tissues and nerves in the development of binocular coordination disorders, Scientific Advisory Committee 3/17/15–3/16/17 such as strabismus, and is developing new technologies for magnetic resonance going clinical studies using laser scan- this stem cell therapy to restore vi- Member, Knights Templar National Eye Institute: Ex Vivo imaging of extraocular muscles and nerves. This research has contributed to the Eye Foundation ning in vivo confocal microscopy in pa- sion in patients who suffer from lim- tients with limbal stem cell deficiency bal stem cell deficiency. Expansion of Human Limbal knowledge of the functional anatomy of extraocular muscles and connective Stem Cells for Transplantation, Council Member, International shows correlated cellular changes in tissues, allowing development of new types of surgeries. Strabismological Association 9/1/12–8/31/17 the cornea and limbus. Damages to Cornea Endothelial Dysfunction Dr. Demer’s research also employs novel micro- and nano-technological tech- Lecture presentation on pediatric the limbal stem cells could be detect- Another area of Dr. Deng’s research niques to study the biomechanical properties of the extraocular muscles and as- ophthalmology and strabismus at ed and correlated with clinical presen- Encampment of Knights Templar is the development of cell therapy sociated tissues, as well as optical and x-ray imaging of the effects of physiological tation. This new technique could al- to treat endothelial dysfunction by forces in the tissues. Reviewer for many medical and low for a better understanding of the regeneration of human corneal endo scientific journals pathophysiology of limbal stem cell thelial cells. Currently, her laboratory deficiency. Another study focuses on focuses on investigating the signa- Research Grants finding a better diagnostic marker for ture genes of cornea endothelial cells National Eye Institute: Biomechanical limbal stem cell deficiency. By using Analysis in Strabismus Surgery, and the regulation of these quiescent 5/1/11–4/30/16 the new diagnostic marker and in vivo cells. Another project aims to increase confocal imaging, a timely diagnosis the efficiency of expansion of corneal Knights Templar Eye Foundation Inc.: and staging of disease progression Roland Tan: Training Mentors in endothelial cells in culture and deri- Developing Countries (TMDC) could be achieved. vation of these cells from pluripotent Pediatric Ophthalmology Fellowship, stem cells. 7/1/14–8/17/15 Dr. Deng’s laboratory studies the microenvironment/niche of the limbal stem cells to elucidate those factors that govern the fate of limbal stem cells. The role of the Wnt signal transduction pathway in human limbal stem/ progenitor cells is under investigation. Recent study in her laboratory reveals that activation of the Wnt/ß-catenin promotes self-renewal of limbal stem cells and that Frizzled 7 might be the receptor that mediates the Wnt activation. Use of small molecules to modulate Wnt signaling is being investigated to increase the efficiency of ex vivo expansion of limbal stem cells for transplantation. Dr. Deng’s laboratory is also trying to achieve patient-specific therapy by regenerating autologous limbal stem cells in a xenobiotic-free culturing system for transplantation. They have

38 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 39 Research Grants Public Service Gordon L. Fain, PhD National Eye Institute: Physiology of Debora B. Farber, PhD, DPhhc Scientific Advisory Board Member, Photoreceptors, 8/1/12–7/31/17 The Foundation Fighting Blindness and Hope for Vision Scientific Advisor, Distinguished Professor of the Departments of Great Lakes Fishery Commission: Karl Kirchgessner Foundation Chair in Vision Science The Vision of Children Foundation Integrative Biology/Physiology and of Ophthalmology Detection of Light by the Sea Lamprey Petromyzon Marinus, 1/14–12/16 Distinguished Professor of Ophthalmology Editorial Board Member: Molecular Member of the Stein Eye Institute Vision; The Open Ophthalmology Member of the Brain Research Institute Journal; Journal of Ocular Biology, Member of the Molecular Biology Institute Diseases, and Informatics; and Stem Cells and Cloning Advances Member of the Stein Eye Institute and Applications RESEARCH SUMMARY Grant Reviewer: National Eye Institute; Physiology of Photoreceptors in the Vertebrate Eye The Foundation Fighting Blindness; The Vision of Children RESEARCH SUMMARY Dr. Fain’s primary research interest is Reviewer for many scientific journals in the physiology of photoreceptors Retinal Biochemistry, Molecular Biology, and in the vertebrate eye. A vertebrate Genetics of Retinal Degenerations Research Grants photoreceptor uses a photopigment Retina International: Regeneration of called rhodopsin and a G-protein cas- functional retinas: treatment with Dr. Farber’s research focuses on the by OA1 of Gai3 is the first step in the human embryonic stem cell-released cade to produce the electrical re- isolation and characterization of genes cascade of events involved in RPE microvesicles, 8/1/14–1/31/15 sponse that signals a change in light involved in inherited retinal diseases. melanogenesis, which is abnormal in intensity. Powerful new techniques Her team has cloned several genes en- ocular albinism. have made it possible to understand coding proteins that play a key role in the working of this cascade in extraor- vision, and that when mutated cause Lately, Dr. Farber’s team pioneered dinary detail. Practically all the protein blinding diseases. These include the the characterization of microvesicles molecules involved in the cascade in a released by embryonic stem cells b-PDE gene (mutations cause blind- photoreceptor—from the pigment mol- ness in rd mice and Irish setter dogs), (ESMVs), determined how they trans- ecule to the G-protein and channels, and in one type of human autosomal fer their cargo to other stem cells or but also including a large number of recessive retinitis pigmentosa (arRP); cells of other origin, and studied the control proteins—are expressed only the RP1 gene (responsible for a type effects that they have on cultured in the photoreceptors and nowhere of autosomal dominant RP); the gene retinal progenitor Müller cells in vitro. else in the body. This has enabled causing disease in rd7 mouse—a mod- These studies led them to investigate scientists to use genetic techniques el for Enhanced S-Cone Syndrome; the a totally unexplored possibility: the to create mice in which these pro- use of ESMVs in the rescue of dam- a-transducin gene, disrupted in the teins have been knocked out, over- or Rd4 mouse, another model of retinal aged retinas. This work is currently under-expressed, or replaced with pro- disease; and the mouse homologue the main focus of Dr. Farber’s group. teins of modified structure. of the gene causing X-linked juvenile Dr. Fain’s laboratory uses electrical retinochisis (Xlrs1). Utilizing gene ther- recording to study the effects of such apy methods, Dr. Farber and collabora- genetic alterations on the light re- tors delivered the normal b-PDE gene sponses of mouse rods, in order to to rd mouse retinas and rescued their understand the role of these proteins photoreceptors. in the visual cascade. His research Dr. Farber’s group also worked on team is especially interested in mod- the mechanisms that regulate tran- ulatory enzymes and their function in scription and expression of retinal light and dark adaptation. Dr. Fain also genes. They found that the transcrip- has a long-standing interest in mecha- tion factor SP4 controls the activity of nisms of photoreceptor degeneration the b-PDE promoter and mutations in genetically inherited disease. His in both SP4 and a-transducin cause laboratory is presently the only labo- digenic arRP and cone-rod dystrophy ratory measuring changes in calcium (arCRD). Other projects included the from mouse rods with fluorescent identification of the novel cone genes, dyes. Findings have implicated both ZBED4 and RHBDD2, and of muta- increases and decreases in calcium tions in them causing arCRD and arRP, concentration as contributing factors respectively; and the characterization in the triggering of apoptosis. Such in- of animal models of ocular albinism, formation may provide insight into the which lack the OA1 gene and are af- mechanisms of retinal degeneration. fected with permanent visual impairment. An important discovery related to this work is that specific activation

40 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 41 Public Service Research Grants JoAnn A. Giaconi, MD Member, Glaucoma Panel, Ben J. Glasgow, MD National Eye Institute: Proteins in the American Academy of Ophthalmology Molecular Mechanisms of Tear Film Knowledge Base Development Project Formation, 9/1/11–8/31/16 Health Sciences Associate Professor of Ophthalmology Edith and Lew Wasserman Professor of Ophthalmology Faculty, Glaucoma section of American Chief of the Ophthalmology Section at the Greater Los Angeles Academy of Ophthalmology’s Professor of Pathology and Laboratory Medicine VA Healthcare System Basic and Clinical Science Course Chief of the Ophthalmic Pathology Division Co-Director of Medical Student Education at the Member, Surgical Advisory Board for David Geffen School of Medicine, UCLA National Veterans Affairs Member of the Stein Eye Institute Member of the Stein Eye Institute Vice President of Membership, Women in Ophthalmology Councilor, California Academy of RESEARCH SUMMARY Eye Physicians and Surgeons RESEARCH SUMMARY Glaucoma Past President, Los Angeles Society Ophthalmic Pathology of Ophthalmology

Dr. Giaconi’s research focuses on the Volunteer, Eye Care America Dr. Glasgow’s research interests are treatment of glaucoma and the effects Reviewer for many scientific journals primarily in the field of ophthalmic pa- of glaucoma surgery on the cornea thology. His major focus is the role of and vision. She is currently working human lacrimal gland proteins in the on a project examining the overtreat- protection and maintenance of the ment or undertreatment of glaucoma eye. His laboratory is investigating in the veteran population. She is also the structure-function relationship of enrolling patients in two clinical stud- tear lipocalin, the principal lipid carrier ies at the Stein Eye Institute. One protein of tears. Currently, the labora- study is examining the effect of vari- tory has developed a technique called ous glaucoma surgeries on the corne- site-directed tryptophan fluorescence al endothelium, which is the layer of to probe and report information re- cells that keeps the cornea clear, and garding molecular motion and solu- the other is investigating the post- tion structure. By studying the mo- operative eye pressure course follow- lecular mechanisms of tear proteins, ing Ahmed valve implant surgery. Dr. Glasgow is seeking to learn the normal functions of tear lipocalin and its role in maintaining the health of the ocular surface and in the prevention of dry eye diseases. It is hoped that this research will lead to new treatments for dry eye and have broad application to numerous other members of this protein family that transport small, in- soluble molecules through the body.

42 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 43 Honors Honors Robert Alan Goldberg, MD Delivered the Plana Lecture at the Lynn K. Gordon, MD, PhD Received an American Academy of XIX International Course on Plastic and Ophthalmology Senior Achievement Aesthetic Surgery on June 16, 2015, Award at the October 2014 American Karen and Frank Dabby Endowed Chair in Ophthalmology in Barcelona, Spain. Vernon O. Underwood Family Chair in Ophthalmology Academy of Ophthalmology annual meeting in Chicago, Illinois. Professor of Ophthalmology Professor of Ophthalmology Public Service Chief of the Orbital and Ophthalmic Plastic Surgery Division President-elect, American Society Senior Associate Dean for Academic Diversity, Public Service David Geffen School of Medicine at UCLA Director of the UCLA Orbital Disease Center of Ophthalmic Plastic and Member, Dermatologic and Ophthalmic Reconstructive Surgery Chair of the College of Applied Anatomy, Drugs Advisory Committee, Federal Co-Director of the UCLA Aesthetic Center Drug Administration Assistant Vice President of David Geffen School of Medicine at UCLA Member of the Stein Eye Institute Professional Education, Member of the Stein Eye Institute Member, Scientific Review Committee, California Academy of Ophthalmology Fight for Sight Committee Member, American Academy of Ophthalmology, Fellowship Program Director, American Basic and Clinical Science Course Academy of Cosmetic Surgery and Section 5, Neuroscience RESEARCH SUMMARY American Society of Ophthalmic RESEARCH SUMMARY Plastic and Reconstructive Surgery Councilor, American Academy Diseases and Therapy of the Eyelid and Orbit of Ophthalmology Editorial Board Member, Archives of Retinal Cell Biology and Inflammatory Disease Ophthalmology, Ophthalmic Plastic Member, Association for Research Research into the various surgical ap- Outcomes of medical and surgical and Reconstructive Surgery, in Vision and Ophthalmology’s Aesthetic Surgery Journal, and Dr. Gordon’s laboratory is involved in important role in immune regulation WEAVR Committee proaches to Graves orbitopathy (thy- treatment of orbital and eyelid dis Archives of Facial Plastic Surgery two primary areas of research. One in retinal formation. PD-1 has a major roid eye disease) has resulted in new orders are being studied in an orga- project investigates the role for epi- function as a negative regulator in the Chair, Neuro-Ophthalmology Research techniques that include less invasive nized, prospective fashion in order to Section Editor, American Academy of Committee, Member of the Board, Ophthalmology, ONE Network thelial membrane protein 2 (EMP2) in immune system. Although previous North American Neuro-Ophthalmology small incision surgical approaches. In better understand which treatments controlling ocular pathologic respons- studies identified PD-1 expression in Society addition, detailed clinical information are most effective. Research Grants es. Dr. Gordon and her colleagues the lymphoid system, Dr. Gordon and gathered from patients with Graves President, California Academy of Premier Research International LLC: identified that EMP2 plays an impor her colleagues have recently identi- Eye Physicians and Surgeons orbitopathy is being recorded in a A Multicenter, Double-Masked, tant role in an in vitro model of pro- fied its expression in neuronal cells of shared database as a way to under- Placebo-Controlled, Efficacy & Safety liferative vitreoretinopathy (PVR) and the retina. This observation raises the Editorial Board Member, Investigative stand the natural history and response Study of RV001, An Insulin-Like Ophthalmology and Visual Science, have evidence that EMP2 is highly ex- possibility of a developmental role for Journal of Neuro-Ophthalmology, and to treatment of this multifaceted dis- Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), pressed in human retinal diseases. In PD-1 in maturation of the ganglion cell Ocular Immunology and Inflammation ease, which is a cause of significant vi- Administered Every 3 Weeks (Q3W) addition, they recently identified that layer and retinal remodeling process sual loss and discomfort. Multicenter By Intravenous (IV) Infusion in Patients EMP2 controls VEGF production in as well as a possible role for PD-1 in Research Grants Suffering from Active Thyroid Eye studies are underway. Dr. Goldberg epithelial cells and in specific tumors. degenerative neuronal diseases. By National Eye Institute: Novel Therapies is also investigating the underlying Disease (TED) Protocol TED01RV, 4/16/13–1/27/16 The laboratory, in collaboration with understanding the role of PD-1 in the to Prevent Blindness Caused by causes of thyroid-related orbitopathy. others at UCLA, has recently devel- retina, we may understand how to im- Proliferative Vitreoretinopathy, 4/1/10–3/31/15 The goal of this research is to develop oped a designer antibody fragment prove the visual outcome for patients better tests to monitor disease activ- that has demonstrated efficacy in in- with optic nerve diseases. National Eye Institute: Pd-Ligand, ity, as well as new treatments to ad- A Paradoxical Role in Experimental vitro studies in the PVR model and Uveitis Pathogenesis and Therapy, dress the basic cause of the disease. in other animal models in vivo. This 4/1/15–3/31/17 antibody has now been successfully Research into orbital and eyelid anato- Quark Pharmaceuticals, Inc.: A Phase I my, currently in progress, is resulting in used to control pathologic neovas- Open Label, Dose Escalation Trial improved techniques and approaches cularization in a corneal burn model, of QPI-1007 Delivered by a Single Intravitreal Injection to Patients with to deep orbital disease. Included is the achieving proof of principle for using this antibody to control disease. Optic Nerve Atrophy (Stratum I), use of high-resolution magnetic reso 3/17/10–3/16/15 nance imaging and high-resolution dy- The second area of interest of Dr. namic ultrasonography to evaluate mo Gordon’s group is the developmental tility problems following trauma and role of programmed death 1 (PD-1), orbital surgery, and three-dimensional a molecule that is known to play an analysis of orbital anatomy. Improved understanding of eyelid and orbital physiology and anatomy is the basis for developing improved surgical techniques. Instrumentation and devices that allow less invasive surgical approaches, such as hyaluronic acid gels, are being developed and studied. In collaboration with the Department of Engineering, custom materials for orbital reconstruction are investigated.

44 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 45 Public Service Public Service Michael B. Gorin, MD, PhD Medical Director, Stein Eye Institute’s David Rex Hamilton, MD, FACS Editorial Board Member, Electronic Medical Record System Ophthalmology, Journal of Refractive Surgery, and Journal of Cataract and Harold and Pauline Price Chair in Ophthalmology Member, Medical Education Health Sciences Associate Clinical Professor of Ophthalmology Refractive Surgery Committee, David Geffen School of Professor of Ophthalmology Medicine at UCLA Director of the UCLA Laser Refractive Center Member, Refractive Leadership Council, Alcon Laboratories Professor of Human Genetics Editorial Board Member, Member of the Stein Eye Institute Current Eye Research and Member, ASCRS Refractive Surgery Chief of the Division of Retinal Disorders and Ophthalmic Genetics Experimental Eye Research Clinical Committee Member of the Stein Eye Institute Advisory Board Member, American Member, ASCRS Refractive Surgery/ Health Assistance Foundation RESEARCH SUMMARY Cataract Clinical Subcommittee Member, Association of University Advanced Intraocular Lenses Member, American Academy Professors of Ophthalmology, of Ophthalmology, Preferred RESEARCH SUMMARY Consortium of Medical Practice Pattern Committee for Hereditable Eye Disorders and Molecular Genetics Education Directors Dr. Hamilton’s research interests are Refractive Surgery Member, Special National Institutes of in the areas of corneal biomechanics Member, American Academy of of Age-Related Maculopathy Health Study Sections for the National and tomography (3D imaging of the Ophthalmology, ONE Network, Eye Institute, National Institute on cornea), screening for corneal ectat- Refractive Surgery Dr. Gorin’s primary research focus work, opportunities have emerged to Aging (Claude Pepper Grants), National ic disorders, and the clinical study of Human Genome Research, Center for is molecular genetics of hereditable investigate the pathogenesis of light Inherited Disease Research intraocular lenses (IOLs) for the treat- eye disorders, specifically age-related sensitivity for individuals who suffer ment of high myopia (phakic IOLs), macular degeneration (AMD). His re- from migraines and/or mild traumatic Scientific Advisory Committee astigmatism (toric IOLs), and presby Member, the American Health search group was the first to identify brain injury. Assistance Foundation and the Knights opia (multifocal and accommodating specific regions of the genome that Templar Eye Research Foundation IOLs). Dr. Hamilton is actively in volved contributed to ARM development in Clinical research efforts are directed in training residents and fellows in the Founding Member of the families, leading to discovery of gene towards developing methods to moni surgical treatment of refractive errors tor and quantify retinal function in pro- von Hippel-Lindau Center of Excellence variations that contribute to the risk at UCLA Medical Center and cataracts. of developing ARM. He continues to gressive retinal disorders (such as diabetic retinopathy, Stargardt disease, Member of the Clinical Research work on studies of the genetics of Governance Committee for UCLA AMD, in particular the use of genetic and retinitis pigmentosa) and in pa- Reviewer for many scientific journals risk profiles to test for clinical mark- tients with potential ocular toxicities ers, including sensitive methods for from systemic medications. Applied Research Grants detecting changes in retinal structure research interests include bioinformat- and function that precede the onset ics in clinical ophthalmic practice and Arnold and Mabel Beckman Foundation: public health issues pertaining to oc- Genetics-based testing of functional of clinical disease. and structural endophenotypes for ular disease. pre- and early-age-related macular Dr. Gorin investigates the molecular degeneration (AMD), 7/1/14–6/30/16 genetics of complex disorders such as cystoid macular edema, age-related cataracts, and glaucoma, as well as monogenic disorders such as hereditary retinal degenerations, glaucoma, cataracts, and ocular syndromes. He is pursuing studies to identify genetic variations that contribute to the severity, complications, and therapeutic responses of these conditions. Dr. Gorin and his clinical team work with the clinical and research human genetics group at UCLA to explore use of new technologies, including next-generation sequencing for clinical utility in ophthalmic genetics. Research also focuses on the neurobiology of ocular pain and photophobia (sensitivity to light) to understand the basic biology and neural pathways that contribute to photophobia so that new therapeutic strategies can be developed. Based upon preliminary

46 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 47 Honors Research Grants Gary N. Holland, MD Featured speaker before the United States Joseph Horwitz, PhD National Eye Institute: Analysis of Congress at the first-ever Congressional Lens Crystallins and Cataractous Jack H. Skirball Chair in Ocular Inflammatory Diseases Briefing on Uveitis on June 3, 2015, in Mutants at High Hydrostatic Pressure, Washington, DC. Oppenheimer Brothers Chair 4/1/14–3/31/19 Professor of Ophthalmology Recipient of the Golden Apple Award for Distinguished Professor of Ophthalmology Director of the Ocular Inflammatory Disease Center Excellence in Teaching at the Class of 2017 Second Year Banquet, David Geffen School Member of the Stein Eye Institute Director of the UCLA Department of Ophthalmology Clinical Research Center of Medicine at UCLA, on April 23, 2015, in Co-Director of Medical Student Education Westwood, California. As the Golden Apple at the David Geffen School of Medicine, UCLA Award recipient, Dr. Holland also received special honors at the David Geffen School RESEARCH SUMMARY Member of the Stein Eye Institute of Medicine at UCLA Hippocratic Oath Ceremony, June 5, 2015, in Westwood, California. Biochemistry and Biophysics of the Crystalline Lens RESEARCH SUMMARY Uveitis and Cornea-External Ocular Diseases Public Service Dr. Horwitz is conducting research Associate Editor, American Journal on the biochemical and biophysical Dr. Holland’s research deals with in of the world because of the AIDS pan- of Ophthalmology properties of normal and cataractous lens proteins. In addition, he is infectious and inflammatory diseases demic. He is also investigating HIV- Editorial Board, EyeNet Magazine (American of the eye, including ocular toxo- related “neuroretinal disorder” (NRD), Academy of Ophthalmology), Section Editor, vestigating the molecular chaperone plasmosis; HIV-related eye disease; a degenerative condition that causes Uveitis properties of the lens’ alpha-crystallin, chronic anterior uveitis in children; deterioration of vision and reduced Executive Committee Member, American a protein that plays an important role and birdshot chorioretinopathy. Clin- quality of life, even among individu- Uveitis Society in keeping the eye lens clear during normal aging. Alpha-crystallin is also ical studies are being performed to als whose immune function has im- International Council Member, International identify populations at greatest risk proved because of antiretroviral drugs. Ocular Inflammation Society involved in age-related macular de- for these ocular diseases and factors NRD is also a marker of non-ocular, generation, as well as in many oth- Organizing and Protocol Committees, er neurodegenerative diseases. New that influence disease severity. Stud- life-threatening diseases among HIV- NEI/FDA Workshop on Clinical Trial End- ies also investigate the course of infected people. points for Inflammatory Eye Diseases spectroscopical techniques are cur- these diseases and response to new rently being developed for studying treatments. Better understanding of Chronic anterior uveitis is a common Research Grants protein function and structure utilizing these conditions may lead to im- complication of juvenile idiopathic Advanced Cell Technology, Inc.: ARO extremely high hydrostatic pressure. proved disease management. arthritis (JIA). Dr. Holland is study- Agreement A Phase I/II, Open-Label, ing risk factors for, and treatment of, Multicenter, Prospective Study to Determine Ocular toxoplasmosis, caused by a vision-threatening complications of the Safety and Tolerability of Subretinal Transplantation…Patients with Stargardt parasite, is the most common retinal JIA-associated uveitis, including glau- Macular Dystrophy SMD, 4/25/11–12/12/16 infection in the general population. coma, and he is interested in the psy- With investigators in North America, chosocial impact of uveitis on children Advanced Cell Technology, Inc.: ARO Agreement A Phase I/II, Open-Label, Brazil, and Europe, Dr. Holland is and their families. Multicenter, Prospective Study to Determine studying human and parasitic genetic the Safety and Tolerability of Subretinal factors that influence risk for ocular Birdshot chorioretinopathy is a chron- Transplantation…Patients with Advanced Dry AMD, 5/31/11–12/12/16 involvement among people infected ic autoimmune disease of the eye. with the parasite. Dr. Holland is participating in sev- Advanced Cell Technology, Inc.: Monitoring eral multicenter studies involving ret- of a Phase I/II, Open-Label, Prospective Dr. Holland continues to study cyto- inal imaging and electrophysiologic Study to Determine the Safety and megalovirus (CMV) retinitis, the most techniques to understand the basis Tolerability of Subretinal Transplantation … Patients with Geographic Atrophy Secondary serious eye problem among HIV- for vision loss among people with to Myopic Macular Degeneration, infected individuals, and still a major the disease. 3/31/14–3/31/16 public-health problem in many areas Xoma (US) LLC: A Randomized, Double- Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious Intermediate Posterior or Panuveitis Currently Controlled with Systemic Treatment Protocol #X052131, 1/8/13–11/25/14 Xoma (US) LLC: A Randomized Double- Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Noninfectious Intermediate Posterior or Panuveitis, 1/8/13–11/25/14 John Hopkins University: Multicenter Uveitis Steroid Treatment (MUST) Trial, 6/1/12–4/30/15 Johns Hopkins University (Prime NEI): Macular Edema Treatment Trials Associated with MUST (META-MUST), 9/30/14–7/31/15 Faculty | Stein Eye Institute 49 Public Service Public Service Wayne L. Hubbell, PhD Member, National Academy Jean-Pierre Hubschman, MD Reviewer for many scientific journals of Sciences

Jules Stein Chair in Ophthalmology Member, American Academy of Assistant Professor of Ophthalmology Research Grants Arts and Sciences National Eye Institute: Intraocular Distinguished Professor of Ophthalmology Member of the Stein Eye Institute Robotic Interventional Surgical System Research Grants for Cataract Surgery Project, Distinguished Professor of Chemistry and Biochemistry 9/30/14–9/29/16 National Eye Institute: Co-Chief of the Vision Science Division Molecular Basis of Membrane Lowry Medical Research Institute: A Associate Director of the Stein Eye Institute Excitation, 5/1/15–4/30/20 RESEARCH SUMMARY Ph 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor National Eye Institute: Core Grant Advanced Vitreoretinal Surgical Interventions (CNTF) for Macular Telangiectasia for Vision Research at the Type 2 (Mac Tel), 8/6/14–6/30/18 Stein Eye Institute, 3/1/10–6/30/15 and Robotics RESEARCH SUMMARY Ophthotech Corporation: A Phase3, Dr. Hubschman’s clinical research fo- RDM, Controlled Trial to Establish the Molecular Basis of Phototransduction Safety and Efficacy of Intravitreous cuses on the development and eval- Administration of Fovista (Anti PDGF-B in the Vertebrate Retina uation of new vitreoretinal surgical Pegylated Apramer) Administered… techniques and robotics for ophthal- ARMD, 12/4/13–12/3/15 Dr. Hubbell’s research is focused highlighted a crucial role for protein mic surgery. Automated surgery uti- Thrombogenics, Inc.: Ocriplasmin on understanding the complex rela- flexibility (dynamics), which has not lizing robotics promises to increase Research to Better Inform Treatment, tionship between molecular struc- been previously appreciated. To ex- surgical precision and accuracy, and 7/16/14–7/15/16 ture, plasticity, and conformational plore molecular flexibility in proteins of improve access to medical care. His changes that control protein function the visual system, Dr. Hubbell’s group publications include research papers in the visual system. Of particular is developing novel methods using as well as a book chapter about the interest are proteins that behave as time-domain and high-pressure EPR. feasibility of robotic surgery in oph- “molecular switches,” that is proteins thalmology. Currently, he is also in- whose structures are switched to an vestigating the use of the terahertz active state by a physical or chemical laser for the evaluation of ocular tis- signal. Examples include rhodopsin, sue hydration. the membrane-bound photoreceptor protein of the retina, and transducin and arrestin, proteins that associate with rhodopsin during function. The overall goal is to determine the structure of these proteins in their native environment, monitor the changes in structure that accompany the tran- sition to an active state, and to understand the role of protein flexibility in function. To investigate these and other proteins, Dr. Hubbell’s laboratory has developed the technique of site-directed spin labeling, a novel and powerful approach to the exploration of protein structure and dynamics. By changing the genetic code, a specific attachment point in the protein is created for a nitroxide spin label probe. Analysis of the electron paramagnetic resonance (EPR) spectrum of the spin label provides information about the local environment in the protein. With a sufficiently large set of labeled proteins, global information on structure is obtained and changes in the structure during function can be followed in real time. While determination of static protein structure is important to understanding function, current research has

50 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 51 Public Service Public Service Sherwin J. Isenberg, MD Past-President, American Association Simon K. Law, MD, PharmD Expert Reviewer, Medical Board for Pediatric Ophthalmology of California and Strabismus Laraine and David Gerber Chair in Ophthalmology Health Sciences Clinical Professor of Ophthalmology Pharmacy Editor, eMedicine Member, Medical Advisory Board Professor of Ophthalmology and Board of Directors; and Member of the Stein Eye Institute Member of the Committee on Aging, Research Committee Chair, American Academy of Ophthalmology Professor of Pediatrics Blind Children’s Center Subcommittee Member, Vice-Chairman of the UCLA Department of Ophthalmology Past President, Costenbader American Academy of Ophthalmology Basic and Clinical Science Course Member of the Stein Eye Institute Pediatric Ophthalmology Society RESEARCH SUMMARY Co-Founder and Delegate, Optic Disc Evaluation Reviewer for many scientific journals International Pediatric Ophthalmology and Strabismus Council RESEARCH SUMMARY Dr. Law’s principal research interest Glaucoma Tube Shunt Procedure focuses on the structural appearance Pediatric Ophthalmology, Amblyopia, and To prevent intraocular pressure spikes of the optic disc in different ocular after an Ahmed valve or tube shunt Ophthalmic Pharmacology diseases, including patients with high procedure for glaucoma, Dr. Law is myopia. Assessment of optic disc size evaluating the effect of using anti- Dr. Isenberg’s research activities have of the eye, which blind approximate- is an important component of the di- glaucoma medications at different concentrated on various aspects of ly 10,000 children annually, has been agnostic evaluation for glaucoma. Pa- times following surgery. Patients are surgical and medical diseases of chil- completed at three sites in India. tients with high myopia are at greater randomized to receive antiglaucoma dren’s eyes. The goal is to decrease risk of developing glaucoma, and they medications either at an early phase the frequency of blindness in children Lastly, a new device that reports blood also have an atypical optic disc that or at the standard time following the worldwide. In a series of studies of gases from the conjunctiva, such as makes diagnosis difficult. The purpose surgical procedure. newborns, Dr. Isenberg has charac- oxygen and carbon dioxide, is being of Dr. Law’s research is to character- terized a number of elements, includ- developed. Preliminary trials have been ize the appearance of the optic disc in Acupuncture and Glaucoma completed in animals and in adults un- ing: the type and source of bacteria eyes with high myopia and to identify Dr. Law is conducting a prospective dergoing cardiac bypass surgery. The of the external eye at birth; the evo- the related risk factors for develop- study to evaluate the effect of acu- hope is to apply the device to the eyes lution of iris structural changes; the ment of glaucoma. puncture in glaucoma. Acupuncture is of premature newborns. The continu- development of the macula, which a popular alternative medicine based ous readout of tissue blood gas levels is the source of central vision; and on traditional Eastern medical theory. should enable the pediatrician to pre- pupillary responses after birth. Re- Its effect on glaucoma has not been vent damage to the baby’s brain and cent publications have characterized objectively and scientifically studied. the production and nature of tears of keep the oxygen at an appropriate lev- infants and the development of the el, minimizing the possibility of blind- cornea in the first year of life. He has ness from retinopathy of prematurity. also reported the ocular signs in newborns whose mothers abuse cocaine, facilitating the diagnosis of newborn cocaine intoxication. In another avenue of research, povidone-iodine eyedrops have been found to treat bacterial conjunctivitis successfully in a three-year, international study with the University of the Philippines. The eyedrops were also found to be safer and more effective in preventing eye infections than the currently used agents. Dr. Isenberg and other investigators have now proven that the povidone-iodine eyedrops can treat the number one cause of preventable pediatric blindness in the world––corneal infections due to bacteria. These studies, conducted in children and adults in India and the Philippines, should reduce the number of 400,000 children now blind from corneal infections. A new study investigating fungal infections

52 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 53 Public Service Public Service Ralph D. Levinson, MD Member, COMPASS, ONE, BCSC Colin A. McCannel, MD Moderator, “Retina Talk” online Committees, American Academy discussion forum, American of Ophthalmology Association of Retina Specialists Health Sciences Clinical Professor of Ophthalmology Professor of Clinical Ophthalmology Member, Knowledge-Based Uveitis Chair, Editorial Committee, Retina and Member of the Stein Eye Institute Panel, American Academy of Member of the Stein Eye Institute Vitreous Basic and Clinical Science Ophthalmology Practicing Course, Section 12, American Ophthalmologists Curriculum Academy of Ophthalmology Reviewing Editor, Ocular Immunology Medical Information Technology RESEARCH SUMMARY and Inflammation RESEARCH SUMMARY Committee Member, American Academy of Ophthalmology Ocular Inflammatory Diseases Institutional Review Board Member, Vitreoretinal Surgery UCLA Reviewer for many scientific journals

Dr. Levinson’s research interest is oc- Reviewer for many scientific journals Dr. McCannel has a longstanding interest in the management of vitreoretinal ular inflammatory diseases. He is the conditions, particularly complex retinal detachments, complications of diabetic primary investigator on international Research Grants retinopathy, macular holes and epimacular membranes, and age-related macu- research projects in both the clinical MacDonald Family Foundation: lar degeneration. His clinical research efforts are directed at the improvement Immunologic and Clinical Studies of aspects of uveitis and the basic mech- Eye Disease at the Stein Eye Institute, of vitreoretinal surgical techniques and outcomes, including the prevention of anisms and immunogenetics of ocular 12/1/08–12/1/14 endophthalmitis following intravitreal injections. inflammation. Current projects include a collaborative longitudinal study of a Dr. McCannel devotes time to educational research as well. Currently, he is in- chronic inflammatory disease, birdshot vestigating the utility of virtual reality surgery simulation in teaching ophthalmic chorioretinopathy, with investigators in surgery. He has several ongoing protocols that assess ophthalmic surgical simula- France. The study focuses on the inter- tion in surgical teaching. relationship of disease factors, as well as the course of disease and response to treatment. Dr. Levinson is also conducting laboratory research on cell-based therapies for uveitis.

54 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 55 Public Service Honors Tara A. McCannel, MD, PhD Reviewer for many scientific journals Kevin M. Miller, MD Presented the Om Prakash Oration at the Delhi Ophthalmological Society meeting on April 12, 2015, in Health Sciences Associate Clinical Professor of Ophthalmology Kolokotrones Chair in Ophthalmology New Delhi, India. Director of the Ophthalmic Oncology Center Professor of Clinical Ophthalmology Public Service Member of the Stein Eye Institute Chief of the Cataract and Refractive Surgery Division Course Director, Southern California Member of the Stein Eye Institute Basic and Advanced Cataract Surgery Courses for Residents and Fellows RESEARCH SUMMARY American Academy of Ophthalmology, RESEARCH SUMMARY Skills Transfer Course Metastatic Ocular Melanoma Advisory Committee Cataract and Refractive Surgery American Academy of Ophthalmology, Dr. McCannel’s primary research in- Annual Meeting Program Committee, terest is metastatic ocular melanoma. Dr. Miller’s research interests are in In addition to refractive cataract sur- Cataract Subcommittee Under her direction, the Ophthalmic cataract and refractive surgery, intra- gery, he also performs DSEK, LASIK, American Society of Cataract Oncology Laboratory is studying mo- ocular lenses, artificial iris implants, and other cornea-based laser refrac- and Refractive Surgery, lecular markers in ocular melanoma to ophthalmic optics, surgical devices, tive procedures. Retina Clinical Committee provide prognostic information to pa- and surgical outcomes. World Congress of Ophthalmology tients and advance understanding of Dr. Miller runs several clinical trials of 2014 Biannual Meeting Program metastatic disease. Discovery of can- Dr. Miller’s clinical practice focuses artificial iris implants to treat congeni Planning Committee, Cataract Section didate genes from tissue of patients primarily on refractive cataract sur- tal and acquired aniridia. He completed American Society of Cataract undergoing surgical treatment for oc- gery and the surgical correction of the multicenter Ophtec 311 clinical trial. and Refractive Surgery ular melanoma is being explored. This presbyopia and astigmatism with pre- He has an individual device exemption Skills Transfer Subcommittee information will be important to estab- mium technology intraocular lenses. from the FDA to study Morcher GmbH American Society of Cataract lish a better understanding of the bi- He developed an astigmatism man- artificial iris implants. He is the only sur- and Refractive Surgery, ology of metastatic ocular melanoma agement service for treating corneal geon in the United States who is per- Cataract Clinical Committee and help develop better treatments astigmatism at the time of cataract mitted by the FDA to implant Morcher Faculty of 1000, Post-Publication for this cancer. New modalities are surgery that optimizes postoperative devices at this time. He is also study- Peer Review, Lens Disorders Section being investigated to predict, detect, uncorrected visual acuity. He devel ing a custom artificial iris implant from International Editorial Board, and ultimately treat choroidal mela oped a nomogram for peripheral cor- Dr. Schmidt Intraocularlinsen, a subsid- Oftalmologia Em Foco noma metastasis. neal relaxing incisions and participated iary of HumanOptics AG. All of these in the clinical trial of the world’s most devices are showing promising results Column Editor, American Society of Cataract and Refractive Surgery, Surgical Approaches to popular toric intraocular lens. He de- in patients who suffer from congenital EyeWorld Magazine Vitreoretinal Disease and Cancer scribed a nonparametric multivariate and acquired iris defects. Editorial Board, Cataract and Dr. McCannel is both a vitreoretinal technique for comparing astigmatism He is also an investigator in the Cal- Refractive Surgery Today surgeon and an ophthalmic oncologist. outcomes between treatment groups. houn Vision light adjustable lens study She manages the spectrum of vitreo- Editorial Board, American Academy of and the Alcon high-power toric lens Ophthalmology, EyeNet Magazine retinal disease in addition to the surgi- post-market approval study. cal management of ocular melanoma, Reviewer for many scientific journals allowing patients to benefit maximally from her wide range of surgical prog- Research Grants nostic and therapeutic expertise. Alcon Laboratories, Inc.: Post Approval Health Psychology and Study of the Acrysof IQ Toric High Vitrectomy with silicone oil placement Ocular Melanoma Cylinder Power Intraocular Lens (IOL), is a novel therapeutic strategy, which Central to incorporating an integra- 4/17/12–2/9/16 was discovered at UCLA to reduce ra- tive approach to health care, the Calhoun Vision, Inc.: A Prospective diation exposure to the healthy struc- concerns and wishes of the patient Randomized Controlled Multicenter as a whole are important aspects of Clinical Study to Evaluate the Safety tures of the eye during plaque surgery and Effectiveness of the Light for melanoma treatment. Dr. McCan- cancer management. In collaboration Adjustable Lens, 7/26/12–10/21/15 nel offers this potentially sight-saving with the UCLA Department of Health Clinical Research Consultants, Inc.: technique to patients who need radi- Psychology and the Jonsson Compre- Safety and Effectiveness of the ation treatment. hensive Cancer Center, Dr. McCannel Customflex Artificial Iris Prosthesis for works closely with health psycholo- the Treatment of Iris Defects (Al-001), gists who are interested in providing 6/12/14–6/14/16 clinical care while researching factors, which predict psychological adjust- ment to cancer.

56 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 57 Honors Honors Bartly J. Mondino, MD Honored for ten years of service Kouros Nouri-Mahdavi, MD, MSc Received an American Academy of as Executive Vice President of the Ophthalmology Achievement Award at Association of University Professors of the October 2014 American Academy Bradley R. Straatsma, MD Endowed Chair in Ophthalmology Ophthalmology at their January 2015 Assistant Professor of Ophthalmology of Ophthalmology annual meeting in annual meeting in Tucson, Arizona. Chicago, Illinois. Distinguished Professor of Ophthalmology Member of the Stein Eye Institute Chairman of the UCLA Department of Ophthalmology Public Service Public Service Member of the UCLA Brain Research Institute Medical Advisory Board Member, Member, American Academy of Braille Institute Ophthalmology Glaucoma Registry Director of the Stein Eye Institute RESEARCH SUMMARY Measures Working Group Board of Trustees Member, Association of University Professors Role of Structural and Functional Measurements for Member, American Glaucoma Society of Ophthalmology Patient Care Committee, Detection of Glaucoma and Its Progression Document Subcommittee RESEARCH SUMMARY Executive Vice-President, Association of University Professors Glaucoma Section Editor, Cornea and External Ocular Diseases and of Ophthalmology Dr. Nouri-Mahdavi’s research is fo- Dr. Nouri-Mahdavi is also interested in Journal of Vision and Eye Research cused on improving methods to de- investigating the structure-function re- Immunological Disorders Editorial Board Member, Ophthalmic tect early glaucoma and glaucoma pro- lationships using the aforementioned Member, Residency Program Surgery, Lasers and Imaging Evaluation Committee gression with spectral-domain optical macular structural and functional mea- Dr. Mondino’s research activity is focused on cornea-external ocular diseases, Editor, Association of University coherence tomography (SD-OCT) and sures. An ongoing study in the Glau- Member, Stein Eye Institute with particular emphasis on immunological disorders. He has studied the role of Professors of Ophthalmology, various perimetry techniques. More coma Division is aimed towards mea- Electronic Medical Record News & Views Implementation Committee lymphocytes and the complement system in the immunopathogenesis of anterior specifically, he is interested in detec- suring the variability of macular OCT segment diseases. In addition, a model of staphylococcal hypersensitivity lesions Board of Directors Member and tion of glaucoma progression in pa- measurements in glaucoma patients Member, Research Committee, of the cornea was explored as well as the immune response to staphylococcal Vice President, National Alliance for American Glaucoma Society Eye and Vision Research/Alliance for tients with advanced disease. SD‑OCT and normal control subjects. endophthalmitis. Other research interests included corneal dystrophies, peripheral Eye and Vision Research has revolutionized glaucoma imaging, Volunteer for EyeCare America corneal ulcers, bullous diseases of the skin and mucous membranes, collagen and Dr. Nouri-Mahdavi is currently ex- Provides ophthalmic patient screening shields, and contact lens-related corneal ulcers. Research Grants ploring the role of macular imaging for at annual Los Angeles charity clinic Research to Prevent Blindness: detection of glaucoma progression. events Departmental Unrestricted Grant Editorial Board Member, Journal of Award (Annual), 1/1/12–12/31/15 Ophthalmic and Vision Research Reviewer for many scientific journals

Research Grants America Glaucoma Society: Intra-Session Variability of Regional Macular Thickness Measurements, 3/1/15– 3/31/16 Fight for Sight, Inc. (Prevent Blindness America): Amini, Navid: Influence of the Disc Size on the Anatomical Relationship of the Clinical Disc Margin and Bruch’s Membrane Opening, 7/1/14–6/30/15 National Eye Institute: Detection of Glaucoma Progression with Macular OCT Imaging, 7/1/12–6/30/17

58 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 59 Public Service Public Service Steven Nusinowitz, PhD Editorial Board Service, Stacy L. Pineles, MD Member, Department of Current Eye Research Ophthalmology Residency Training Committee and Department of Associate Professor of Ophthalmology Grant Reviewer: Foundation Fighting Assistant Professor of Ophthalmology Ophthalmology Residency Blindness, Medical Research Council Selection Committee Co-Director of the Visual Physiology Laboratory of Canada, Wellcome Trust, Member of the Stein Eye Institute Matilda Zeigler Foundation, and Associate Residency Director, Director of the Live Imaging and Functional Evaluation (LIFE) Core National Eye Institute (ad hoc) Department of Ophthalmology Member of the Stein Eye Institute Scientific Advisor: The Mouse Mutant Secretary/Treasurer, UCLA Stein Eye Resource, The Jackson Laboratory; RESEARCH SUMMARY Institute Alumni Association, Novartis Pharmaceuticals; Allergan, Department of Ophthalmology Inc.; and Isis Pharmaceuticals, Inc. Pediatric Neuro-Ophthalmology, Amblyopia, and Member, Research Committee, RESEARCH SUMMARY Data Safety Management: Neurologic Causes of Strabismus American Academy of Pediatric New Drug Investigations, Ophthalmology and Strabismus Mechanisms of Retinal Degeneration Isis Pharmaceuticals, Inc. Dr. Pineles’ research interests include Member, Professional Education Reviewer for many scientific journals evaluating the surgical outcomes of Committee, American Academy Dr. Nusinowitz’s primary research in strabismus surgery and studying pe- of Pediatric Ophthalmology terest is focused on understanding and Strabismus diatric optic nerve diseases. With her the cellular contributions to noninva- dual training in pediatric ophthalmol- Member, Adult Strabismus Task Force, sive measures of visual function and ogy and neuro-ophthalmology, she American Academy of Pediatric defining the sites and mechanisms of Ophthalmology and Strabismus has a special interest in pediatric disease action in inherited retinal and neuro-ophthalmic diseases, as well Member, Young Neuro- visual pathway disorders. His main as adult patients with amblyopia and Ophthalmologists Committee, approach to gaining an understanding North American Neuro-Ophthalmology neurologic causes of strabismus. of the site and underlying mechanism Society of disease action in humans is to Member, Walsh Committee, study the patterns of electrophysio- North American Neuro-Ophthalmology logical and psychophysical responses Society obtained from mice in which the dis- Member, Ophthalmic Technology ruption of different cells or pathways Assessment Committee Pediatric Ophthalmology and Strabismus, in the visual system are specifically American Academy of Ophthalmology targeted by genetic manipulation. By comparing the patterns of responses Reviewer and editorial board member for many scientific journals in human disease with the patterns of responses from rodents with target- Research Grants ed cellular disruption, Dr. Nusinowitz Jaeb Center for Health Research: is able to test hypotheses about the Pediatric Eye Disease Investigator underlying pathophysiology in human Group (PEDIG), 2/28/11–12/31/18 disease and to provide a mechanism NIH/National Eye Institute: for the development of specific diag- Binocular Summation in Strabismus, nostic tools that are sufficiently sen- 9/1/11–8/31/16 sitive for early detection and better Research to Prevent Blindness, Inc.: diagnosis of clinical disease. RPB Walt and Lily Disney Award for Amblyopia Research, 7/1/14–6/30/19 University of California, Riverside: Integrating Perceptual Learning Approaches into Effective Therapies for Low Vision: 9/1/13–7/31/15

60 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 61 Honors Public Service Natik Piri, PhD Recipient of the 2015 Spitzer Grant Pradeep S. Prasad, MD Reviewer for the scientific Research Program award for support journal Ophthalmology of groundbreaking medical research Associate Professor of Ophthalmology at UCLA. Health Sciences Assistant Clinical Professor Ophthalmology Clerkship Director at the UCLA School of Medicine Member of the Stein Eye Institute Chief, Division of Ophthalmology, Harbor-UCLA Medical Center Public Service Editorial Board Member, Journal of Member of the Stein Eye Institute Synthesis Theory and Applications, Advances in Medicine: Ophthalmology, RESEARCH SUMMARY and the Journal of Neurophysiology and Neurological Disorders Retinal Ganglion Cell Biology, Glaucomatous RESEARCH SUMMARY Neurodegeneration, and Neuroprotection Reviewer for many scientific journals Vitreoretinal Surgery and Disease Management The main directions in Dr. Piri’s re- Another area of investigation focuses Dr. Prasad specializes in the medi- search are defining the mechanisms on understanding the degeneration of cal and surgical management of dis- leading to retinal ganglion cell (RGC) RGCs and their axons, which is a hall- eases of the retina and vitreous. His degeneration in glaucomatous neurop mark of glaucoma. Dr. Piri’s laboratory research is focused on teleretinal athy; developing strategies for preserv- is analyzing retinal gene expression screening for diabetic retinopathy, ap- ing RGCs against neurodegeneration; profiles from the glaucoma model plications of wide field fundus photog and identifying and character izing the with the aim of identifying factors in- raphy for retinal vascular disease, and genes critical for RGC function and in volved in the initiation and execution health care delivery for low-income tegrity. Different types of RGCs have of RGC apoptosis. Study results have populations. Dr. Prasad also provides been identified based on their mor implicated several members of the clinical supervision and instruction phological and physiological character crystallin superfamily in this process, to resident physicians and vitreoret- istics, yet current knowledge of RGC including alpha crystallins. Dr. Piri is inal fellows as chief of the Division molecular biology is very limited. Char- also studying the involvement of oxi- of Ophthalmology at Harbor-UCLA acterization of RGC-expressed genes dative stress and proteins of the thio Medical Center. is fundamental to a better understand- redoxin system, particularly in RGC ing of normal RGC physiology and degeneration in the glaucoma model, pathophysiology. and the neuroprotective effects of these proteins against glaucomatous RGC death.

62 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 63 Public Service Honors Alapakkam P. Sampath, PhD Member, Association for Research David Sarraf, MD Awarded membership in the American in Vision and Ophthalmology Ophthalmological Society in May 2015 Publications Committee for his thesis, “Retinal pigment Associate Professor of Ophthalmology Health Sciences Associate Clinical Professor of Ophthalmology epithelial tears in the era of intravitreal Member, Neurotransmitters, pharmacotherapy: risk factors, Member of the Stein Eye Institute Transporters, Receptors and Member of the Stein Eye Institute pathogenesis, prognosis and treatment Calcium Study Section, NIH (an American Ophthalmological Society thesis),” published in the journal Research Grants Transactions of the American Ophthalmological Society in July 2014. RESEARCH SUMMARY National Eye Institute: Functional RESEARCH SUMMARY Characteristics of Rod Pathways Molecular Mechanisms Underlying Early Visual Processing in the Retina, 2/1/14–7/31/16 Age-Related Macular Degeneration and Retinal Imaging Public Service Associate Editor: Retinal Cases and University of Southern California: Brief Reports, OSLI Retina The Sampath laboratory is interest- Experimental and Clinical Dr. Sarraf has published approximate- dry AMD and for the research trial to ed in understanding the molecular Investigations of Retinal Stimulation, ly 100 research papers, case reports, evaluate the new antiVEGF drug Abi Editorial Board Member, Retina mechanisms underlying early visual 10/1/13–2/28/15 reviews, and book chapters, and he cipar to treat wet AMD. Committee Member: BCSC Retina processing. In particular, the focus has been awarded achievement and Committee, American Academy of laboratory researchers has been secretariat awards by the American Dr. Sarraf has become a leading of Ophthalmology on elucidating mechanisms that set Academy of Ophthalmology. authority and researcher in retinal imaging, specifically optical coherence Executive Committee and Chair the sensitivity of night vision. Night of the Young Member’s Committee, blindness, or nyctalopia, is a condition Dr. Sarraf’s research focus is the dry tomography (OCT), and was the first Macula Society that results from abnormal signaling and wet form of age-related macular to describe ischemia of the deep ret- degeneration (AMD), and he has pub- Member: The American Society of by the rod photoreceptors, or the retinal capillary plexus, as identifiedby Retinal Specialists, Retina Society, inal circuits that process rod-driven lished numerous papers studying the spectral domain OCT, and its asso- Macula Society, and Gass Club imaging of pigment epithelial detach- ciation with various retinal disorders signals. Using physiological and ge- Co-Director: Pacific Retina Club netic methods, the laboratory studies ment and retinal pigment epithelial including retinal venous and artery oc- and International Retinal Imaging signal transmission in these retinal tears in wet AMD and their response clusion. Dr. Sarraf has also pioneered Symposium to therapy. Dr. Sarraf is principal in- the clinical application of OCT angiog- rod pathways to identify how these Reviewer for many scientific journals processes are optimized to allow our vestigator for the AMD study at the raphy in the study of retinal vascular Stein Eye Institute evaluating the ef- disease and wet AMD and is a world exquisite visual sensitivity. Research Grants fect of lampalizumab to reduce the leader on this subject. Gentech Inc.: A Phase III, Multicenter, progression of geographic atrophy in Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, 11/21/14–9/27/18 Southern California Desert Retina Consultants: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment (EVEN Study), 2/7/13–10/21/15

64 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 65 Honors Public Service Steven D. Schwartz, MD Recognized by the American Society Hui Sun, PhD Ad hoc Reviewer, National Science of Retina Specialists in 2014 for Foundation, National Eye Institute outstanding service to the Society’s (United States), Health Research Board The Ahmanson Chair in Ophthalmology scientific and educational programs, Professor of Physiology and Ophthalmology (Ireland), and Medical Research original papers, panel discussions, and Council (United Kingdom) Professor of Ophthalmology instructional courses. Howard Hughes Medical Institute Reviewer for many scientific journals Chief of the Retina Division Member of the Stein Eye Institute Public Service Director of the UCLA Diabetic Eye Disease and Retinal Vascular Center Research Grants Program Committee Member, Director of the Macula Center Association for Research in Vision National Eye Institute: Molecular and Ophthalmology Mechanism of Vitamin A Uptake for Professor-in-Residence of Ophthalmology RESEARCH SUMMARY Vision, 12/1/13–11/30/17 Diabetic Eye Disease Screening, Member of the Stein Eye Institute Venice Family Clinic Molecular Mechanism of Vitamin A Transport for Vision; Howard Hughes Medical Institute: Identification of New Therapeutic Targets Early Career Scientist Award, 9/1/09–8/31/15 Research Grants for Blinding Diseases Advanced Cell Technology, Inc.: Research to Prevent Blindness: RESEARCH SUMMARY A Phase I/II, Open-Label, Multicenter, Ophthalmic Research Award, Prospective Study to Determine the Dr. Sun’s laboratory studies the mo- 1/1/12–12/31/14 Stem Cell Research Safety and Tolerability of Subretinal lecular mechanism of vitamin A trans- Transplantation…in Patients with port for vision and new therapeutic Dr. Schwartz is leading two new in which screening for diabetic retinop- Stargardt Macular Dystrophy (SMD), 3/23/11–2/24/16 targets for blinding diseases such clinical trials testing the use of stem athy is conducted with a nonmydriatic as age-related macular degeneration. cell-derived retinal pigment epithelial camera (a camera that does not re- Advanced Cell Technology, Inc.: Vitamin A is essential for vision be- cells to address vision loss in people quire dilation of the eyes) as part of A Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the cause it is the precursor for the chro- suffering from Stargardt macular dys- each patient’s regular diabetes treat- Safety and Tolerability of Subretinal mophore of photoreceptor proteins trophy and dry age-related macular ment. Results are telecommunicated Transplantation…in Patients with and also plays critical roles in eye degeneration. to specialists at the Stein Eye Institute Advanced Dry (AMD) 4/5/11–2/24/16 development. Plasma retinol binding for interpretation and further action. Advanced Cell Technology, Inc.: protein (RBP) is the principal carrier of Retinal Diseases Research with Retinal Cells Derived vitamin A in the blood and is essential Dr. Schwartz’s primary areas of re- from Stem Cells for Geographic Atrophy Secondary to Myopic Macular for mobilizing the hepatic vitamin A search include early diagnosis and Degeneration, 4/10/14–9/1/16 store. Dr. Sun’s laboratory identified treatment of diseases such as reti- the long-sought RBP receptor as a Gen Vec, Inc.: Long Term Follow-Up nopathy of prematurity (ROP), diabet- Protocol for Genvec Inc. Gene Transfer multitransmembrane protein of previ- ic eye disease, and macular degener- Product Candidates in Clinical ously unknown function. It functions ation. Additionally, his focus includes Development…, 2/27/09–2/26/24 simultaneously as a membrane re- development and evaluation of novel Neurotech Pharmaceuticals, Inc.: ceptor and a membrane transporter medical device technologies, imag- Phase I Multicenter Open Label that mediates cellular uptake of vita- ing technologies, surgical equipment Safety and Tolerability Clinical Trial of min A. His laboratory is using a vari- (including surgical robots), and drug- Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasis ety of techniques to study this mem- delivery systems, with particular em- Type 2, 7/19/11–7/18/17 brane transport system. phasis on diagnostic and treatment applications. Dr. Schwartz’s clinical Lowy Medical Research Institute: Dr. Sun is also identifying new ther- A Natural History of Macular apeutic targets. Specifically, his labo- research focuses on trials of novel (Parafoveal) Telangiectasia, pharmacotherapeutic agents to dis- 9/1/05–12/31/15 ratory recently identified new factors cover treatments for both wet and that protect cone photoreceptor cells Genentech, Inc.: A Phase III, and membrane receptors for a factor dry age-related macular degeneration, Multicenter, Randomized Double- ROP, and diabetic retinopathy. Masked, Sham-Controlled Study to that has broad therapeutic value. The Assess the Efficacy and Safety of overall goal is to uncover novel mech- Through innovative teleophthalmolog- Lampalizumab Administered anisms that protect retina and photo- ical approaches to screen for eye dis- Intravitreally to Patients with Geographic Atrophy Secondary to receptor cells as strategies in treating eases, such as diabetic retinopathy ARMD, 11/18/14–9/27/18 blinding diseases. and ROP, Dr. Schwartz is dedicated to improving both the quality of and access to specialized ophthalmology care. Currently, a collaborative program with UCLA’s Gonda Diabetes Center and Venice Family Clinic is underway,

66 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 67 Public Service Public Service Gabriel H. Travis, MD Scientific Advisory Panel Member, Irena Tsui, MD Committee Member, UCLA Women in the Karl Kirchgessner Foundation Medicine and Science Vision Science Program Charles Kenneth Feldman Chair in Ophthalmology Assistant Professor of Ophthalmology Care Harbor LA Free Clinic Grant Reviewer, National Institutes of Professor of Ophthalmology Health: The Biology and Diseases of Member of the Stein Eye Institute Reviewer for many scientific journals the Posterior Eye Study Section Co-Chief of the Vision Science Division Reviewer, Howard Hughes Medical Associate Director of the Stein Eye Institute Institute Investigators RESEARCH SUMMARY Reviewer for many scientific journals Clinical Vitreoretinal Research RESEARCH SUMMARY Research Grants Biochemistry of Vertebrate Photoreceptors and Bruce Ford and Anne Smith Bundy Dr. Tsui’s research focuses on im- Foundation: 8/16/11–8/15/15 proving clinical outcomes in patients Mechanisms of Retinal Degeneration National Eye Institute: The Role of with retinal diseases. Her areas of Müller Cells in Visual Pigment interest include retinopathy of prema- Dr. Travis’ laboratory uses biochemi- Still another project in Dr. Travis’ lab- Regeneration, 7/1/15–6/30/18 turity, diabetic retinopathy, ultra-wide cal and genetic approaches to study oratory concerns the mechanism of National Eye Institute: Vision Science field imaging, surgical techniques, and the visual cycle and its role in retinal visual-pigment regeneration in cone Training Grant for the Stein Eye studying patient-centered outcomes and macular degenerations. Vision in photoreceptors. Despite the impor- Institute (Principal Investigator), 9/30/11–9/29/16 in veterans. vertebrates is mediated by two types tance of cones, little is known about of light-sensitive cells: rods and cones. how visual pigments are replenished In addition to providing patient care at These cells contain light-detecting mol- to permit sustained vision under day- the Stein Eye Institute in Westwood, ecules called opsin pigments. Detec- light conditions. Recent results from Dr. Tsui also sees patients at the tion of a single light particle bleaches Dr. Travis’ group point to the exis- Doheny Eye Center UCLA–Arcadia. the opsin pigment. Restoring light sen- tence of a new enzymatic pathway sitivity to a bleached opsin involves an for regenerating visual pigments in enzymatic pathway called the visual cones. His group is currently working cycle. Mutations in the genes for many to purify and clone the enzymes that proteins of the visual cycle cause in- define this new biochemical pathway. herited blinding diseases. One project in Dr. Travis’ laboratory studies the function of a transporter protein in rods and cones called ABCA4. Mutations in the human ABCA4 gene cause recessive Star- gardt macular degeneration and cone- rod dystrophy. Dr. Travis’ group generated mice with a null mutation in this gene. Biochemical analysis of the phenotype in these ABCA4 “knock- out” mice led them to the function of ABCA4 in photoreceptors, and the biochemical etiology of Stargardt disease. This understanding suggested a pharmacological strategy to reverse the biochemical defect in patients with Stargardt disease and age-related macular degeneration. A phase II clinical trial is currently underway to test a drug based on this strategy as a treatment for age-related macular degeneration. Another ongoing project in Dr. Travis’ laboratory characterizes Rpe65, which catalyzes the critical isomerization step in the visual cycle. Previously, Dr. Travis and co-workers identified Rpe65 as the retinoid isomerase.

68 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 69 Public Service Honors Federico G. Velez, MD Editorial Board Advisory Panel Member, David S. Williams, PhD Presented with a Distinguished Treatment Strategies—Pediatrics, Service Award by the International The Cambridge Research Centre Society for Eye Research on July 23, Health Sciences Associate Clinical Professor of Ophthalmology Jules and Doris Stein Research to Prevent Blindness Professor of Ophthalmology 2014, in San Francisco, California. Editorial Board Member, Journal of Member of the Stein Eye Institute the American Association of Pediatric Professor of Neurobiology Ophthalmology and Strabismus, Public Service Journal of the Colombian Society of Member of the Stein Eye Institute Scientific Advisory Board Member, Ophthalmology, and Video Journal Foundation Fighting Blindness of Ophthalmology RESEARCH SUMMARY Executive Board Member, Member, American Academy of Sustainability Council of New Zealand Strabismus and Childhood Eye Disorders Ophthalmology, American Association RESEARCH SUMMARY for Pediatric Ophthalmology and Committee Member, ARVO/ Strabismus, Latin American Council of Cell Biology of the Retina and Inherited Retinal Disease International Society for Dr. Velez’s primary research interest Strabismus, Latin American Pediatric Ocular Cell Biology is studying the mechanisms of con- Ophthalmology Society, Colombian Dr. Williams’ laboratory focuses on the Associate Editor, Visual Neuroscience genital and acquired forms of stra- Society of Ophthalmology, and Colombian Society of Pediatric cell biology of photoreceptor and reti- bismus. He has participated in the Ophthalmology and Strabismus nal pigment epithelium cells. His group Research Grants development of guidelines for preop- Reviewer for many scientific journals is especially interested in proteins National Eye Institute: RPE Cell erative assessment and surgical ap- that function in transport and com- Biology of Myosin VIIa, 7/1/09–6/30/15 proaches to patients with convergent partmentalization within these cells. (esotropia), divergent (exotropia), and National Eye Institute: These proteins include those that un- The Photoreceptor Cilium, vertical forms of strabismus, and has derlie Usher syndrome and macular 5/1/13–4/30/18 developed new techniques to treat degeneration. A translational area of pediatric patients with eyelid abnor- Research to Prevent Blindness: his research involves gene therapy Doris and Jules Stein Research to malities and cataracts. experiments aimed at preventing the Prevent Blindness Professorship, 1/1/08–12/31/14 Dr. Velez has recently completed stud- blindness that ensues from Usher syn- ies that apply bioengineering technol- drome type 1B. University of Pennsylvania: Degradative Processes in ogy to the correction of ocular motil- RPE-Photoreceptor Renewal, ity disorders. He has also identified 2/1/14–1/31/16 a new ocular motility disorder in pa- UCLA Broad Stem Cell Research tients with the human immunodefi- Center: IPSC-JSEI Collaboration ciency virus. He provides patient care Project, 4/1/14–8/31/15 at the Stein Eye Institute in West- University of Santa Barbara: wood and the Doheny Eye Center Photoreceptor Disk Membrane UCLA–Orange County. Morphogenesis, 4/1/15–3/31/16

70 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 71 Public Service Public Service Xian-Jie Yang, PhD Ad Hoc Grant Reviewer, Foundation Jie J. Zheng, PhD Ad hoc Member, Program Project Fighting Blindness, National Science Review Committee, NIH National Foundation, Medical Research Council Heart, Lung, and Blood Institute Ernest G. Herman Chair in Ophthalmology and Wellcome Trust in the United Professor of Ophthalmology Kingdom, the Research Grant Council Editorial Board Member, Professor of Ophthalmology of Hong Kong, Biomedical Research Cell Communication and Signaling Member of the Stein Eye Institute Council and National Medical Research Council of Singapore, Israel Science Research Grants Foundation, and the National Science RESEARCH SUMMARY Foundation of China National Institute of General Medical Therapeutic Development in Ophthalmology Sciences, R01 GM100909, Structural Investigation of Focal RESEARCH SUMMARY Standing Member, National Institutes of Health, Biology of the Visual System Adhesion Formation and Disassembly, Development and Disease Therapy of the Retina study section Dr. Zheng’s research is at the inter- The current focus of the laboratory 5/1/2012–4/30/2016 face of biochemistry, computational is to develop proteins and small Editorial Board Member, Visual biology, systems pharmacology, and molecules that can modulate signal Dr. Yang is interested in the molecular and cellular mechanisms underlying retinal Neuroscience, Translational Vision Science & Technology drug discovery with an emphasis on transduction pathways, such as Wnt, development and disease. Her research efforts are directed toward understanding therapeutic development in ophthal- Hedgehog, BMP, and Hippo pathways, Reviewer for many scientific journals how retinal progenitor (precursor) cells become different types of mature retinal mology. Taking advantage of increas- in an effort to better understand the neurons during formation of the retina. To achieve these goals, her laboratory uses ing computer capability, Dr. Zheng’s biological functions of these signaling a variety of molecular and cellular approaches to study genes involved in cell-to-cell research group finds that the combi- pathways and to explore the thera- communication and neuronal differentiation. As important research tools Dr. Yang nation of experimental and compu- peutic potential of these compounds utilizes special laboratory-based viruses to mediate gene transfer and advanced tational studies gives them a unique and proteins. Aiming to establish transgenic technologies. In addition, Dr. Yang’s laboratory is developing stem cell- strength, and on the basis of this new translational research within the based cell therapy for retinal degenerative diseases. Her research will enhance strength, Dr. Zheng’s laboratory has vision research community at UCLA, researchers’ capabilities to manipulate retinal progenitor and stem cells, thereby achieved great successes. the goal of Dr. Zheng’s research is to contributing to the effort to combat retinal degenerative diseases. develop novel therapies for retinal degenerative diseases, glaucoma, and corneal disorders.

72 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 73 Faculty Doheny Eye Center UCLA Through the historic alliance between the UCLA Stein Eye Institute and the Doheny Eye Institute, Doheny physician scientists are now faculty members in the UCLA Department of Ophthalmology. The affiliation introduced the Doheny Eye Center UCLA, Vikas Chopra, MD Brian A. Francis, MD, MS Gad Heilweil, MD Hugo Y. Hsu, MD Alex A. Huang, MD, PhD which provides comprehensive Health Sciences Health Sciences Clinical Professor Clinical Instructor of Ophthalmology Health Sciences Assistant Professor eye care covering the full dis- Associate Clinical Professor Associate Clinical Professor Medical Director, Doheny Eye Center ease spectrum. The Doheny Eye RESEARCH SUMMARY RESEARCH SUMMARY Center UCLA locations in Arca- Medical Director, UCLA–Orange County Doheny Eye Center UCLA–Pasadena RESEARCH SUMMARY dia, Orange County, and Pasa- Degenerative Retinal Disease Glaucoma RESEARCH SUMMARY Cornea and dena offer neighborhood conve- Dr. Heilweil’s research activities in- Dr. Huang’s clinical specialties in- RESEARCH SUMMARY External Diseases nience and expanded ties with Glaucoma clude stem-cell therapy for degenera- clude glaucoma, minimally invasive Glaucoma patients, community ophthal- Dr. Francis’ clinical specialties are glau- tive retinal disease; retinal and uveal Dr. Hsu specializes in corneal infec- glaucoma surgery, trabeculectomy, mologists, and local physicians Dr. Chopra specializes in glaucoma, coma and cataract. His research activ drug toxicity; and pharmacokinetics tion and inflammation, corneal trans- glaucoma drainage devices, cyclode- whose patients require ophthal- and his research activities include ad- ities include: innovative glaucoma sur- of intravitreal drugs. In addition to plantation, anterior segment reconstruction, and complex cataracts. His mic care. vanced optic nerve and retinal nerve geries, minimally invasive glaucoma providing patient care at the Doheny struction, and cataract surgery. His research activities involve character- fiber layer imaging for early glaucoma surgery, novel visual field techniques, Eye Center UCLA, Dr. Heilweil sees research interests include corneal izing post-trabecular meshwork and detection, as well as development glaucoma diagnostic and functional patients at the Stein Eye Institute infection, ophthalmic antibiotics, and scleral changes in glaucoma, optical and validation of novel parameters for imaging, anterior segment imaging in Westwood. cataract extraction. coherence tomography visualization use in anterior segment optical coher- (ultrasound biomicroscopy and Fouri- of aqueous humor outflow pathways ence tomography devices as principal er domain optical coherence tomogra- PRACTICE LOCATIONS PRACTICE LOCATIONS in the eye, and angiographic visualiza- investigator at the Doheny Image phy), and glaucoma laser surgery. Doheny Eye Center UCLA–Arcadia Doheny Eye Center UCLA–Arcadia tion of aqueous humor outflow in the Reading Center. Dr. Chopra also eval- eye. His goal is to provide the most Doheny Eye Center UCLA– Doheny Eye Center UCLA– uates laser and surgical techniques Research Grants Orange County Orange County individual centric care, and through for the management of glaucoma. Quark Pharmaceuticals Inc.: Phase IIA the use of research, develop means Doheny Eye Center UCLA–Pasadena Doheny Eye Center UCLA–Pasadena Double-Masked Randomized Sham to customize glaucoma management PRACTICE LOCATIONS Controlled Trial Of Qpi-1007 Delivered by and surgery for each patient. a Single Intravitreal Injection to Subjects Doheny Eye Center UCLA–Arcadia with Acute Primary Angle-Closure Research Grants Doheny Eye Center UCLA–Pasadena Glaucoma (APACG), 9/25/14–9/24/16 American Glaucoma Society: Real-time PRACTICE LOCATIONS Imaging of Aqueous Humor Outflow, 1/1/15–12/31/15 Doheny Eye Center UCLA–Arcadia National Eye Institute: Discovery and Doheny Eye Center UCLA– Characterization of Anterior Sclera Orange County Pathology in Glaucoma, 9/30/14–9/29/19 Doheny Eye Center UCLA–Pasadena PRACTICE LOCATION Doheny Eye Center UCLA–Pasadena

The Huntington Pavilion is home to the Doheny Eye Center UCLA–Pasadena.

74 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 75 John A. Irvine, MD Anne R. Kao, MD Olivia L. Lee, MD Kenneth L. Lu, MD Peter A. Quiros, MD Daniel B. Rootman, MD, Health Sciences Health Sciences Health Sciences Health Sciences Health Sciences MS Clinical Professor Assistant Clinical Professor Assistant Clinical Professor Associate Clinical Professor Associate Clinical Professor Assistant Professor Medical Director, Medical Director, Doheny Eye Center RESEARCH SUMMARY RESEARCH SUMMARY RESEARCH SUMMARY Doheny Eye Center UCLA UCLA–Arcadia RESEARCH SUMMARY Orbit and Ophthalmic Cornea/External Diseases and Neuro-Ophthalmology RESEARCH SUMMARY RESEARCH SUMMARY Orbit and Ophthalmic Plastic Surgery; Uveitis; Corneal Imaging Specializing in neuro-ophthalmology, Plastic Surgery Cornea and External Diseases Neuro-Ophthalmology Cataract and the clinical specialties of Dr. Quiros Dr. Lee practices two subspecialties Dr. Rootman is an orbit and oph Refractive Surgery are: optic nerve disease, including op- Dr. Irvine’s clinical specialties are cor Dr. Kao specializes in orbit and oph- of ophthalmology: cornea/external dis- thalmic plastic surgery specialist. His tic neuritis and multiple sclerosis; dou- nea and external diseases (eg, tumors, thalmic plastic surgery, and neuro- eases and uveitis. She has particular Dr. Lu specializes in cataract and re- clinical expertise includes Graves dis- ble vision and adult strabismus; eye infections), anterior segment surgical ophthalmology. Her clinical specialties interest in inflammatory ocular sur- fractive surgery, and his research ac- ease, orbital surgery, orbital tumors, pain, headache, and idiopathic intra- consultation, and prosthetic replace- include ptosis (drooping eyelids), eye- face disease, corneal melts, pterygia, tivities are focused in the same areas. ptosis, lacrimal disorders, blepharo cranial hypertension; Graves disease; ment of the ocular surface ecosystem lid tumors, orbital tumors, thyroid eye and anterior segment complications plasty, blepharospasm, Botox®, cos- Practice Location orbital inflammatory syndromes; and (PROSE). His research activities focus disease, blepharospasm, optic nerve of uveitis. Dr. Lee performs all types metic dermal fillers, endoscopic eye- stroke. Dr. Quiros’ research activities on ocular infections. disorders, optic nerve sheath fenes- of corneal transplants (eg, penetrat- Doheny Eye Center UCLA–Arcadia brow lift, eyelid surgery, eyelid tumors, include idiopathic intracranial hyperten- tration, strabismus (ie, eye muscle ing, lamellar, endothelial and femto- and trauma. Research activities are sion, headache, ocular myasthenia gra- PRACTICE LOCATIONS disorders), and strabismus surgery. second laser-assisted keratoplasty), on developing and refining patient- vis, Graves disease, optic neuritis and Doheny Eye Center UCLA–Arcadia as well as complex cataract surgery centered outcome measures for sur- PRACTICE LOCATIONS multiple sclerosis, and visual rehabili- in uveitic eyes. gical care; randomized clinical trials in Doheny Eye Center UCLA– tation after stroke. Dr. Quiros was the Orange County Doheny Eye Center UCLA– Dr. Lee’s research interests focus on surgery, including ptosis, Graves orbi- Orange County principal investigator for the recently anterior segment imaging applied to topathy and lacrimal disease; health Doheny Eye Center UCLA–Pasadena completed idiopathic intracranial hyper- Doheny Eye Center UCLA–Pasadena the tear film, cornea, and conjunctiva. economics of eyelid and facial sur- tension treatment trial and is currently With her expertise in corneal imaging, gery; sociodemographics of facial the principal investigator for the longi- a specular microscopy reading center trauma; physiology and pathobiology tudinal idiopathic intracranial hyperten- was developed at the Doheny Image of ptosis; new approaches to surgery; sion treatment trial. Dr. Quiros is also a Reading Center, where she serves as and measurement and assessment member of the Neuro-Ophthalmology an investigator. in medical education. In addition to Researcher and Disease Investigators providing patient care at the Doheny Consortium (NORDIC) and is the local RESEARCH GRANTS Eye Center UCLA, Dr. Rootman sees NORDIC director. Xoma (US) LLC: A Randomized, Double- patients at the Stein Eye Institute Masked, Placebo-Controlled Study of the in Westwood. Safety and Efficacy of Gevokizumab in RESEARCH GRANTS the Treatment of Subjects with Non- National Eye Institute: Long-Term PRACTICE LOCATIONS Infectious Intermediate Posterior or Follow-up of the Cohort from a Pan-Uveitis Currently Controlled with Multicenter, Double-Masked, Doheny Eye Center UCLA– Systemic Treatment, 1/8/13–12/10/15 Randomized, Placebo-Controlled Study Orange County Xoma (US) LLC: A Randomized Double- of Weight-Reduction and/or Low-Sodium Doheny Eye Center UCLA–Pasadena Masked, Placebo-Controlled Study of the Diet Plus Acetazolamide vs. Diet plus Safety and Efficacy of Gevokizumab in Placebo in Subjects with Idiopathic Stein Eye Institute–Westwood the Treatment of Active Non-Infectious Intracranial Hypertension with Mild Intermediate Posterior, or Pan-Uveitis, Visual Loss, 1/7/14–1/31/15 1/8/13–12/10/15 PRACTICE LOCATIONS PRACTICE LOCATIONS Doheny Eye Center UCLA– Doheny Eye Center UCLA–Arcadia Orange County Doheny Eye Center UCLA–Pasadena Doheny Eye Center UCLA– Patient suites at the Doheny Eye Center Orange County The Doheny Eye Center UCLA–Orange County. UCLA–Arcadia. Doheny Eye Center UCLA–Pasadena

76 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 77 SriniVas R. Sadda, MD Alfredo A. Sadun, MD, PhD Deming Sun, MD James C. Tan, MD, PhD

Professor Flora Thornton Chair of Professor Associate Professor COUNTY Olive View-UCLA Medical Center Vision Research SYLMAR President and Chief Scientific Officer, Doheny Eye Institute Vice Chairman, Doheny Eye Center RESEARCH SUMMARY RESEARCH SUMMARY UCLA Research Scientist Glaucoma LOS ANGELES RESEARCH SUMMARY Dr. Sun is a researcher whose pri- Dr. Tan is a dual fellowship-trained Doheny Eye Center UCLA

RESEARCH SUMMARY VENTURA COUNTY Retinal and Macular Diseases mary areas of investigation include glaucoma specialist. He treats the full PASADENA Neuro-Ophthalmology Dr. Sadda specializes in age-related uveitis, autoimmune diseases, optic spectrum of cataract and glaucoma Clinical specialties of Dr. Sadun include neuritis, animal disease models, and conditions, ranging from mild to com- Stein Eye Institute UCLA macular degeneration, hereditary ret- WESTWOOD inal degenerations, diabetic retinopa- neuro-ophthalmology, optic nerve, op- T-cell biology. plex. His treatments and surgeries fo- Doheny Eye Center UCLA thy, venous occlusive disease, tele- tic neuropathies (eg, posterior ische cus on safe and effective outcomes ARCADIA medicine screening and consultation mic optic neuropathy, anterior ische using advanced techniques. Dr. Tan mic optic neuropathy, and traumatic has authored over 100 scientific pa- programs, as well as retinal disease Veteran's Affairs diagnosis and classification. His re- optic neuropathy), Leber hereditary pers, abstracts, book chapters, and Stein Eye Center UCLA Healthcare Center WEST LOS ANGELES search activities include: quantitative, optic neuropathy, toxic and nutrition- books. His research addresses ad- SANTA MONICA automated retinal image analysis; al optic neuropathies, vision in Alzhei- vanced imaging, molecular pathogen- retinal substructure assessments; ad- mer’s, AIDS, and other central ner- esis, drug development, and surgical LOS ANGELES COUNTY ORANGE COUNTY vanced retinal imaging technologies; vous system disorders. Dr. Sadun’s techniques. He has received awards genotype-phenotype correlative stud- research activities focus on human from the National Institutes of Health, ies; and vision restoration technolo visual neuroanatomy; retinal ganglion Research to Prevent Blindness, and Harbor-UCLA Medical Center TORRANCE gies, such as stem cells and pros- cell degeneration and regeneration; the American Glaucoma Society. thetic vision. axon populations in the human optic nerve in development, aging, and dis- RESEARCH GRANTS PRACTICE LOCATIONS ease; and mitochondrial impairments National Eye Institute Role of Trabecular Meshwork Contractility in Modulating Doheny Eye Center UCLA–Arcadia as a cause of optic neuropathy and other forms of neurodegeneration. Outflow Resistance, 9/1/14–8/31/15 Doheny Eye Center UCLA Doheny Eye Center UCLA–Pasadena ORANGE COUNTY PRACTICE LOCATIONS UCLA Ophthalmology PRACTICE LOCATION Doheny Eye Center UCLA–Arcadia LA and Beyond Doheny Eye Center UCLA–Pasadena Doheny Eye Center UCLA–Pasadena

From the westside to the eastside and south to Orange County, access to the UCLA Department of Ophthalmology physicians you know and trust has never been easier.

78 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 79 STEIN EYE INSTITUTE MEMBERS hypothesis that certain neuropeptides is being developed and pioneered by Dario L. Ringach, PhD neuron with receptors. He is studying Navid Amini, PhD BASED AT OTHER SITES are modulators of retinal neurons and Dr. Coleman at the Institute’s Center the mechanisms by which the synap- Professor of Neurobiology Assistant Research Ophthalmologist circuitry that influence light and dark for Eye Epidemiology. and Psychology, tic vesicles attach (“dock”) to the pre- adaptation; they also influence retinal synaptic membrane. He uses structur- James W. Bisley, PhD Biomedical Engineering Program RESEARCH SUMMARY circuitry that mediates form vision. al (electron microscopy), biochemical, Member of the Stein Eye Institute Associate Professor of Neurobiology Other experimental work has investi- Antoni Ribas, MD and electrophysiological techniques Mobile Health and Psychology gated the photoreceptor synaptic triad, Professor of Medicine, Surgery, and RESEARCH SUMMARY in an attempt to identify, purify, and Dr. Amini’s research interests lie in Member of the Stein Eye Institute a specialized synaptic complex that is Molecular and Medical Pharmacology characterize the channels and trans- the area of mobile health. He devel- the site of initial transfer of visual in- Visual Perception porters of both junctions in an effort to ops signal-processing techniques in Member of the Member of the Stein Eye Institute Brain Research Institute formation from photoreceptors and is and Neurophysiology increase understanding of the mecha- ophthalmic research, and more spe- critically important for visual process- RESEARCH SUMMARY Dr. Ringach’s research focuses on nisms mediating cell communication. cifically, he utilizes such techniques RESEARCH SUMMARY ing. Experimental studies are testing the relationship between eye move- in quantitative assessment of major the idea that a vesicular mechanism The Immune System and ments and visual perception, as well ocular diseases, including glaucoma. Cognitive Processing of Oncogene-Targeted Therapies Visual Information underlies transmitter release from hor- as how motor planning and execution, In addition, Dr. Amini investigates the izontal cells in this triad to mediate in the Treatment of Cancer such as reaching, grasping, navigat- PROFESSIONAL RESEARCH behavior of non-visual sensory sys- Dr. Bisley’s research revolves around SERIES feedback and feed forward signaling, Dr. Antoni Ribas conducts research ing, and adjusting body posture, is tems and the effects of low vision on understanding the neural mechanisms which is critically important for the for- focused on melanoma, an aggres- influenced by visual information and activities of daily living. underlying the cognitive processing mation of visual receptive fields. These sive form of skin and eye cancer. His impaired vision. In collaboration with Novruz Ahmedli, PhD of visual information. These cognitive Dr. Amini was recipient of the April investigations are fundamental steps research aims at developing more a team of neurosurgeons at UCLA, processes include visual perception, Associate Research Ophthalmologist 2015 Chancellor’s Award. The Honor- in establishing the retina’s functional effective and less toxic therapies for Dr. Ringach’s laboratory is also record- visual memory, and visual attention. ary Mention acknowledges achieve- organization and provide the basis for patients with advanced melanoma by ing the brain activity of patients with RESEARCH SUMMARY His recent work has focused on how ments in postdoctoral research at understanding the pathophysiology of studying how the immune system epilepsy who are undergoing clinical the responses of neurons in the pos- Studies on Müller Cells UCLA. retinal dysfunction. can be effectively used to fight cancer evaluation for surgical treatment. This terior parietal cortex are involved in and also how targeted therapies can unique opportunity is shedding new Zbed4 is a multifunctional protein that the allocation of visual attention to specifically block cancer genes. His light into the processes involved in plays a key role in the cells where it neurons in visual cortices and how Barry L. Burgess, BS Patrick T. Dowling, MD, MPH projects include laboratory and clinical object recognition and perception. is expressed. Dr. Ahmedli’s results they guide eye movements in goal- translational research in adoptive cell indicate that this important protein Research Specialist I directed visual search. Chairman of the UCLA Department of Family Medicine transfer therapy using T-cell receptor appears early in embryonic life and engineered lymphocytes designed to Guido A. Zampighi, PhD while in mouse retina it is detected RESEARCH SUMMARY Kaiser Permanente Endowed only in Müller cells, in humans it is ex- Nicholas C. Brecha, PhD Professor of Community Medicine seek out melanoma cells, with the Professor of Neurobiology Degenerative Retinal application of molecular imaging and pressed in cones and Müller cells. In Disease Research Professor of Neurobiology Member of the Stein Eye Institute Member of the Stein Eye Institute addition, he has found that the length advanced monitoring of the immune Mr. Burgess provides research sup- and Medicine system to better study how it can and shape of Müller cell processes Health Care Policy and Access RESEARCH SUMMARY port for the Photoreceptor/RPE Cell Vice Chair of the Department depend on the levels of Zbed4. Dr. for Underserved Populations fight cancer. Another way to engage Biology Laboratory of Dr. David Wil- of Neurobiology an anti-cancer immune response is Intercellular Junctions Ahmedli’s work aims to identify the Dr. Dowling is a member of the liams. Research interests include pro- through the use of immune modulat- and Communication pathway that is essential for proper Member of the Stein Eye Institute California Community Foundation’s duction of differentiated RPE cells ing antibodies, in particular by releas- functioning of Zbed4 in Müller cells. Member of the Board of Directors and the Board of A fundamental property of cells or- from human stem cell precursors and ing the immune breaks CTLA4 and Brain Research Institute Trustees at the Charles Drew Univer- ganized in tissues is their ability to developing in vitro models of oxida- PD-1. He is also testing, both in the sity of Medicine and Science. He has communicate with each other via tive stress involved in degenerative Member of CURE: Center for laboratory and the clinic, novel target- Christian Altenbach, PhD Digestive Diseases received numerous grants for interna- highly specialized areas of plasma retinal disease progression. ed therapies blocking cancer-causing Research Ophthalmologist tional medical graduate training, res- membrane contact, called junctions. events that result in melanoma, as RESEARCH SUMMARY idency training, and family medicine Dr. Zampighi is studying the gap junc- well as the potential clinical applica- RESEARCH SUMMARY training. He has made unparalleled tion and the chemical synapse, two Rajendra Gangalum, PhD Functional and Structural tions of nanoparticle delivery of siRNA, contributions to the community and specialized junctions that mediate Structure and Function Organization of the which interferes with gene expres- Assistant Research Specialist III to the training of physicians to sup- electrical and chemical transmission, of Rhodopsin Mammalian Retina sion related to cancer. Dr. Ribas’ goal port the community at a primary level. respectively. The gap junction is com- The membrane protein rhodopsin is a RESEARCH SUMMARY Dr. Brecha’s research focuses on the is to bring new concepts from the lab- He is a prior Commissioner of Public posed of specialized channels con- critical first step in visual transduction, elucidation of the structural organiza- oratory to the clinic to help patients Function and Regulation Health for the Los Angeles County taining small hydrophilic pores that converting light energy into a chem- tion of the outer and inner retina for with advanced melanoma. of Small Heat Shock Department of Health and currently span the two plasma membranes and ical form in the photoreceptor cell understanding visual information pro- Protein aB-crystallin has funding for an innovative program the intervening extracellular space of the eye. To understand this processing by the retina. Morphological in Health and Disease to increase the number of Hispanic (the cell-to-cell channel). He is inves- cess on a detailed molecular level, Dr. studies have defined cell types and physicians in California. Dr. Dowling tigating the high-resolution structure Altenbach is using site-directed spin Dr. Gangalum’s research seeks to classes, and microcircuitry organiza- worked closely with Dr. Anne Cole- of the channels as well as the mech- labeling and electron paramagnetic gain understanding of the physiolog tion in the retina, and neurochemical man on the Remote Area Medical anisms of assembly, insertion, and re- resonance spectroscopy to study the ical function of aB-crystallin in the de- studies have investigated the action Program, which provided care to the trieval of the connexin proteins that structure of rhodopsin in the absence veloping ocular lens and non-ocular tis- of neurotransmitters and neuroactive homeless and indigent in the Los An- form them. The chemical synapse is of light, as well as the changes in sues. aB-crystallin has been shown to peptides in retinal microcircuits. Ex- geles community. Dr. Dowling’s pres- composed of a presynaptic neuron structure caused by light. associate with pathologies such as cat- perimental work has clarified the unc-f ence as a member of the Stein Eye filled with small diameter vesicles aracts, cancer, age-related macular de- tional role of neuropeptides in the in- Institute adds a new dimension that that contain a high concentration of generation (AMD), and various neuro- ner retina and supports the current neurotransmitters and a postsynaptic degenerative diseases. Dr. Gangalum

80 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 81 has discovered that aB-crystallin is a Joanna J. Kaylor, PhD Anna Matynia, PhD is a co-investigator in collaborative re- Alberto C. Ruiz-Morales engineered human embryonic stem Golgi-associated membrane protein, search efforts with the University of cell-derived microvesicles enriched in Assistant Research Ophthalmologist Associate Research Ophthalmologist Research Specialist IV secreted into extracellular medium Pittsburgh and Neurokinetics, Inc. OA1 mRNA/protein for the treatment via exosomes from retinal pigment RESEARCH SUMMARY RESEARCH SUMMARY RESEARCH SUMMARY of ocular albinism. epithelial cells. These findings explain how aB-crystallin is detected in the Characterization and Neural and Molecular Basis Roxana A. Radu, MD Visual Cycle Identification of the Enzymes of Photoallodynia protein-lipid deposits known as dru- Associate Research Ophthalmologist Mr. Ruiz is a molecular biologist who sen in AMD. Dr. Gangalum is using a of the Cone Visual Cycle Dr. Matynia is investigating the mech- has been directly involved in the clon- PROFESSIONAL CLINICAL SERIES gene silencing approach and knock- Bright light vision is solely mediated anisms of photoallodynia, a condition RESEARCH SUMMARY ing and characterization of important out mouse model to investigate the by the cone photoreceptor cells of in which normal levels of light pro- Retinoids Metabolism enzymes critical for the proper func- function of B-crystallin. His recent tioning of the visual cycle, such as the Gavin G. Bahadur, MD a the retina. Recent biochemical evi- duce or enhance ocular or headache in the Eye and findings have demonstrated that B- lecithin retinol acyltransferase (LRAT) a dence supports the existence of a pain. Using a combination of behav- Underlying Mechanisms of Associate Physician Diplomate crystallin silencing (aBshRNA) in reti- new metabolic pathway in the retina ioral, molecular, and cellular approach- enzyme. Another area of investiga- Macular Degeneration Clinical Instructor of Ophthalmology nal pigment epithelial cells inhibits se- for the regeneration of cone opsin es in genetic mouse models, the goal tion is the generation and evaluation cretion and enhances endo-lysosomal visual pigment. Dr. Kaylor is using is to identify mechanisms of light- Dr. Radu’s research focuses on the vi- of knock-out mouse models for LRAT Comprehensive fusion. Dr. Gangalum has also gen biochemistry and molecular biology pain association for different causes sual cycle and underlying biochemical and a second visual cycle enzyme, Ophthalmology, Including erated the transgenic mice model of techniques to characterize and identi- of photoallodynia, including corneal, and molecular mechanisms of macu- the retinol binding protein receptor Cataract, Pterygium, and childhood lamellar cataract. Cataracts fy the enzymes responsible. Her work retinal, and central causes such as lar degeneration. She studies the in STRA6. Currently, Mr. Ruiz is analyzing Glaucoma Surgery in infants are debilitating because has led to the identification of the first dry eye injury, achromatopsia, and vivo association of the complement genes, such as ARMS2 and HTRA1, Dr. Bahadur teaches medical students opacities in the fiber cells are con- vitamin A retinol isomerase, dihydro migraine, respectively. The research negative regulator genes and age- which are thought to be involved in during their ophthalmology surgical fined to the lens nucleus that hinder ceramide desaturase-1 (DES1). Under- findings will form the basis of treat- related macular degeneration (AMD) age-related macular degeneration. subspecialties clinical rotation. He is the transmission of light to the retina, standing the role of DES1 in vision is ment strategies for this condition. development. The mechanism by a full-time comprehensive ophthal- which impairs the development of vi- the current focus of her research. which dysfunction of complement fac- sual cortex in the brain. Dr. Gangalum tor H (CFH, one of the complement Ned Van Eps, PhD mologist at the Stein Eye Center in Santa Monica. is using next generation sequencing, Maria Carolina Ortube, MD regulatory genes) causes AMD is not Assistant Research Ophthalmologist known. To investigate the relationship cell and molecular biology approach- Jacky M. K. Kwong, PhD Assistant Research Ophthalmologist between abnormal build-up of vitamin es to understand the molecular basis Associate Research Ophthalmologist RESEARCH SUMMARY of lamellar cataract pathology in sin- Clinical Director of Research Studies, A-based toxic compounds such as Laura Bonelli, MD Retinal Disorders and Ophthalmic The Molecular Mechanism A2E and the complement system, Associate Physician Diplomate gle lens fiber cells. This model sys- RESEARCH SUMMARY Genetics Division of Transducin Activation tem is the only paradigm available for Dr. Radu will generate a mouse lack- Neuro-Ophthalmology Degeneration of ing both genes ABCA4 and CFH. This The conversion of light energy into rod future investigations on early child- RESEARCH SUMMARY and Comprehensive hood cataracts. Retinal Ganglion Cells complex mouse genetic model will cell impulse responses requires signal and Neuroprotection Ocular Genetics advance understanding of the rela- transfer between a photoreceptor, rho- Ophthalmology Dr. Kwong’s research goal is to iden- Dr. Ortube is a fellowship-trained tionship between lipofuscin accumu- dopsin, and a rod cell protein called Dr. Bonelli provides clinical supervi Sonia Guha, PhD tify novel neuro-protective therapies specialist in pediatric ophthalmology, lation, complement activation, and transducin. Dr. Van Eps is studying the sion to resident physicians at the strabismus, and pediatric genetic con- structural changes in transducin that University Ophthalmology Associates Assistant Project Scientist for glaucoma. To understand the loss photoreceptor degeneration in AMD, of retinal ganglion cells in glaucoma, ditions. She is an investigator in four and it will be a valuable tool for devel- are necessary for signal relay between and teaches medical students during RESEARCH SUMMARY his research focuses on the response clinical and translational research proj- oping new treatments for this disease. the two proteins. The techniques of their ophthalmology surgical subspe- ects related to ocular genetics. The gesite-directed spin labeling and electron cialties clinical rotation. She is collab- Unraveling New Therapeutic and the cell death pathway of retinal ganglion cells in animal models related netics of inherited eye disorders and paramagnetic resonance are used orating on a study to learn and better Targets for Ocular Albinism to optic nerve injury and glaucoma. Stargardt protocols provide clinical Charles “Dutch” Ratliff, PhD to follow transducin conformational understand giant cell arteritis (GCA), Dr. Guha’s research aims to study Dr. Kwong and his colleagues recent- characterization of affected individu- Assistant Project Scientist changes that are important for its an inflammation of the lining of the ar- the genes that may be associated ly found retinal ganglion cell-specific als and at-risk family members. The function and catalytic cycle. teries. GCA frequently causes blurred with the misrouting of retinal gan- proteins. He is utilizing these proteins Genetics of Age-Related Maculopathy RESEARCH SUMMARY or double vision, and if left untreated, glion cell (RGC) axons at the brain’s study focuses on the genetic and en- may result in loss of vision. She is to visualize retinal ganglion cells and Information Processing and optic chiasm in individuals affected vironmental risk factors that contribute Alejandra Young, PhD also a co-investigator for the National to investigate their function in retinal Metabolism in the Retina with X-linked Ocular albinism type 1 ganglion cells during degeneration. He to age-related maculopathy. The proto- Assistant Project Scientist Eye Institute-sponsored study of idio- (OA1). This disease, caused by muta- is also applying pharmacologic tech- cols use state-of-the-art imaging and Dr. Ratliff investigates the mecha- pathic intracranial hypertension. tions in the OA1 gene that is mainly niques to evaluate therapies that en- functional technologies in conjunction nisms by which the retina creates a RESEARCH SUMMARY metabolically efficient representation expressed in the retinal pigment epi hance endogenous neuroprotective with molecular genetic testing to iden- Ocular Albinism thelium (RPE), is also characterized responses against glaucomatous, ex- tify causative genes and mutations. of visual information. This work com- by hypopigmentation and presence of citotoxic, and axonal damage to nerve Dr. Ortube has a special interest in bines techniques from patch-clamp Dr. Young’s research is focused on macromelanosomes in the RPE. How cells, and is utilizing multidisciplinary children born with craniofacial ocular electrophysiology, mathematical mod- the study of the molecular mech- the reduced pigmentation of OA1 methods to understand the protec- disorders. She is also investigating eling, and molecular simulations. anisms that cause ocular albinism RPE exerts its effects on the RGCs tive mechanisms. a simple, noninvasive, rapid method type 1 (OA1), a disease caused by to influence the misrouting of their for widespread screening of diabetics mutations in the OA1 gene and char- axons at the optic chiasm remains using the pupillary light reflex. This acterized by hypopigmentation of the unsolved. Thus, Dr. Guha’s research study aims to identify those who may retinal pigment epithelium and ab findings have the potential to unravel require medical attention and/or thera- normal crossing of the optic axons at new therapeutic targets for OA1. py for diabetic retinopathy. Dr. Ortube the optic chiasm. She is investigating the potential therapeutic use of

82 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 83 Melissa W. Chun, OD Hamid Hosseini, MD Batool Jafri, MD Susan S. Ransome, MD Mehryar “Ray” Taban, MD, STEIN EYE INSTITUTE Associate Clinical Professor Clinical Instructor of Ophthalmology Associate Physician Diplomate Associate Physician Diplomate FACS EMERITUS FACULTY of Ophthalmology Retinal and Macular Assistant Clinical Professor Clinical Instructor of Ophthalmology Assistant Clinical Professor Director of the UCLA of Ophthalmology of Ophthalmology Dean Bok, PhD Vision Rehabilitation Center Eye Disease Cytomegalovirus Retinitis Cornea/External Disease/ Associate Physician Diplomate Dolly Green Chair of Ophthalmology Dr. Hosseini is a clinician and vitreo- Dr. Ransome is participating in a Vision Rehabilitation Refractive Surgery retinal surgeon with special interest in clinical research study involving HIV- Aesthetic and Reconstructive Professor of Ophthalmology Emeritus (Active Recall) Dr. Chun’s clinical research interests retinal and macular conditions, such Dr. Jafri provides patient care as well infected patients who have diabetes Oculoplastic Surgery are in the areas of vision rehabilita- as macular degeneration, diabetic reti- as supervision to resident physicians to see whether there is increased risk Dr. Taban provides clinical supervision Distinguished Research Professor tion outcomes and training techniques nopathy, and retinal detachment. He and cornea fellows at the Stein Eye In- of development or progression of dia to resident physicians and oculoplas- of Neurobiology that maximize visual function. She is a participates in all activities of the Ret- stitute. Her focus is medical and surgi- betic retinopathy when subjects are tic fellows at the Stein Eye Institute. Member of the member of the Low Vision Research ina Division, including research, edu- cal treatment of diseases of the cornea, treated for abdominal lipodystrophy He focuses on nonsurgical and surgi- Brain Research Institute Network, a nationwide collaboration of cation, and clinical care. external disease, and refractive condi- with Egrifta (tesamorelin). cal management of disorders of the Member of the Stein Eye Institute low vision specialists for multicenter tions like near and far sightedness. She eyelid, orbital, and lacrimal system. clinical studies. She is currently partic- also provides general ophthalmic care ipating in the Low Vision Rehabilitation Catherine J. Hwang, MD, and offers cataract surgery with pre Meryl L. Shapiro-Tuchin, MD Michael O. Hall, PhD Outcomes Study, a multicenter pilot MPH mium intraocular lens implants. study that utilizes surveys and ques- Associate Physician Diplomate LECTURER Professor of Ophthalmology Emeritus Associate Physician Diplomate tionnaires to assess outcome and ef- Assistant Clinical Professor Founding Member of the fectiveness of low vision rehabilitation. Assistant Clinical Professor of Ophthalmology Stein Eye Institute of Ophthalmology Monica R. Khitri, MD Kathleen L. Boldy, VMD Associate Physician Diplomate Co-Director of the Ophthalmology Thyroid Eye Disease, Inpatient Consultation Service Lecturer in Ophthalmology Rachel Feit-Leichman, MD Robert S. Hepler, MD Ocular Surface Disease, and Pediatric Ophthalmic Comprehensive Associate Physician Diplomate Eyelid Disorders Diseases and Strabismus Professor of Ophthalmology Emeritus Ophthalmology (Active Recall) Dr. Hwang’s research includes studies Dr. Khitri specializes in the evaluation Cataract Surgery Dr. Shapiro-Tuchin provides clinical su- Founding Chief of the involving thyroid eye disease (Graves and treatment of pediatric ophthalmic Dr. Feit-Leichman divides her time pervision to resident physicians. She Neuro-Ophthalmology Division disease), ocular surface disease, and diseases as well as childhood and between supervising residents and functions as Co-Director of the Oph- eyelid disorders such as blepharo- adult strabismus. She teaches resi- Member of the Stein Eye Institute providing patient care at the Stein Eye thalmology Inpatient Consultation Ser- spasm. Dr. Hwang has a dedicated dents and fellows at both the Stein Institute’s Urgent Care Clinic, Univer- vice, assisting resident physicians in thyroid eye disease clinic to investigate Eye Institute and Harbor-UCLA Medi- sity Ophthalmology Associates; and their evaluation of inpatients admitted the clinical course of the disease and cal Center, where she heads the pedi- Allan E. Kreiger, MD teaching cataract surgery and over- to the Ronald Reagan UCLA Medical treatments, as well as to provide ed atric ophthalmology service. Dr. Khitri Professor of Ophthalmology Emeritus seeing residents at the ophthalmol- Center and the UCLA Medical Center, ucation and patient support. The clinic is also actively involved with the UCLA (Active Recall) ogy clinic of the Harbor-UCLA Med- Santa Monica. is the first in the country to provide Mobile Eye Clinic, bringing high quali- Founding Chief of the Retina Division ical Center. Dr. Feit-Leichman is also an orbital specialist, Dr. Hwang, and ty eye care to children with otherwise active in striving to improve patient a rheumatologist, Dr. Ben-Artzi, who poor access to ophthalmic providers. access to eye care in the greater Los work together to evaluate and treat Bradley R. Straatsma, MD, JD Angeles County Healthcare System. patients affected with thyroid eye Professor of Ophthalmology Emeritus disease. Dr. Hwang will be starting a Tania Onclinx, MD (Active Recall) Karen Hendler, MD blepharospasm clinic in order to better Clinical Instructor of Ophthalmology Founding Chairman of the educate patients, form support groups, Associate Physician Diplomate Department of Ophthalmology Clinical Instructor of Ophthalmology and aid in clinical studies. In addition, Founding Director of the UCLA Mobile Eye Clinic Dr. Hwang collaborates with research- Urgent Care and Stein Eye Institute ers from other departments, such as Clinical Supervision Dr. Hendler works with the UCLA interventional radiology and head and Dr. Onclinx attends at the Urgent Care mobile eye clinic providing services neck surgery, on various projects. Barry A. Weissman, OD, PhD to the underserved children of Los Walk-In service at the Stein Eye Insti- Angeles County as part of the Center tute. She teaches resident physicians Professor of Ophthalmology Emeritus (Active Recall) for Community Outreach and Policy and medical students at the Univer at UCLA. The goal is to determine sity Ophthalmology Associates during their subspecialty clinical rotation. She the need for prescriptive lenses in Marc O. Yoshizumi, MD preschool children and to detect the also provides clinical supervision to presence of amblyopia or other eye resident physicians at Ronald Reagan Professor of Ophthalmology Emeritus conditions or diseases. Dr. Hendler UCLA Medical Center and UCLA Med- Member of the Stein Eye Institute is also participating in epidemiologic ical Center, Santa Monica. studies on the outcome of screening of preschool children. Richard W. Young, PhD Professor of Neurobiology Emeritus Member of the Stein Eye Institute

84 Stein Eye Institute | Faculty Faculty | Stein Eye Institute 85 86 Stein Eye Institute | Faculty Programs Stein Eye Center–Santa Monica University Ophthalmology Patient Care Services The Ophthalmology Inpatient Consul Associates tation Service, operating through the The Institute’s program of care for Stein Eye Center–Santa Monica, pro Comprehensive and subspecialty eye patients encompasses the full range vides consultation and treatment to care in all medical and surgical areas of eye diseases. Nationally and inter pediatric and adult patients admitted of ophthalmology is offered through nationally renowned faculty, along to the hospital’s medical, surgical, and University Ophthalmology Associates. with highly skilled clinical fellows psychiatric inpatient services. Led by Dr. John D. Bartlett is medical direc and physician residents, provide in tor, and ophthalmologists who are tegrated consultation and treatment, Dr. Laura Bonelli, the consultation team consists of physician-residents. members of the UCLA Medical Group including new diagnostic and ther staff the practice. apeutic procedures that have been Subspecialty coverage from faculty is made available through recent scien provided as needed. Stein Eye Institute, Westwood tific advances. Skilled optometrists, 100 Stein Plaza, UCLA orthoptists, technicians, and nurses Los Angeles, CA 90095 support institute ophthalmologists Surgical Services Referral Service: (310) 794-9770 in their efforts. Care is delivered in Emergency Service: (310) 825-3090 distinctive subspecialty treatment Ophthalmic surgery of every kind, After-Hours Emergency Service: centers, service areas, and clinical from cataract extraction to removal laboratories, as well as in specially of ocular and orbital tumors, is per (310) 825-2111 equipped ophthalmic surgical suites. formed in the Institute’s dedicated In addition, the Stein Eye Center– operating rooms. Additionally, laser Santa Monica and the Doheny Eye vision-correction surgeries, such as Stein Eye Center– Center UCLA offer premier eye care laser-assisted in situ keratomileusis Santa Monica services in convenient neighbor (LASIK) and certain aesthetic and The Stein Eye Center–Santa Monica, hood locations. retinal laser surgeries and injection under the direction of Dr. Colin A. Mc- procedures, are performed in desig Cannel, offers the world-renowned nated outpatient procedure rooms. comprehensive and subspecialty eye Faculty members perform surgical care of the Stein Eye Institute at a procedures according to their specific convenient location in Santa Monica. Faculty Consultation Service ophthalmic specialty. They are joined Established in 2011, the Stein Eye by other medical specialists, including Institute faculty members provide Center–Santa Monica features well- anesthesiologists, nurses, and tech direct consultation and treatment, equipped exam rooms, an optical shop, nicians to ensure the highest quality including emerging therapies, to pa on-site parking for easy access, and preoperative and postoperative care. tients through the Ophthalmology testing facilities offering a wide range Faculty Consultation Service. Faculty The award-winning Edie & Lew of examinations, including visual field, members have extensive, advanced Wasserman Building houses the In corneal mapping (corneal topography), training in ophthalmic subspecialties, stitute’s expanded surgery center, intraocular lens measurement, fluores providing referring physicians and pa which enables the Stein Eye Institute cein angiography, spectral domain op tients with a valuable resource for to provide a greater number of surgi tical coherence tomography, and other special eye problems. cal services to patients in need. diagnostic retinal imaging techniques. Six operating suites, a sterile process Nearly all the evaluation, diagnosis, testing, and treatment services avail Inpatient Consultation ing area, procedure treatment units, able at the Stein Eye Institute in Service and postoperative areas serve all ophthalmic specialties, including ret Westwood are offered at the Stein Stein Eye Institute–Westwood ina, glaucoma, cataract, strabismus, Eye Center–Santa Monica by experts The Ophthalmology Inpatient Consul cornea, and oculoplastics. In addition, in retinal disorders, corneal disorders, tation Service, operating 24 hours a there are three procedure rooms for glaucoma, neuro-ophthalmology, and day through the Ronald Reagan UCLA physicians to perform minor laser laser refraction surgery. For surgeries Medical Center, provides consultation treatments and ophthalmologic surgi- and seldom-needed tests requiring and treatment to pediatric and adult cal procedures. specialized laboratories, patients can patients admitted to the hospital’s be referred to the Institute’s main fa medical, surgical, and psychiatric in cility in Westwood. patient services. Led by Dr. Meryl Stein Eye Center–Santa Monica L. Shapiro-Tuchin, the consultation 1807 Wilshire Boulevard, Suite 203 team consists of physician-residents. Santa Monica, CA 90403 Subspecialty coverage from faculty is Telephone: (310) 829-0160 provided as needed. Fax: (310) 829-0170

88 Stein Eye Institute | Patient Care Services Doheny Eye Center UCLA– Doheny Eye Center UCLA– Doheny Eye Center UCLA Orange County Pasadena The UCLA Department of Ophthal The Doheny Eye Center UCLA– The Doheny Eye Center UCLA– mology and the Doheny Eye Institute Orange County opened on May 15, Pasadena, which opened on July 1, formed a historic affiliation in 2014, 2014, in the Orange Coast Memorial 2014, serves as the primary hub of the and patient access to eye care was Medical Center, broadening the reach Doheny Eye Center UCLA. Located immediately broadened across Los of the UCLA Department of Ophthal on the second floor of the Hunting Angeles and into Orange County, mology south to Orange County. ton Pavilion, the Doheny Eye Center with the opening of three Doheny UCLA–Pasadena provides expanded Newly renovated, the Orange County Eye Center UCLA locations: Arcadia, vision care services and clinics devot location, overseen by Medical Direc Orange County, and Pasadena. The ed to retina and cornea; comprehen tor , offers com Doheny and Stein Eye Institutes share Dr. Brian A. Francis sive ophthalmology and oculoplastics; prehensive ophthalmology, as well as a long tradition of excellence, and neuro-ophthalmology; and glaucoma. glaucoma, retina, and cornea subspe through this partnership, the respec Each subspecialty clinic has dedi cialty services. The Doheny Eye Cen tive strengths that gained each Insti cated, state-of-the-art diagnostic laser ter UCLA–Orange County includes 12 tute an international reputation have suites, as well as in-office procedure exam rooms, dedicated diagnostic been combined. The board-certified rooms. More complex procedures are equipment, and inviting patient areas. Doheny ophthalmologists that pa performed at the Huntington Pavilion tients and referring physicians know Doheny Eye Center UCLA– Surgical Suites, which are located on and trust are now members of the Orange County the building’s third floor. UCLA Department of Ophthalmology. Orange Coast Memorial The Doheny Eye Center UCLA is un- The Huntington Pavilion is home to a Medical Center der the supervision of Vice Chairman wide variety of medical practitioners, 18111 Brookhurst St., Suite 6400 Dr. Alfredo A. Sadun and Medi which provides physicians with ease Fountain Valley, CA 92708 cal Director Dr. John A. Irvine. Dr. of referral for patients requiring spe Telephone: (714) 963-1444 SriniVas R. Sadda is the president cialized eye care and provides pa Fax: (714) 963-1234 and chief scientific officer of the tients with the added convenience of Doheny Eye Institute. seeing their doctors and having any necessary services all in one location. Doheny Eye Center UCLA– The Medical Director of the Doheny Arcadia Eye Center UCLA–Pasadena is Dr. As Medical Director of the Doheny Eye Vikas Chopra. Center UCLA–Arcadia, Dr. Kenneth L. Doheny Eye Center UCLA–Pasadena Lu oversees a renovated office that Huntington Pavilion includes 12 exam rooms, dedicated 625 S. Fair Oaks Blvd., 2nd Floor diagnostic equipment, and attractive Pasadena, CA 91105 patient areas. The Center provides Telephone: (626) 817-4747 comprehensive ophthalmology, and Fax: (626) 817-4748 nearly all subspecialty services, includ ing glaucoma, retina, and cornea. The Doheny Eye Center UCLA– Arcadia, which opened April 1, 2014, serves patients in the broader Arcadia region and San Gabriel area, expand ing the UCLA Department of Oph thalmology’s reach in Los Angeles County. The Arcadia Center is easily accessible from two freeways and provides on-site, free parking.

Doheny Eye Center UCLA–Arcadia 622 W. Duarte Road, Suite 101 Arcadia, CA 91007 Telephone: (626) 254-9010 Fax: (626) 254-9019

Patient Care Services | Stein Eye Institute 89 Summary of Patient Care Statistics Center for Community 2013–2014 2014–2015 Outreach and Policy

Faculty Consultation Service The Stein Eye Institute’s Center for Patient visits 101,807 Community Outreach and Policy, under the direction of Dr. Anne L. University Ophthalmology Associates Coleman, is dedicated to the prin Patient visits 28,170 ciple that all individuals deserve the Inpatient Consultation Service best vision attainable. Building upon Patient evaluations 424 the Institute’s long tradition of com munity service and leadership at the Clinical Laboratories interface of ophthalmology and public Procedures 51,278 health, the Center conducts vital re Surgery Services search in public-health ophthalmology Number of procedures 27,750 through the UCLA Center for Eye Epi demiology and provides high-impact Mobile Eye Clinic community-based services, such as Number of patients seen 16,791 the UCLA Mobile Eye Clinic. Ocular abnormalities 16% Number of trips 427 UCLA Center for Eye Epidemiology The UCLA Center for Eye Epidemiol ogy was established in 1997 to pro mote interdisciplinary investigations Aesthetic Center into blinding diseases of public health Research and The Aesthetic Center, under the di importance. It is supported by private Treatment Centers rection of Dr. Robert Alan Goldberg, donations, including an endowment provides services to patients who are established by The Ahmanson Foun dation. The Center maintains and im The Ophthalmology Treatment interested in enhancing their appear proves vision health through public Centers provide subspecialty care ance through aesthetic surgery. Drs. health research and intervention, and from faculty physicians who are Catherine J. Hwang and Daniel B. actively involved in related re Rootman also see patients. Estab serves as a coordinating body for ex search, enabling emerging and ex lished in 1998, the Center has earned panding and sharing information. perimental treatment options to be a reputation for high quality, individual Center members have expertise in epi developed for a gamut of eye dis ized care delivered by surgeons trained demiology, biostatistics, health policy, orders. In addition to comprehen in both ophthalmic and plastic surgery. sive treatment, the centers provide public health, and international health. both patients and physicians with Surgical services include upper and Members draw on their diverse back expert diagnostic and consulta lower eyelid blepharoplasty, endo grounds and complementary skills to tion services for diseases that are scopic forehead lifting, endoscopic promote an understanding of issues difficult to identify and treat. Oph midface surgery, lifting of the neck related to vision health as it affects thalmology faculty work closely and face, liposuction, fat transfer, and individuals, communities, and society. with other specialists, both within skin treatment, as well as dermal fill The Center encourages collaborative the Stein Eye Institute and in other er and other cosmetic injections to research among faculty and inves UCLA clinical departments, to cre tigators from various UCLA depart ate a multidisciplinary team cus smooth facial lines. Minimally invasive ments and other institutions around tomized for each patient’s unique approaches are utilized to provide the the world to advance knowledge re medical needs. optimal aesthetic result. A major goal of the Center is to conduct research lated to the causes and prevention of focused on improving understanding specific eye diseases. of facial aging, surgical healing, and on developing new techniques for aesthetic surgery. Center physicians have pioneered minimal incision sur gical techniques to enhance the nor mal function and appearance of the eyes and face, and often receive re ferrals for complex and re-operative plastic surgery cases.

90 Stein Eye Institute | Research and Treatment Centers UCLA Mobile Eye Clinic completed a study showing its ef studies. This support involves vital, fectiveness in treating corneal ulcers behind-the-scenes activities that fa For more than 40 years, the UCLA that now blind more than 400,000 cilitate the clinical research process. Mobile Eye Clinic has supported pa children worldwide. A second study, Dr. Gary N. Holland serves as Direc tient care and screening programs in which evaluated the solution’s effec tor of the CRC working with full-time neighborhoods where poverty and tiveness in treating fungal corneal administrator, Ms. Ellen Pascual, and vision disabilities intersect. The dedi infections, a major cause of pediatric a Board of Directors composed of cation and hard work of UCLA Mobile blindness in tropical countries, has Department of Ophthalmology faculty Eye Clinic ophthalmologists, techni shown promise in treating the milder members. The CRC has an in-house cians, and volunteers have touched fungal infections. statistician, Fei Yu, PhD. CRC staff the lives of hundreds of thousands members interact with granting agen of individuals. cies and government regulatory bod The UCLA Mobile Eye Clinic, a 39- Center for Regenerative ies, assist with the preparation of grant foot-long bus specially outfitted with Medicine in Ophthalmology applications, participate in the design eye examination equipment, is sup Representing a milestone in the thera and management of clinical studies, ported by charitable contributions to peutic use of stem cells, in 2011, Stein and perform data collection and analy the Stein Eye Institute. The UCLA Eye Institute clinician-scientists suc sis functions for investigators at both Mobile Eye Clinic’s staff of trained cessfully transplanted the first human the UCLA Stein Eye Institute and the ophthalmic personnel provides gen embryonic stem-cell-derived retinal Doheny Eye Institute. eral eye care to over 20,000 under pigment epithelial cells into the eyes Institute faculty members are cur served adults and children annually of legally blind patients with Stargardt rently conducting more than 75 clin throughout Southern California. Ser disease and dry macular degeneration. ical research studies (listed in the Ap vices include vision screening, oph pendices). Patients can volunteer to thalmic examination and refraction, The Center for Regenerative Medicine participate in studies that contribute diagnosis of potential or existing eye in Ophthalmology (CRMO), under the to a better understanding of ocular disorders, treatment of some ocular co-direction of Drs. Sophie X. Deng disorders or that evaluate new, po diseases, and appropriate referral of and Gabriel H. Travis, is building tentially better treatments for various patients who need additional care. upon these efforts, using stem cells for the treatment of corneal disorders diseases of the eye. and retinal degenerative diseases. The Center to Prevent CRMO fosters collaboration between Contact Lens Center Childhood Blindness basic scientists and clinicians, includ ing Drs. Debora Farber, Jean-Pierre The Contact Lens Center, under the The Center to Prevent Childhood Hubschman, Steven D. Schwartz, supervision of Dr. Vivian Phan Shi- Blindness, under the direction of Dr. and Xian-Jie Yang, to translate ad bayama, serves patients with all Sherwin J. Isenberg, is committed vances in basic science research into ophthalmic diagnoses that can be to reducing pediatric blindness. UCLA new and improved clinical therapies. treated with contact lenses. The Cen physicians and basic scientists, in ter’s primary focus is on customized cluding Drs. Gary N. Holland, Ste- Many of the blinding eye diseases, in specialty lenses that visually rehabili ven Nusinowitz, and Irwin Weiss, cluding glaucoma, macular degenera tate conditions, such as keratoconus, collaborate on research, education, tion, and corneal diseases, are due to corneal transplants, corneal scarring, and patient care programs designed the loss of functional tissue. The devel- postrefractive surgery ectasia, ocular to increase awareness and help treat opment of effective and safe individu surface disease, and aphakia. Dr. Shi pediatric blindness. Significant em alized stem-cell-based therapies relies bayama also prescribes contact lens phasis is on the development and on robust basic science, translational, es to address farsightedness, near evaluation of ophthalmic medical and and clinical research. The CRMO sup sightedness, and presbyopia. surgical options for children. ports current stem cell studies and pursues new research programs to The specialty lenses that are avail- Center members are developing a diagnose, treat, and ultimately cure able through the Contact Lens Cen new noninvasive method of mea and prevent blinding eye diseases. ter include rigid gas permeable con suring blood gases from the surface tact lenses, multifocal contact lenses, of the eye, which may be critical in hybrid lenses, scleral lenses, custom preventing retinopathy of prematurity, Clinical Research Center soft lenses, soft lenses for irregu a leading cause of blindness in pre lar corneas, prosthetic soft lenses, mature newborns. In another avenue The UCLA Department of Ophthalmol pediatric aphakic lenses, and adult of research, the Center developed ogy Clinical Research Center (CRC) aphakic lenses. an extremely inexpensive antisep was established in 1998 to provide tic solution to treat pediatric corneal core support to faculty members who infections in developing areas and are conducting patient-based research

Research and Treatment Centers | Stein Eye Institute 91 Dr. Shibayama’s clinical research is inception. In 1980, the Eye Trauma each patient a chance for a brighter focused on keratoconus and scleral and Emergency Center was formally future and a life filled with sight. lenses for the treatment of ocular established to encompass all levels of Stein Eye Institute researchers, surface disease. A large majority ocular trauma within the UCLA hospi Drs. , , of her patients require custom con tal system, including support to affili Anne L. Coleman JoAnn A. Giaconi , , tact lenses and are referred by cor- ated institutions. Jacky M. K. Kwong Simon K. Law , and neal specialists. Kouros Nouri-Mahdavi Natik Patients are commonly referred to Piri, are working with researchers and the Center for such ocular traumas statisticians from the UCLA School of Diabetic Eye Disease and as ruptured globe, intraocular foreign Public Health to identify individuals at Retinal Vascular Center bodies, acute orbital hypertension, greatest risk for vision loss, to devel retinal detachment, chemical burns op and assess therapeutic strategies, Under the direction of Dr. Steven D. of the cornea and conjunctiva, and and to implement new treatments to Schwartz, the Diabetic Eye Disease acute vitreous hemorrhage. The Cen preserve vision. and Retinal Vascular Center provides ter offers complete evaluation and diabetic patients with comprehensive treatment of the traumatically injured ophthalmic care. Established more eye, including vitreoretinal and/or or UCLA Laser Refractive Center than a decade ago, the Center has bital and ophthalmic plastic surgery, The UCLA Laser Refractive Center is contributed significantly to the under anterior segment surgery, and medi under the direction of standing, treatment, and prevention Dr. David Rex cal follow up. Expertise is provided for . Founded in 1991, the Cen of diabetic eye disease. Current focus Hamilton both urgent primary repair and sched ter specializes in refractive surgery of is on innovation in technologies and uled secondary repair. both the cornea and lens of the eye, techniques that expand the standard including clinical and research appli of treatment, such as new lasers and cations of new laser technology. The laser strategies, refinement of micro Gerald Oppenheimer Family Center is one of a few in the United surgical techniques specific to diabet Foundation Center for the States to pioneer investigations into ic eye diseases, and nontraditional Prevention of Eye Disease laser eye surgery. treatment approaches. Established with a generous pledge The UCLA Laser Refractive Center of The Center’s treatment philosophy is from Gail and Gerald H. Oppen- fers all cornea refractive procedures, based upon the systemic nature of heimer, the Gerald Oppenheimer including LASIK and LASEK/PRK, astig- diabetes. Patient care is coordinated Family Foundation Center for the Pre matic keratotomy, conductive kerato with other UCLA departments to ad vention of Eye Disease is committed plasty, and intracorneal ring implanta dress the special needs of diabetics to the discovery of agents and meth tion. Advanced intraocular lens (IOL) that lie outside the field of ophthal ods to prevent ophthalmic diseases. procedures are also available, includ mology. Center treatment interven Areas of study supported by the ing presbyopia-correcting IOLs (multi tions include laser and ophthalmic Foundation include genetic and envi focal and accommodating), toric IOLs, surgery. Recognizing the special care ronmental factors that may cause eye and phakic IOLs. Patients referred to needed for diabetics in any surgical disease, and pharmacologic and natu the Center undergo a complete ocu situation, Center physicians perform ral agents to prevent eye disease. The lar examination that includes corneal all eye surgeries for diabetics, includ Center complements an expanding topographic mapping, wavefront anal ing those specific to the disease, as array of research in many other fields ysis, and corneal biomechanical mea well as vitrectomy, cataract surgery, at UCLA, where rigorous scientific surements to identify conditions that and retinal reattachment. methods are being applied to study may interfere with surgical correction novel approaches to health care. of refractive errors. Candidates for la Eye Trauma and ser or intraocular lens surgery receive Emergency Center Glaucoma Center intensive education to understand the for Excellence in benefits, risks, and alternatives to sur The Eye Trauma and Emergency Cen Care and Research gery. Participation in clinical trials for ter, under the direction of Dr. Robert new refractive devices and techniques Alan Goldberg, provides immediate In the United States, glaucoma is the to treat nearsightedness, farsighted response to ophthalmic emergencies second cause of irreversible legal ness, and presbyopia may be an op through an eye trauma team avail blindness. If glaucoma is detected ear tion for qualified patients. For more able 24 hours a day for consultative, ly, however, vision loss can be slowed information about the UCLA Laser Re medical, and surgical care involving or even prevented. Under the direc fractive Center, go to: www.uclaser. both primary and secondary ocular tion of Dr. Joseph Caprioli, the Glau com and lasik.ucla.edu. repairs. Ophthalmic emergency care coma Center for Excellence in Care has been provided by the UCLA De and Research is committed to giving partment of Ophthalmology since its

92 Stein Eye Institute | Research and Treatment Centers Center faculty members were the Macular Disease Center first to describe cytomegalovirus ret Optic Neuropathy Center The Macular Disease Center, under the initis as an ophthalmic manifestation Under the direction of Dr. Anthony direction of Dr. Steven D. Schwartz, of AIDS; today the Center is a na C. Arnold, the Optic Neuropathy Cen was created in 1994 in response to the tionally recognized site of expertise ter provides multidisciplinary consul growing national incidence of macu- for AIDS-related ophthalmic disease. tation, diagnosis, and treatment for lar degeneration. The Center’s mis Other special clinical and research patients with complex diseases in sion is threefold: provide high-quality programs have been developed in the volving the optic nerve. Established patient care, utilizing standard and de following areas: ocular toxoplasmosis, in 1991, the Center incorporates spe veloping treatments; offer associated uveitis in children, birdshot chorioret cialized facilities and equipment for rehabilitation services, such as low- inopathy, immunogenetics of inflam diagnostic testing and offers consul vision aids and counseling, in order matory eye diseases, unusual corneal tation from neuro-ophthalmologists, to enhance quality of life for patients; infections, and mediators of intraocu orbital surgeons, neurologists, neuro and promote collaborative translation lar inflammation. radiologists, and neurosurgeons. al research between clinicians and ba Patients referred to the Optic Neurop sic science researchers into the cause athy Center receive advanced diag of macular disease. Ophthalmic Oncology Center nostic testing of the orbit and optic Patients with the atrophic or dry form The Ophthalmic Oncology Center, nerve to assist in evaluation. Extensive of macular disease are evaluated and under the direction of Dr. Tara A. analysis of diagnostic data, together often considered for clinical trials, such McCannel, is renowned for its exper with information from the patient’s as the stem cell programs, and their tise in teaching, research, and clinical medical history and comprehensive cases are followed at the Macular management of adult posterior seg physical examination, enables Center Disease Center in conjunction with ment tumors. Established in the early physicians to determine the nature of services offered by the Vision Re 1980s by the Institute’s Founding Di- the disease and devise a treatment habilitation Center. Patients with the rector, Dr. Bradley R. Straatsma, the plan. Treatment may be medical or exudative or wet form of macular dis Center is internationally recognized for surgical depending on the nature of ease are diagnosed and treated with the diagnosis and management of oc the referral and the patient’s disease cutting-edge therapies. Treatment op ular melanoma. The Center serves as status. As part of the Center’s clinical tions for wet macular disease include a hub for national, long-term studies research effort, physicians are refin therapy and participation in clinical investigating ocular melanoma, and ing disease classifications along with studies that are matched to the pa played an important role in the Collab diagnostic and treatment approaches tient’s disease status. A patient coor orative Ocular Melanoma Study spon to further the field of optic neuropathy dinator is available to answer ques sored by the National Eye Institute. and improve options for patients with tions and provide information on an The Center’s clinical goal is success these complex disorders. ongoing basis. ful treatment of the primary eye tu mor. Patients diagnosed with ocular melanoma may be offered highly so Orbital Disease Center Ocular Inflammatory phisticated treatment plans coordinat The Orbital Disease Center, under Disease Center ed with UCLA radiation physicists and the direction of Drs. Daniel B. Root- The Ocular Inflammatory Disease radiation oncologists. Patients may man and Robert Alan Goldberg, Center, under the direction of Dr. also qualify to participate in clinical was founded in 1991. The Center Gary N. Holland, was established in research studies in partnership with brings multidisciplinary expertise to 1985 to coordinate research, educa the UCLA Jonsson Comprehensive the treatment and study of orbital tional activities, and patient-care ser Cancer Center. The Center’s primary diseases arising from trauma, cancer, vices related to a broad spectrum of research goal is to gain a fundamental inflammation, and infection. Care is inflammatory eye disorders, including understanding of the molecular biolo organized around a team of experts in uveitis, infectious corneal ulcers, en gy of metastatic ocular melanoma. In ophthalmology, neuroradiology, neuro dophthalmitis, autoimmune diseases addition to providing genetic prognos surgery, head and neck surgery, radia of the cornea and ocular surface, and tic information to patients on their risk tion oncology, and craniofacial surgery, the ophthalmic manifestations of HIV of tumor metastasis, the Center has bringing to the treatment of orbital disease. The Center has a long history identified key genes associated with diseases a depth of knowledge and of participating in clinical studies and metastatic tumors. experience not available elsewhere in drug-therapy trials that have furthered Southern California. the understanding and treatment of these diseases.

Research and Treatment Centers | Stein Eye Institute 93 The Center provides both medical and surgical management of orbital Vision Proteomics Center Vision Rehabilitation Center diseases. The team performs proce Genes encode the sequences of pro The Vision Rehabilitation Center, un dures that are not usually available in teins, and knowledge of the struc der the direction of Dr. Melissa W. the community, including orbital de ture and function of these proteins Chun with Dr. Steven D. Schwartz compression microsurgery for orbital is required to unlock the secrets of as medical advisor, was established apical tumors, optic canal decompres the cell. That task is now set before to provide rehabilitation to maximize sion, combined interventional neuro current and future generations of visual function and quality of life of pa radiology procedures for vascular scientists, and a new field of study, tients with low vision, defined as best tumors, and bony reconstruction to Proteomics, has been born. It is only corrected vision of 20/70 or worse address traumatic or congenital de through an understanding of protein in the better eye. These outcomes fects. The Center has an active pro function at the molecular level that are accomplished with a rehabilitation gram in thyroid eye disease, where researchers can learn the fundamen plan tailored to each patient’s specific new surgical techniques are evalu tal origins of disease and develop ra needs and goals. ated, and basic science research is tional therapeutic designs to correct The Center provides assistance in the carried out to advance understanding defects in the molecular machinery. about the disease. form of patient consultation and train The Vision Proteomics Center at the ing, including reading and computer Stein Eye Institute, under the direc training, as well as evaluation with Vision Genetics Center tion of Dr. Wayne L. Hubbell, with re the latest low-vision devices that can searchers Drs. Ben J. Glasgow, Dean help patients adapt to their visual re Initially established in 1978 as the Bok, Joseph Horwitz, and Gabriel strictions. The Center utilizes a wide UCLA Retinitis Pigmentosa Registry, H. Travis, has pioneered the develop array of technologically advanced de the Vision Genetics Center, under the ment of site-directed spin labeling–– vices, such as magnifiers, telescopes, direction of Dr. Michael B. Gorin, is the only one of its kind in the world, and digital and computer technology. an integrated clinical and research ushering in a new era of exploration Customized for each patient’s individ program that addresses the full spec of structure/function relationships in ual needs, services may range from trum of hereditary eye disorders. Cen proteins. Research groups at the Stein simple solutions to specialized ap ter members, representing multiple Eye Institute, departments at UCLA, proaches. One unique feature of the disciplines, combine their efforts to and other major institutions through Center is a special “lending library” of understand the underlying molecular out the United States and abroad, select low-vision devices that enables basis of a broad range of ocular con are taking advantage of the singular patients to try devices at home or in ditions, including those involving the opportunities provided by the Vision the office prior to purchase. When development of the eye, cornea, lens, Proteomics Center. appropriate, referrals are provided to extraocular muscles, retina, vitreous, assist independent living through oc and optic nerve. Areas of interest cupational therapy and orientation and include both simple inherited condi mobility training. tions caused by alterations in single genes, as well as conditions in which multiple genetic variations and other risk factors play a role. The Center offers patients and their family members state-of-the-art di agnosis and care of the hereditary eye or vision condition. Services in clude genetic counseling, and when appropriate, DNA testing either as a clinical diagnostic service, a research program, or in combination. The Cen ter’s faculty members collaborate with a number of genetic research groups around the world to ensure that patients can participate in the most advanced research for their particular condition.

94 Stein Eye Institute | Research and Treatment Centers Glaucoma Photography Ophthalmic Photography Clinical Laboratories Laboratory Clinical Laboratory

The Ophthalmology Clinical Labora The Glaucoma Photography Laborato The Ophthalmic Photography Clini tories provide precise measurements, ry, under the direction of Dr. Joseph cal Laboratory, under the direction of photographs, and quantitative stud Caprioli, provides specialized photo Dr. Tara A. McCannel, provides a ies of the eye and the visual system. graphs for new and follow-up patients wide array of photographic techniques Quantitative information of this type to assist the ophthalmologist in the important in patient care, research, enhances patient care by increasing management of patients with glau and teaching. The primary purpose the accuracy of diagnosis and en coma. The GDX Nerve Fiber Analyzer of ophthalmic photography in patient larging the parameters employed utilizes polarized light in place of dila care is to record the present state of to assess the clinical course and ef tion to measure the thickness of the the eye, and in cases of abnormality, fectiveness of treatment. Addition nerve fiber layer. This test is partic to establish a baseline and monitor the ally, the clinical laboratories expand the scope of treatment alternatives, ularly useful in diagnosing new glau patient’s condition over time. Patient promote clinical research, and gen coma. Heidelberg retinal tomography, care services include photographic erally augment the effectiveness of using confocal laser light, measures ad documentation of anterior segment ophthalmic disease management. ditional parameters of the optic nerve diseases involving corneal problems The laboratories are available to all and provides more information on the like growths, infection, and trauma; ophthalmologists in the community. nerve fiber layer. Optical coherence photographs of ocular motility to re tomography utilizes reflected light to cord abnormalities in eye movement; measure the nerve fiber layer as well fundus photography, which captures as to measure macular holes as a pictures of the retina; and diagnostic staging procedure for surgical repair. testing using fluorescein and indo Corneal An ophthalmic fundus camera photo cyanine green angiography, which re Diagnostic Laboratory graphs the optic nerve in stereo. The cords the dynamics of blood flow in Laboratory is conducting clinical stud the eye. The Laboratory also supports The Corneal Diagnostic Laboratory, ies to evaluate the effectiveness of the research and teaching activities of under the direction of Dr. Anthony J. each photographic modality in terms the Stein Eye Institute by preparing Aldave, offers a comprehensive array of predictive accuracy and early de and duplicating graphic materials for of corneal imaging modalities. Ser tection of glaucoma. presentation and publication. vices include imaging of the anterior and posterior corneal surfaces with the Marco OPD-Scan III and Bausch Ocular Motility Clinical and Ophthalmic Ultrasonography and Lomb Orbscan topographers and Basic Science Laboratory Clinical Laboratory the Ziemer GALILEI Dual Sch eimpflug Analyzer, and imaging of the cor- The Ocular Motility Clinical and Basic The Ophthalmic Ultrasonography Clini neal endothelium for assessment of Science Laboratory, under the direc cal Laboratory, directed by Dr. Steven corneal endothelial cell morphology tion of Dr. Joseph L. Demer, records D. Schwartz, performs clinical exam and density using the KONAN Cell- and quantitatively analyzes eye move inations that are useful in diagnosing Chek XL specular microscope. Full- ment abnormalities resulting from oc both ocular and orbital eye diseases. thickness confocal microscopic im ular and neurological disorders, such Diagnostic examinations include stan- aging of the cornea, a useful tool in as ocular myasthenia gravis. Several dardized A-scan, B-scan, and bio the diagnosis of suspected fungal, types of tests are performed. The microscopy. Standardized A-scan is acanthamoebic, and other parasitic Hess test utilizes specialized eye useful in tissue differentiation and infections of the cornea, is performed charts and lenses to assist in the di is commonly employed to diagnose with the Heidelberg HRT3 confocal agnosis of a number of problems, in ocular and orbital tumors, including microscope. This instrument can also cluding double vision. Magnetic scler choroidal melanoma. B-scan provides perform optical pachymetry to non al search coil techniques are utilized location and contour information and invasively measure LASIK residual in clinical research studies to detect is particularly useful in differentiat bed thicknesses and flap thicknesses fine movements not evident through ing vitreous membranes from retinal as well as evaluate the LASIK inter normal visual examination. Another detachment. Ultrasound biomicros face for possible infections, diffuse test involves the visual recording of copy provides exquisitely detailed, lamellar keratitis, and ingrowth. eye movement using a video cam high-resolution views of the anterior era. The Laboratory also engages in segment of the eye and is a critical basic science research to further un- tool for the evaluation of ocular pa derstanding of eye movement, as well thology, especially in opaque corneas. as diseases of the eye, brain, and muscles, and related tissues of the inner ear.

Clinical Laboratories | Stein Eye Institute 95 Biometry and intraocular lens calcula tions are also performed in the Lab oratory, under the direction of Dr. Ralph Levinson. Biometry measures the axial eye length, anterior chamber depth, and lens thickness; intraocular lens calculations are performed to de termine the power of the lens implant for cataract patients.

Perimetry Laboratory The Perimetry Laboratory, under the direction of Dr. Joseph Caprioli, per forms visual field examinations that determine the sensitivity of central and peripheral vision. Examinations are conducted with advanced Hum phrey automated perimetry equip ment. Testing detects visual field defi cits associated with certain kinds of eye diseases such as glaucoma, ret inal disorders, and neuro-ophthalmic conditions. Utilizing pinpoints of light around a perimetry bowl, the test eval uates different areas of the field of vision. Test results are computerized Visual Physiology and compared to a range of normal Clinical Laboratory values by age group. Patterns of di The Visual Physiology Clinical Lab minished fields of vision are related oratory, under the direction of Drs. to specific eye diseases. Perimetry Michael B. Gorin and Steven Nusi testing is employed for diagnostic pur nowitz, quantitatively evaluates the poses and to monitor visual field sensi function of the retina and visual path tivity over time, especially for glaucoma ways. Patients are referred for func patients. Both standard and shortwave tional testing to confirm a specific automated techniques are available, in diagnosis, or in cases where the eti addition to frequency-doubling perim ology is unknown, to rule out alter etry and motion-detection perimetry. native diagnostic possibilities. Elec- trophysiological tests, including both the full-field and multifocal electro retinograms (ERG and mfERG), the electro-oculogram (EOG), and visual ly evoked cortical potentials (VECP), record electrical signals from different layers of the visual system to identify the site responsible for visual symp toms. Psychophysical tests require the participation of the patient in specific tasks to evaluate visual functions like color blindness, contrast sensitivity, and visual acuity. In many cases, both electrophysical and psychophysical tests are performed together to ob tain the optimum amount of informa tion for diagnosis.

96 Stein Eye Institute | Clinical Laboratories also attend several afternoon work center during the course of training, Training Programs shops during which they learn eye thereby ensuring clinical experience examination skills and treatments for with a wide range of problems and pa The Stein Eye Institute and the eye problems that can be managed tient populations. Certification by the UCLA Department of Ophthalmol by non-ophthalmologists. During their American Board of Ophthalmology is ogy jointly provide comprehensive third year of instruction, medical stu a natural objective of the program. training in ophthalmology and vi dents interested in additional training sion science to medical students, and experience can elect to spend two Clinical Rotations residents, and clinical and research weeks of their surgical clerkship on Clinical rotations at the Stein Eye In fellows. The programs encompass the Ophthalmology Service, examin stitute include both general ophthal the gamut of ophthalmic and vi- ing patients in clinic and observing eye mology and subspecialties. In gener sion science education, representing surgeries. During the fourth year of in every level of training and incorpo al, ophthalmology residents work as a struction, a series of advanced clinical rating a full range of subjects in the team, handling clinics, emergencies, electives are available to medical stu study of the eye. The residency pro and walk-in patients. They also serve gram is rated one of the top in the dents who plan eventually to practice as an ophthalmology consult service country. A large patient population ophthalmology as their specialty. for inpatients in the UCLA Medical with diverse vision problems offers Center. Residents assigned to subspe innumerable training opportunities cialty service rotations are provided UCLA Medical Student for both residents and clinical fel with intensive exposure to the various Research Program lows. The availability of more than divisions within the Department, work 15 research laboratories ensures a At the Stein Eye Institute, medical stu ing closely with faculty members in a wide choice of vision science proj ects for all trainees. Predoctoral and dents have taken laboratory and clin private practice environment. At the postdoctoral research fellows partic ical research electives for decades, UCLA-affiliated medical centers, resi ularly benefit from the wealth of new however, there has been no formal dents work in teams that provide both and unfolding research generated by program wherein a medical student general and subspecialty patient care. vision scientists at the Institute. could obtain salary and research sup port. The Medical Student Research Didactic Education Program allows select medical stu Residents receive didactic education dents to familiarize themselves with in the classroom on an ongoing basis. laboratory or clinical vision science Once each week, all residents attend research. Each year, a committee a mandatory half-day program that in selects one or two medical student cludes faculty lectures that, over the researchers to receive salary and re course of the three-year program, cov UCLA search support for six to 12 months in er each of the required subjects in the Medical Student Program the laboratory or clinical research area American Academy of Ophthalmolo of the student’s mentor. The goal of Each academic year, the UCLA De gy Basic and Clinical Sciences Course. the program is to encourage medical partment of Ophthalmology and the These lectures are followed by Grand students to pursue careers in aca Institute extend instruction to UCLA Rounds, which consist of presenta demic ophthalmology. medical students in their second, tion and discussion of specific patient third, and fourth years of instruc cases, and faculty lectures on clinical topics related to ophthalmic subspe tion. Through lectures, small group UCLA Ophthalmology cialties. Throughout the week, clini- discussions, and clinical experience, Residency Program all students have numerous training cal conferences in ophthalmic sub sessions from which to gain knowl The Department of Ophthalmology specialties are held where problems edge about eye diseases and develop conducts an accredited three-year res are presented and discussed. eye examination skills that should be idency program for 24 residents; eight known by all physicians, regardless of new residents begin training each July. Surgery Training their specialties. Those students who The full breadth of ophthalmology train Residents begin to perform surgery in are interested in ophthalmology as a ing is offered, including experience in their first year of training and continue career have additional learning oppor general ophthalmology and ophthalmic to operate throughout their residen tunities in elective courses. subspecialties. Training incorporates cy. Surgical cases are assigned com the resources of the UCLA Stein Eye mensurate with level of training and In their second year of instruction, Institute, Harbor-UCLA Medical Cen experience. First-year residents begin all medical students attend a series ter, Olive View-UCLA Medical Center, in the Institute’s Microsurgery Labo of lectures covering various topics and the Veterans Affairs Greater Los ratory, an organized surgical course related to eye diseases distributed Angeles Healthcare System at West that includes computerized surgical throughout their yearlong Human Bi Los Angeles and Sepulveda. Every res- simulators. This facility is available to ology and Disease course. Students ident has exposure to each medical

Training Programs | Stein Eye Institute 97 residents throughout their training. clinical practice in a five-year or six- science research and have active lab Residents first assist on selected sur year curriculum. EyeSTAR graduates oratories. The scope and nature of the gical cases, and by the end of their are trained to compete not just with training program for each predoctoral residency, they are performing proce clinical scientists but also with top or postdoctoral fellow is developed by dures independently. basic scientists from all institutions. the trainee and his/her faculty mentor. Trainees select their faculty mentors Research from the Vision Research Division of Fellowship in Cornea– External Ocular Diseases and An understanding of and an appreci the Stein Eye Institute or from the Refractive Surgery ation for research are major prerequi David Geffen School of Medicine at sites for assimilating future develop UCLA, College of Letters and Sci Under the direction of Drs. Anthony ments in ophthalmology. Accordingly, ences, School of Public Health, Clini J. Aldave, Sophie X. Deng, David ophthalmic research is an integral com cal Scholars Program, and RAND Grad Rex Hamilton, Batool Jafri, Kevin ponent of residency training. Residents uate School. Miller, and Bartly J. Mondino, one- year fellowships are offered in the are expected to undertake indepen EyeSTAR is recognized by the Nation study of diseases of the cornea, ex dent investigation or to participate al Eye Institute and the Association of ternal eye, anterior segment, and re in ongoing clinical or basic science University Professors of Ophthalmol fractive surgery. Clinical experience research projects in ophthalmology. ogy as a model training program for consists of participation in the cornea Residents present the results of their clinician-scientists in ophthalmology. work at the Stein Eye Institute Clini faculty practices, including surgery, cal and Research Seminar during their and in the care of emergency cornea second and third years of residency. UCLA Clinical Ophthalmology cases at the Stein Eye Institute. Fel They are also encouraged to report and Vision Science lows work in the microsurgical labora their studies at regional and nation Fellowship Programs tory and assist in teaching microsurgi al meetings and publish their results cal skills to ophthalmology residents. The Stein Eye Institute offers particu in scientific journals. Residents with Under the direction of faculty, they larly well-qualified persons the oppor special clinical or research interests also perform primary surgical proce tunity to receive fellowship training in have an opportunity to use elective dures in the UCLA Laser Refractive specific areas of clinical ophthalmolo time to increase their exposure to Center. In addition to in-depth training gy or vision science research. a particular area of ophthalmology. at the Institute, fellows provide medi This time can be spent with full-time Following successful completion of a cal and surgical care to patients at the or volunteer faculty at UCLA or at residency program, a clinical fellow Veterans Affairs Greater Los Ange other institutions. ship combines outpatient, inpatient, les Healthcare System at West Los and surgical experience in an ophthal Angeles and Sepulveda and at Harbor- mic subspecialty. The clinical fellow UCLA Medical Center. Fellows typi EyeSTAR Program assumes increasing responsibility for cally complete an original clinical or laboratory research project, and fre For physicians who are interested in patient care under the supervision of quently co-author a book chapter or academic careers and professional faculty members responsible for the review during their training. leadership as clinician-scientists, the program. In addition to receiving train Stein Eye Institute offers an Ophthal ing from faculty, the fellow instructs Fellowship in Glaucoma mology Specialty Training and Ad medical students and residents. Re vanced Research Program, referred search is considered an important Under the direction of Drs. Joseph to as EyeSTAR, which offers vision aspect of specialty training and a ma- Caprioli, Anne L. Coleman, JoAnn science training combined with an jor prerequisite for assimilating fu A. Giaconi, Simon K. Law, and ophthalmology residency. Appointees ture developments in ophthalmology. Kouros Nouri-Mahdavi, the one- complete a residency program leading Clinical fellows are expected to un year or two-year glaucoma fellow to certification in ophthalmology, as dertake independent investigation or ship provides clinical and laboratory well as laboratory research experience to participate in one of the ongoing experience in glaucoma diagnosis and leading to a doctorate, or postdoctoral research projects in a field related to management. Fellows gain clinical ex training in the event that the trainee their specialty. perience by examining patients in the already has a doctorate. EyeSTAR consultation suite and participating Vision-science fellowship training is trainees work under the guidance of a in the clinical and surgical manage laboratory based and offers both pre faculty advisory panel representing the ment of patients. Fellows work in the doctoral and postdoctoral opportuni trainee’s clinical and research interests. Glaucoma Microsurgical Laboratory, ties to trainees in specific areas of vi participate in microsurgery courses, sion science that encompass a wide The unique program began in 1995 assist in the Glaucoma Clinic, and range of topics. Trainees work under and is geared to physicians commit develop expertise in the various di the supervision of Institute faculty ted to academic careers in ophthal agnostic techniques used in glauco members who are engaged in basic mology, combining basic science with ma treatment through preceptor -type

98 Stein Eye Institute | Training Programs relationships with faculty. Fellows par- to participate in genetic and imaging Fellowship in Orbital and ticipate in glaucoma teaching at the conferences as well as other rele- Ophthalmic Plastic Surgery Stein Eye Institute and affiliated in vant meetings. Fellowships in orbital and ophthal stitutions, present cases at teaching mic plastic surgery, under the over rounds, and prepare presentations for Fellowship in all supervision of Drs. Robert Alan regularly scheduled glaucoma confer Neuro-Ophthalmology Goldberg, Jonathan Hoenig, and ences. Fellows also undertake at least The one-year fellowship in neuro- Norman Shorr, provide training for one research project, which may be ophthalmology, under the direction ophthalmologists who are interested a clinical study or an applied research of Dr. Anthony C. Arnold, involves in specializing in orbital and adnexal project in the laboratory, in cooperation a close preceptor-preceptee relation disorders, and in aesthetic and recon with the faculty advisor. ship, participation in teaching rounds, structive orbitofacial surgery. The two- and work in the private consultation year fellowship program is approved Fellowship in Medical Retina suite. The David Geffen School of by the American Society of Ophthal and Genetics Medicine at UCLA maintains major mic Plastic and Reconstructive Sur This one-year fellowship, under the clinical and research programs in gery. Fellows participate in orbital and directorship of Dr. Michael B. Gorin, neurology, neurosurgery, and neuro ophthalmic plastic surgery outpatient provides clinical knowledge pertain radiology. Fellows attend the weekly consultation, inpatient care, and surgi ing to the diagnosis and management Neurology and Neurosurgery Grand cal procedures at the Stein Eye Insti of a broad array of retinal disorders, Rounds, take an active part in see tute and affiliated hospitals. They also including age-related macular degen ing relevant inpatient consultations participate extensively in the continu eration, diabetic retinopathy, retinal throughout the Medical Center, and ing education and research activities vascular disease, inflammatory reti assist in selected surgical procedures of the Orbital and Ophthalmic Plastic nopathies, drug-related toxic retinop of interest to neuro-ophthalmologists. Surgery Division. In addition to pub athies, and retinal and macular de Attendance at the weekly neuro lishing results of original research in generations and dystrophies. Fellows radiology teaching conferences is en peer-reviewed scientific journals, fel are instructed in the proper use and couraged. Time is allotted for scientif lows complete a formal thesis that interpretation of noninvasive diagnos ic reading and for research activities. partially satisfies the membership re tic tools, and training includes genetic Participation in clinical research, such quirements of the American Society counseling and the proper use of mo as studies of eye movement disorders of Ophthalmic Plastic and Reconstruc lecular genetic diagnostics. Fellows and disturbances of visual pathways, tive Surgery. International research gain experience with a diverse set of is expected. fellows also participate in the pro- interventional skills, including a wide gram annually. spectrum of retinal laser procedures Fellowship in and periocular and intravitreal injec Ophthalmic Pathology Fellowship in Pediatric tion of various classes of drugs. Under the direction of Dr. Ben J. Ophthalmology and Strabismus Fellows divide their time among the Glasgow, this fellowship provides The division of Pediatric Ophthalmol clinical practices of Drs. Gorin, David preparation for an academic career in ogy and Strabismus offers one-year Sarraf, and Colin A. McCannel with ophthalmic pathology. One-year, two- fellowships, under the directorship in the Division of Retinal Disorders year, and three-year training programs of Drs. Sherwin J. Isenberg and and Ophthalmic Genetics as well as are available depending on the back Jos eph L. Demer. Clinical experience in the Retinal Diagnostics Unit and ground of the applicant. Training en consists of supervised participation the Visual Physiology Laboratory di compasses many aspects of ophthal in the ophthalmic care of pediatric rected by Dr. Steven Nusinowitz at mic pathology. Fellows may choose patients seen at the Stein Eye Insti UCLA. Dr. McCannel’s clinic provides between a research or clinical-based tute, Harbor-UCLA Medical Center, exposure to surgical retinal decision- curriculum. Clinical fellows gain ex and Olive View-UCLA Medical Cen making and management issues. The pertise in surgical pathology; autopsy ter. Specific activities include partic fellows also provide care and teach pathology; cytology, including fine- ipation in University Ophthalmology residents in retina subspecialty clinics needle aspiration; electron microsco Associates, the Nursery and Neona at two UCLA-affiliated hospitals. Fel py; immunohistochemistry; DNA in tal Intensive Care Units, Ophthalmic lows are strongly encouraged to en situ hybridization; Southern blot anal Plastic and Reconstructive Surgery gage in translational clinical research ysis; and polymerase chain reaction Service, and the Pediatric Retinal Ser and/or clinical trials and descriptive techniques for diagnostic work. The vice. Other activities in pediatric oph retrospective studies and develop an fellowship programs are individualized thalmology include experience in the in-depth working knowledge of the according to the credentials and capa private consultation suites and partic current scientific literature of medical bilities of each fellow. ipation in pediatric cases that are han and genetic retina. They are expected dled through other services. Fellows may collaborate with vision scientists,

Training Programs | Stein Eye Institute 99 including biochemists, physiologists, Fellowship in and international meetings and pub pathologists, and anatomists, on re Vitreoretinal Diseases lish scientific papers. They gain a search projects of mutual interest. and Surgery broad background in the vision sci Under the co-directorship of Drs. Allan ences by interacting with members Fellowship in Uveitis and E. Kreiger and Steven D. Schwartz, of adjacent laboratories and collab Inflammatory Eye Diseases the Vitreoretinal Diseases and Surgery orating with faculty members other This one-year fellowship, under the Fellowship in the Department of Oph than their own preceptors. Postdoc direction of Dr. Gary N. Holland, thalmology at the Stein Eye Institute toral research fellowships are offered offers comprehensive training in the is a two-year program designed to pro for one to three years. Each one is evaluation and management of uveitis vide medical and surgical training and unique with research programs estab and other inflammatory eye diseases. clinical and vision science research lished according to mutual agreement Fellows participate in the practices of opportunities related to vitreoretinal between trainees and mentors. Re Drs. Holland and Ralph D. Levinson disease. Major components of the search areas for postdoctoral fellows at the UCLA Stein Eye Institute and fellowship relate to diabetic retinopa include molecular biology, genetics, the practice of Dr. Olivia L. Lee at the thy, diseases of the macula and ret biophysics, biomechanics, cell biolo Doheny Eye Center UCLA in Pasade ina, hereditary retinal degenerations, gy, eye development, and biochemis na. In addition, fellows see patients in ocular trauma, ophthalmic oncology, try. Upon completion of their fellow the Uveitis Clinic at the Harbor–UCLA rhegmatogenous retinal disease, vit ships, trainees usually pursue careers Medical Center, under the supervision reoretinal surgery, pediatric retinal dis- in academia or industry. of Dr. Michael A. Kapamajian. They ease, and diagnostic imaging. Clini assist with diagnostic evaluations, cal training includes the prevention, International Fellowship and Exchange Program emergency cases, management of im- diagnosis, and treatment of retinal, munomodulatory therapies, and peri choroidal, vitreous, and related ocular To promote and encourage research operative care of patients undergoing disease. Fellows participate in retinal and education interaction with oph surgical procedures. Fellows also in clinics and surgical procedures at the thalmology institutions throughout the teract closely with members of other Stein Eye Institute and four UCLA- world, the Stein Eye Institute offers clinical services who are involved in affiliated hospitals. Clinical, laborato an International Ophthalmology Fel the care of patients with inflammatory ry, or translational research is encour lowship and Exchange Program con eye diseases and related conditions aged. Other activities include teaching sisting of one-year to two-year fellow (ie, Retina, Glaucoma, Cornea, and Pe of vitreoretinal diseases at the Stein ships under the supervision of specific diatric Ophthalmology Services; Adult Eye Institute and affiliated institutions Institute faculty. Candidates for these and Pediatric Rheumatology Services; and case presentations at teaching fellowships are nominated by presti Infectious Disease Service). sessions. The program also includes gious institutions outside the United the participation of several interna States and often hold academic po Research is an integral part of the tional fellows. sitions within their own countries. fellowship program. Fellows may be- Fellows participate in the clinical and come involved in patient-based or Fellowship in Vision Science research activities of ophthalmic sub laboratory-based projects, including specialties according to their train- the special research programs of the Predoctoral and postdoctoral fellow ing needs. Ocular Inflammatory Disease Center ships in vision science are offered to and collaborations with investigators individuals who have an interest in at other institutions. Fellows typical specific research areas being pursued ly complete and publish one or two by Institute faculty in highly special original research articles, frequently ized laboratory environments. These prepare a book chapter or review on fellowships are supported either by a subject of interest, and present their individual funds available to Institute research results at national academ professors or as part of a special pro ic meetings. Support is provided for gram offered under the auspices of fellows to participate in the activities a National Eye Institute Vision Sci of related subspecialty organizations, ence Training Grant and directed by such as the annual meetings of the Dr. Gabriel H. Travis. American Uveitis Society. Predoctoral fellows take a defined program of core courses and carry out eye-related research, obtaining doc torates in about six years. Fellows are required to present their research at informal and formal seminars, and are encouraged to participate in national

100 Stein Eye Institute | Training Programs Appendices Associate Clinical Professors Assistant Clinical Professors Volunteer and of Ophthalmology of Ophthalmology Charles Barnes, MD (Senior Status) David H. Aizuss, MD Consulting Faculty Gerrald Barron, MD (Senior Status) Malvin B. Anders, MD Arnold Barton, MD (Senior Status) Richard K. Apt, MD Volunteer Faculty Kevin J. Belville, MD Reginald G. Ariyasu, MD, PhD in Ophthalmology Louis Bernstein, MD (Senior Status) Arthur A. Astorino, MD Clinical Professors W. Benton Boone, MD Mark A. Baskin, MD of Ophthalmology Harvey Brown, MD Arthur Benjamin, MD Andrew E. Choy, MD Katherine L. Bergwerk, MD J. Bronwyn Bateman, MD Melissa W. Chun, OD Betsy E. Blechman, MD Henry I. Baylis, MD Founding Chief of the Orbital and Ophthalmic Peter J. Cornell, MD Cynthia A. Boxrud, MD Plastic Surgery Division Bernard Davidord, MD (Senior Status) Amarpreet S. Brar, MD Uday Devgan, MD Almira W. Cann, MD, PhD Bruce B. Becker, MD Chief of Ophthalmology Arnett Carraby, MD Michael S. Berlin, MD Olive View–UCLA Medical Center Vicki K. Chan, MD Norma Byer, MD (Senior Status) Paul B. Donzis, MD Andrew M. Chang, MD William P. Chen, MD David R. Fett, MD Candice Chen, MD Paul Deiter, MD (Senior Status) Donald S. Fong, MD, MPH Thomas B-H. Choi, MD Donald Dickerson, MD (Senior Status) Donald I. Goldstein, MD Milton W. Chu, MD Leland M. Garrison, MD Michael J. Groth, MD Robert A. Clark, MD John D. Hofbauer, MD Thomas A. Hanscom, MD Charles A. Cooper, MD Kenneth J. Hoffer, MD Andrew Henrick, MD Yadavinder P. Dang, MD C. Richard Hulquist, MD Edwin P. Hill, MD Jonathan M. Davidorf, MD Barry M. Kerman, MD David F. Kamin, MD John L. Davidson, MD Roger A. Kohn, MD Stanley Kopelow, MD (Senior Status) Sanford S. Davidson, MD Howard R. Krauss, MD Joseph Lambert, MD (Senior Status) Louise Cooley Davis, MD Benjamin C. Kwan, MD Brian L. Lee, MD Farid Eghbali, OD Jeremy Levenson, MD (Senior Status) Jonathan I. Macy, MD Troy R. Elander, MD Ezra Maguen, MD Gene Matzkin, MD (Senior Status) Naomi L. Ellenhorn, MD Robert K. Maloney, MD Joan E. McFarland, MD Calvin T. Eng, MD Samuel Masket, MD James McKinzie, MD (Senior Status) Robert E. Engstrom, MD Albert T. Milauskas, MD Alan Norton, MD (Senior Status) Doreen T. Fazio, MD Anthony B. Nesburn, MD John F. Paschal, MD (Senior Status) Sanford G. Feldman, MD Leon G. Partamian, MD Sidney Penn, MD (Senior Status) Laura E. Fox, MD George Primbs, MD (Senior Status) George M. Rajacich, MD Ronald P. Gallemore, MD Yaron S. Rabinowitz, MD Michael Reynard, MD George H. Garcia, MD Teresa O. Rosales, MD David S. Robbin, MD Kathryn M. Gardner, MD Robert J. Schechter, MD (Senior Status) David E. Savar, MD Leslie C. Garland, MD (Senior Status) Stephen Seiff, MD (Senior Status) Timothy V. Scott, MD W. James Gealy, Jr., MD Alan L. Shabo, MD Albert Sheffer, MD Damien Goldberg, MD Norman Shorr, MD James D. Shuler, MD Lawrence “Tim” Goodwin, MD Robert Sinskey, MD (Senior Status) Yossi Sidikaro, MD, PhD Lawrence H. Green, MD (Senior Status) Roger W. Sorenson, MD (Senior Status) Matthew Sloan, MD Richard Havunjian, MD Ronald J. Smith, MD Man M. Singh Hayreh, MD Alfred Solish, MD, MS Matthew L. Hecht, MD Kenneth D. Steinsapir, MD Jonathan A. Hoenig, MD William C. Stivelman, MD Jeffrey Hong, MD Hector L. Sulit, MD Catherine J. Hwang, MD, MPH Rosalind C. Vo, MD Morton P. Israel, MD Kamal A. Zakka, MD Steven J. Jacobson, MD Batool Jafri, MD Véronique H. Jotterand, MD J. David Karlin, MD David S. Katzin, MD James F. Kleckner, MD (Senior Status) Jerome R. Klein, MD Craig H. Kliger, MD Howard E. Lazerson, MD (Senior Status) Steven Leibowitz, MD Robert T. Lin, MD Joanne E. Low, MD Bryant J. Lum, MD

102 Stein Eye Institute | Appendices Assistant Clinical Professors Clinical Instructors Consulting Members of the of Ophthalmology continued in Ophthalmology Stein Eye Institute Michael C. Lynch, MD Gavin G. Bahadur, MD Robert W. Baloh, MD M. Polly McKinstry, MD Eduardo Besser, MD Professor of Neurology and Surgery Ashish M. Mehta, MD Maria Braun, MD (Head and Neck) Kenneth J. Miller, MD (Senior Status) Neil D. Brourman, MD Ferdinand V. Coroniti, PhD David R. Milstein, MD Stephen S. Bylsma, MD Professor, Department of Physics Ronald L. Morton, MD Andrew Caster, MD and Astronomy Lee T. Nordan, MD (Senior Status) Joseph H. Chang, MD David Eisenberg, DPhil Roger L. Novack, MD, PhD Hajir Dadgostar, MD Investigator, Howard Hughes Medical Institute Director, UCLA-DOE Institute Alpa A.S. Patel, MD Paul J. Dougherty, MD for Genomics and Proteomics James H. Peace, MD Sean Dumars, MD Professor, Departments of Chemistry Gilbert Perlman, MD (Senior Status) Daniel Ebroon, MD and Biochemistry, and Biological Chemistry Cheryl J. Powell, MD Brad S. Elkins, MD Molecular Biology Institute John R. Privett, MD (Senior Status) Satvinder Gujral, MD Alan M. Fogelman, MD Firas Rahhal, MD Lawrence M. Hopp, MD, MS Castera Professor and Executive Chair, Laurence N. Roer, MD Aarchan Joshi, MD Department of Medicine Gerald Sanders, MD (Senior Status) Anisha J. Judge, MD Alan D. Grinnell, PhD Barry S. Seibel, MD Jason Jun, MD Professor of Physiology and Meryl Shapiro-Tuchin, MD Rajesh Khanna, MD Physiological Science David M. Shultz, MD Julie A. King, MD Director, Jerry Lewis Neuromuscular Research Center Eliot B. Siegel, MD Mark H. Kramar, MD Director, Ahmanson Laboratory Lance M. Siegel, MD Daniel Krivoy, MD of Neurobiology John D. Slaney, MD Laurie C. McCall, MD Sherman M. Mellinkoff, MD Robert J. Smyth, MD David Paikal, MD Professor Emeritus of Medicine Kenneth O. Sparks, MD Jayantkumar Patel, MD Former Dean, UCLA School of Medicine Sadiqa Stelzner, MD Susan S. Ransome, MD C. Kumar Patel, PhD Mehryar “Ray” Taban, MD, FACS Steven H. Rauchman, MD Professor, Department of Physics Robert C. Tarter, MD Richard H. Roe, MD and Astronomy Debra G. Tennen, MD Aaron Savar, MD Leonard H. Rome, PhD Teddy Y. Tong, MD Kayar Shah, MD Senior Associate Dean for Research Sterling M. Trenberth, MD (Senior Status) Mark Silverberg, MD Professor of Biological Chemistry Robert C. Tudor, MD (Senior Status) Abraham Soroudi, MD Peter C. Whybrow, MD Henry E. Ullman, MD Sharon N. Spooner-Dailey, MD Judson Braun Professor and Executive Chair, Tay J. Weinman, MD (Senior Status) Homayoun Tabandeh, MD Department of Psychiatry and Irwin S. Weiss, MD (Senior Status) Dana P. Tannenbaum, MD Biobehavioral Sciences Sidney J. Weiss, MD William L. Trotter, MD Director and Physician in Chief Neuropsychiatric Institute Scott Whitcup, MD Mark Volpicelli, MD David L. Williams, MD (Senior Status) Mathew Wang, MD Jeffrey V. Winston, MD Peter H. Win, MD David M. Winters, MD (Senior Status) David L. Wirta, MD Barry J. Wolstan, MD Wilson C. Wu, MD, PhD Michael C. Yang, MD Patrick C. Yeh, MD Richard H. Yook, MD Peter D. Zeegen, MD (Senior Status)

Appendices | Stein Eye Institute 103 Pediatric Ophthalmology Postdoctoral Residents and Fellows and Strabismus Research Fellows Jieun Anna Kim, MD Negin Ashki Ghouravan, MD, PhD Residents Uveitis and Inflammatory Abhishek Chadha, PhD Eye Disease Doug Chung, PhD Third-Year Residents 2012–2015 Jonathan P. Heston, MD Jeremy Cook, PhD Matthias Elgeti, PhD Jamie K. Alexander, MD Vitreoretinal Diseases and Surgery Julian Esteve-Rudd, PhD Melinda Y. Chang, MD Sujit Itty, MD Sheyla Gonzalez-Garrido, PhD Robert A. Lalane, MD Michael Klufas, MD Lei Gu, PhD Wenjing Liu, MD Elizabeth Richter, MD Sonia Guha, PhD Aaron Nagiel, MD, PhD Ryan Wong, MD Mei Jiang, PhD P. James Sanchez, MD Justyna Kanska, PhD Second-Year Residents International Fellows Vanda Lopes, PhD 2013–2016 Carlos Lopez, PhD Cornea Research Jenny Chen, MD Hua Mei, PhD Somporn Chantra, MD Xuejing Chen, MD Johan Pahlberg, PhD Thailand Diana Katsman, MD, PhD (EyeSTAR) Yu “Christie” Qin, PhD Andres Codriansky Berdichewsky, MD Kwang Sup “Andrew” Shin, PhD Wonchon Liu, MD Chile Kaushali Thakore-Shah, PhD Grant Moore, MD JaeWoong Koh, MD Mitra Nejad, MD South Korea Stefanie Volland, PhD Julia Nemiroff, MD Chulaluck Tangmonkongvoragul, MD Hongxing Wang, PhD Christian Sanfilippo, MD Thailand Yanjie Wang, PhD Zhongyu Yang, PhD Mauricio E. Vargas, MD, PhD (EyeSTAR) Comprehensive Ophthalmology/ Jang “Lawrence” Yoo, PhD First-Year Residents Cataract Chi Zhang, PhD 2014–2017 None Joseph Christenbury, MD Glaucoma Melinda Fry, MD Predoctoral Eun Ah Kim, MD Janet Lee, MD Research Fellows South Korea Theodor Sauer, MD Ji Woong Lee, MD Guo Cheng Daniel Su, MD South Korea Austin Dean Andrew Tye, MD Arezoo Miraftabi, MD Jun Deng Rany Woo, MD Iran Kevin Eden Chengjie Zheng, MD Sara Nowroozizadeh, MD Katherine Fehlhaber Iran Roni Hazim EyeSTAR Trainees Farideh Sharifipour, MD Yifeng Ke Iran Margaux Kreitman Diana Katsman, MD, PhD Orbital and Ophthalmic Alan Le Tamara L. Lenis, MD Plastic Surgery Michael Lerch David Stark, MD, PhD Shani Golan, MD Joseph Park Victoria Tseng, MD Israel Yingqian Peng Mauricio E. Vargas, MD, PhD Allison Sargoy Pediatric Ophthalmology Helen Voung Clinical Fellows Rui Hao, MD Wei Wang China Tongzhou Xu Corneal and External Ocular Roland Joseph Tan, MD Diseases and Refractive Surgery Philippines Anjali Tannan, MD Soh Youn Suh, MD South Korea Neil Vyas, MD Glaucoma Pathology (Eye) None Peng Lei, MD Grace Richter, MD, MPH Uveitis Medical Retina None and Ophthalmic Genetics Visual Physiology Michael Fikhman, MD None Orbital and Ophthalmic Vitreoretinal Diseases and Surgery Plastic Surgery Tatsuhiko Sato, MD Erin Lessner, MD Japan Payam Morgan, MD Gavin Tan, MBBS Singapore

104 Stein Eye Institute | Appendices Phacoemulsification Course Glaucoma Weekly Conference Educational Offerings September 27, 2014 This conference is designed to teach May 9, 2015 residents and fellows a basic understanding of the pathophysiology and Ophthalmology and Course Director: clinical care of glaucoma. Faculty, Vision Science Kevin M. Miller, MD fellows, and residents all participate Training Programs This course is a key component of the in case and subject presentations and discussions. The conferences are Ophthalmology Basic and residency-training program, as well as coordinated by Joseph Caprioli, MD. Clinical Science Course a resource for practicing ophthalmologists. Both classroom and laboratory Course Chairman: Neuro-Ophthalmology Conference Bartly J. Mondino, MD instruction are offered, covering in detail the procedural and anatomical This conference meets bimonthly and This course is a major segment of the components of modern sutureless includes full-time and volunteer clinical educational program for ophthalmol- phacoemulsification. faculty and visitors from the commu- ogy residents, as well as a review nity who discuss neuro-ophthalmology course for ophthalmologists. Sections 20th Annual cases presented by fellows and resi are presented each year in a rotation Vision Science Conference dents. The coordinator for the year was Anthony C. Arnold, MD. designed to provide complete review October 10–12, 2014 of all sections in a three-year period. First-year residents participate in a At this annual event, sponsored jointly Oculoplastics Conference more intensive curriculum in order by the Stein Eye Institute and the This conference meets bimonthly and to obtain a comprehensive founda- National Eye Institute Vision Sci- includes full-time and volunteer clinical tion of ophthalmologic knowledge. ence Training Grant, pre- and post- faculty and visitors from the com- In 2014–2015, the following course doctoral fellows and faculty discuss munity who discuss oculoplastics and components were offered: a wide range of topics in vision orbital cases presented by fellows and science research. residents. The coordinator for the year Retina was Robert Alan Goldberg, MD. Steven D. Schwartz, MD Ophthalmology September 3, 2014–November 5, 2014 Clinical Conferences Ophthalmic Pathology Conference Coordinators: Faculty and residents meet daily to Pediatrics review pathological findings from Joseph L. Demer, MD, PhD Anthony C. Arnold, MD Gary N. Holland, MD current ophthalmology cases. The November 12, 2014–January 21, 2015 coordinator for the year was Ben J. Optics The Clinical Conferences are offered Glasgow, MD. Kevin M. Miller, MD in conjunction with the regular weekly January 28, 2015–February 18, 2015 Ophthalmology Basic and Clinical Pediatric Ophthalmology and Science Course. These conferences Strabismus Conference Neuro-Ophthalmology review patient care activities of the At monthly meetings rotating among Anthony C. Arnold, MD UCLA Department of Ophthalmology, Harbor-UCLA Medical Center, Olive February 25, 2015–April 22, 2015 present general topics in ophthalmic View-UCLA Medical Center, and the Uveitis science, and promote discussion of Stein Eye Institute, difficult pediatric Gary N. Holland, MD relevant aspects of ophthalmic pathol- ophthalmology and strabismus cases April 29, 2015–June 10, 2015 ogy and pharmacy. are presented and discussed. These conferences were coordinated for the Study Groups year by Sherwin J. Isenberg, MD, at Focusing on specific topics in clinical Harbor-UCLA Medical Center, Federico ophthalmology, study groups meet Velez, MD, at Olive View-UCLA Medi- regularly under the leadership of fac- cal Center, and Joseph L. Demer, MD, ulty members who are acknowledged PhD, at the Stein Eye Institute. specialists in their respective fields. The study groups are an integral part Pediatric Rheumatology and of the residency and clinical fellow- Uveitis Conference ship training programs and serve as Members of the Uveitis Service an informal resource for practicing meet each week with members of ophthalmologists in the community. the Rheumatology Service from the Department of Pediatrics to discuss Retinal Imaging Conference patient-care issues and research top- Arranged by the clinical fellows in ics of mutual interest. The conference vitreoretinal studies, this conference is attended by faculty, clinical fellows convenes periodically to review cur- from the Departments of Ophthalmol- rent angiograms representing disease ogy and Pediatrics, and research staff. entities, unusual abnormalities, and The conference is coordinated by controversial interpretations of angio- Gary N. Holland, MD. graphic findings. Steven D. Schwartz, MD, and other members of the Retina Division, supervise the conference.

Appendices | Stein Eye Institute 105 Vision Science Seminar Series Comprehensive Ophthalmology 46th Jules Stein Lecturer Coordinators: Review Course Stuart L. Fine, MD Sophie X. Deng, MD, PhD February 19–22, 2015 Visiting Clinical Professor David S. Williams, PhD Department of Ophthalmology Course Directors: University of Colorado This seminar series, conducted Sherwin Isenberg, MD School of Medicine throughout the academic year, allows John Irvine, MD Aurora, CO faculty within the Stein Eye Institute The Stein Eye Institute and the to present their research to other 13th Bradley R. Straatsma Lecturer Doheny Eye Institute sponsored members of the Institute, thereby David M. Gamm, MD, PhD the Eighth Annual Comprehensive fostering the exchange of knowledge RRF Emmett A. Humble Ophthalmology Review Course. and cooperation. The series frequently Distinguished Director Developed to serve ophthalmology- includes presentations by eminent visi- McPherson Eye Research Institute training programs in Southern Cali tors to the UCLA campus. Associate Professor fornia, the program concentrated on Department of Ophthalmology the epidemiology, clinical presenta- and Visual Science Continuing Education tion, diagnosis, and management of University of Wisconsin ophthalmological disease. Programs School of Medicine and Public Health Madison, WI Aesthetic Eyelid and Stein Eye Institute Clinical Facial Rejuvenation Course and Research Seminar 13th Thomas H. Pettit Lecturer Robert K. Maloney, MD August 1–2, 2014 June 12, 2015 Director Coordinators: Coordinators: Maloney Vision Institute Henry I. Baylis, MD Anthony C. Arnold, MD Clinical Professor Robert Alan Goldberg, MD Robert Alan Goldberg, MD Department of Ophthalmology Jonathan A. Hoenig, MD Bartly J. Mondino, MD David Geffen School of Medicine Catherine J. Hwang, MD Xian-Jie Yang, PhD at UCLA Norman Shorr, MD Los Angeles, CA Geared to physicians and basic sci- The Orbital and Oculoplastic Surgery entists, this seminar is an intensive Division held its annual Aesthetic course in which UCLA and guest Eyelid and Facial Rejuvenation course faculty present current concepts and at the Stein Eye Institute. The event recent advances in ophthalmology. attracted ophthalmologists, dermatolo- The Jules Stein Lecture, the Bradley R. gists, and cosmetic surgeons from Straatsma Lecture, and the Thomas H. around the world. The two-day event Pettit Lecture, which commemorate combined surgical demonstrations, each doctor’s contributions to ophthal- a cadaver dissection, and didactic mic science at UCLA and throughout lectures that informed participants the United States, are held in conjunc- of the latest advances in the field of tion with this seminar and are among aesthetic and reconstructive surgery the academic highlights of the year. for the eyelids and face.

106 Stein Eye Institute | Appendices Research Contracts and Grants July 1, 2014–June 30, 2015

Vision Science Grants Total Award Anthony J. Aldave, MD Identification and Characterization of the Genetic Basis of PPCD National Eye Institute Duration: 12/1/12–11/30/17 $245,000 Genetic Factors in Keratoconus National Eye Institute Sub-award from Cedar Sinai Medical Center Duration: 12/1/14–11/30/15 $5,400

Suraj P. Bhat, PhD Childhood Cataractogenesis: Heterogeneity of Gene Expression National Eye Institute Duration: 1/1/15–12/31/18 $250,000

Dean Bok, PhD Identification and Cellular Localization of Gene Products that Affect Photoreceptor Survival in Inherited Retinal Degeneration Macula Vision Research Foundation Duration: 4/1/08–3/31/16 $50,000

Joseph Caprioli, MD The Efficacy and Safety of Bimatoprost Sr in Patients with Open-Angle Glaucoma or Ocular Hypertension Allergan Pharmaceutical Corp. Duration: 4/22/15–1/31/19 $323,745 Clinical Research Program in Glaucoma Simms-Mann Family Foundation Duration: 7/1/14–6/30/16 $93,500

Anne L. Coleman, MD, PhD UCLA Mobile Eye Clinic Child Vision Program LA County Children and Families First (First 5 LA) Duration: 7/1/13–6/30/16 $866,000 Center for Community Outreach Jules Stein Eye Institute at UCLA 2014–2015 The Nicholas Endowment Duration: 1/1/15–12/31/15 $97,143 UCLA Mobile Clinic Project and UCLA Mobile Eye Clinic Andrea Bocelli Foundation Duration: 2/6/14–12/31/15 $25,000

Joseph L. Demer, MD, PhD Biomechanical Analysis in Strabismus Surgery National Eye Institute Duration: 5/1/11–4/30/16 $370,732 Training Mentors in Developing Countries Pediatric Ophthalmology Fellowship (Roland Tan, MD, Fellow) Knights Templar Eye Foundation Inc. Duration: 7/1/14–8/17/15 $60,000

Appendices | Stein Eye Institute 107 Sophie X. Deng, MD, PhD Ex Vivo Expansion of Human Limbal Stem Cells for Transplantation National Eye Institute Duration: 9/1/12–8/31/17 $245,000 Regeneration of Functional Human Corneal Epithelial Progenitor Cells California Institute for Regenerative Medicine (CIRM) Duration: 3/1/11–4/30/15 $455,718

Debora B. Farber, PhD, DPhhc Regeneration of Functional Retinas: Treatment with Human Embryonic Stem Cell-Delivered Microvesicles Retina International Duration: 8/1/14–1/31/15 $10,000

Lynn K. Gordon, MD, PhD Pd-Ligand, A Paradoxical Role in Experimental Uveitis Pathogenesis and Therapy National Eye Institute Duration: 4/1/15–3/31/17 $150,000

Michael B. Gorin, MD, PhD Genetics-based Testing of Functional and Structural Endophenotypes for Pre- and Early-Age-Related Macular Degeneration (AMD) Arnold and Mabel Beckman Foundation Duration: 7/1/14–6/30/16 $100,000

Gary N. Holland, MD Multicenter Uveitis Steroid Treatment (MUST) Trial National Eye Institute Sub-award from Johns Hopkins University Duration: 6/1/12–4/30/15 $30,434 Macular Edema Treatment Trials Associated with MUST (META-MUST) National Eye Institute Sub-award from Johns Hopkins University Duration: 9/30/14–7/31/15 $5,000

Joseph Horwitz, PhD Analysis of Lens Crystallins and Cataractous Mutants at High Hydrostatic Pressure National Eye Institute Duration: 4/1/14–3/31/19 $147,000

Alex A. Huang, MD, PhD Discovery and Characterization of Anterior Sclera Pathology in Glaucoma National Eye Institute Duration: 9/30/14–9/29/19 $203,981 Real-time Imaging of Aqueous Humor Outflow American Glaucoma Society Mentoring for Advancement of Physician-Scientists (MAPS) Award Duration: 1/1/15–12/31/15 $10,000

Wayne L. Hubbell, PhD Molecular Basis of Membrane Excitation National Eye Institute Duration: 5/1/15–4/30/20 $352,182 Core Grant for Vision Research for all Researchers at the Stein Eye Institute National Eye Institute Duration: 3/1/10–6/30/15 $453,566

108 Stein Eye Institute | Appendices Jean-Pierre Hubschman, MD Intraocular Robotic Interventional Surgical System for Cataract Surgery Project National Eye Institute Duration: 9/30/14–9/29/16 $30,049

Bartly J. Mondino, MD RPB Unrestricted Grant Research to Prevent Blindness, Inc. Duration: 1/1/12–12/31/15 $115,000

Kouros Nouri-Mahdavi, MD Detection of Glaucoma Progression with Macular OCT Imaging National Eye Institute Duration: 7/1/12–6/30/17 $212,166 Influence of the Disc Size on the Anatomical Relationship of the Clinical Disc Margin and Bruch’s Membrane Opening (Navid Amini, PhD, Postdoctoral Fellow) Fight for Sight, Inc. (Prevent Blindness America) Duration: 7/1/14–6/30/15 $20,000 Intra-Session Variability of Regional Macular Thickness Measurements American Glaucoma Society Duration: 3/1/15– 3/31/16 $40,000

Stacy L. Pineles, MD Binocular Summation in Strabismus NIH/National Eye Institute Duration: 9/1/11–8/31/16 $200,237 Integrating Perceptual Learning Approaches into Effective Therapies for Low Vision National Eye Institute Sub-award from University of California Riverside Duration: 8/1/13–7/31/15 $28,197 RPB Walt and Lily Disney Award for Amblyopia Research Research to Prevent Blindness, Inc. Duration: 7/1/14–6/30/19 $100,000

Alappakam P. Sampath, PhD Functional Characteristics of Rod Pathways in the Retina National Eye Institute Duration: 2/1/14–7/31/16 $245,000 Experimental and Clinical Investigations of Retinal Stimulation National Eye Institute Sub-award from University of Southern California Duration: 10/1/13–2/28/15 $91,889

Gabriel H. Travis, MD The Role of Müller Cells in Visual Pigment Regeneration National Eye Institute Duration: 7/1/15–6/30/18 $319,829 Vision Science Training Grant to Researchers at the Stein Eye Institute National Eye Institute Duration: 9/30/11–9/29/16 $227,365 Instrumentation Grant for Stein Eye Investigators Bruce Ford and Anne Smith Bundy Foundation Duration: 8/16/11–8/15/15 $100,029

Appendices | Stein Eye Institute 109 David S. Williams, PhD The Photoreceptor Cilium National Eye Institute Duration: 5/1/13–4/30/18 $245,000 Degradative Processes in RPE-Photoreceptor Renewal National Eye Institute Sub-award from University of Pennsylvania Duration: 2/1/14–1/31/16 $24,500 IPSC-JSEI Collaboration Project UCLA Broad Stem Cell Research Center Duration: 4/1/14–8/31/15 $37,000 Photoreceptor Disk Membrane Morphogenesis National Eye Institute Sub-award from University of California, Santa Barbara Duration: 4/1/15–3/31/16 $125,000

Jie Zheng, PhD Structural Investigation of Focal Adhesion Formation and Disassembly National Institute of General Medical Sciences Duration: 5/1/12–3/31/16 $190,000

Professional Research Series Roxana Radu, PhD Gene Therapy to Prevent Visual Loss in Macular Degenerations by Increasing Expression of Complement Negative-Regulatory Proteins in the RPE Macula Vision Research Foundation Duration: 10/1/13–9/30/16 $100,000

Alejandra Young, PhD Stem Cell Derived, OA1-Enriched, Microvesicles: Do They Rescue Ocular Albinism? The Vision of Children Duration: 11/1/13–10/31/16 $179,962

Sonia Guha, PhD Role of Doublecortin in Axonal Misrouting in Oal Mice Vision of Children Duration: 7/1/14–6/30/16 $93,219

Clinical Trials Sophie X. Deng, MD, PhD An 8-week Phase II, Multicenter, Randomized, Double-Masked, Vehicle Controlled Parallel Group Study with a 24 or 32 Week Follow-Up Period to Evaluate the Efficacy of a Formulation Containing Antioxidant of Recombinant Human Nerve Growth Factor Dompe Pharmaceutical Duration: 3/17/15–3/16/17 $64,828

Brian Francis, MD Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered By a Single Intravitreal Injection to Subjects with Acute Primary Angle-Closure Glaucoma Quark Pharmaceuticals, Inc. Duration: 9/25/14–9/24/16 $64,609

110 Stein Eye Institute | Appendices Jean-Pierre Hubschman, MD Ocriplasmin Research to Better Inform Treatment (ORBIT-Protocol# TG-MV-018) Thrombogenics, Inc. (Belgium) Duration: 7/16/14–7/15/16 $6,040 A Ph 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (Mac Tel) Lowry Medical Research Institute Duration: 8/6/14–6/30/18 $75,848

Peter Quiros, MD Long-Term Follow-up of the Cohort from a Multicenter, Double-Masked Randomized Placebo-Controlled Study of Weight-Reduction and/or Low-Sodium Diet plus Acetazolamide vs. Diet plus Placebo in Subjects with Idiopathic Intracranial Hypertension with Mild Visual Loss National Eye Institute Sub-contract from St. Luke’s Roosevelt Institute for Health Sciences Duration: 11/7/14–1/31/15 $1,116

Alfredo A. Sadun, MD, PhD Emergency Administration of EPI-743 to a Single Patient with Leber’s Hereditary Optic Neuropathy (LHON) Edison Pharmaceuticals, Inc. Duration: 10/17/14–10/17/16 $55,860

David Sarraf, MD A Phase III, Multicenter, Randomized Double-Masked Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD Genentech, Inc. Duration: 11/21/14–9/27/18 $298,606

Steven D. Schwartz, MD A Phase III, Multicenter, Randomized Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD Genentech, Inc. Duration: 11/18/14–9/27/18 $296,281 A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasis Type 2 Neurotech Pharmaceuticals, Inc. Duration: 7/19/11–8/18/17 $40,372

Appendices | Stein Eye Institute 111 Contracts and Grants of Faculty Administered by Doheny Eye Center UCLA

Vision Science Grants Alex A. Huang, MD, PhD Structure and Function of Aqueous Humor Outflow American Glaucoma Society and Allergan Young Clinician Scientist Award Duration: 3/17/15–3/16/16 $20,000

SriniVas R. Sadda, MD Multimodal Image Analysis in Age-Related Macular Degeneration Macula Vision Research Foundation Duration: 1/1/15–12/31/18 $100,000/year Advanced Image Analysis Tools for Diabetic Retinopathy Eyenuk, Inc. Sub-award on NIBI EB013585 Duration: 07/15/14–06/30/17 $48,581 Automated Image-Based Biomaker Computation Tools for Diabetic Retinopathy Eyenuk, Inc. (Sub-award on NCATS Grant TR000377) $101,147 Duration: 9/26/14–6/30/17

Deming Sun, MD Regulation by Gamma/Delta T Cells of Autoimmune Uveitis National Eye Institute Duration: 5/1/12–4/30/16 $147,000

James C.H. Tan, MD, PhD, FRCOphth Karl Kirchgessner Foundation Vision Research Grant The Karl Kirchgessner Foundation Duration: 10/17/09–Open $50,000

Clinical Trials SriniVas R. Sadda, MD Genetic Epidemiology of Age-Related Macular Degeneration in the Older Order Amish University of Pennsylvania (Sub-award on NEI Grant EY023164) Duration: 2/1/13–1/31/18 $59,568

112 Stein Eye Institute | Appendices Grants Still Active: Totals Reported in Previous Years

Vision Science Grants Anthony J. Aldave, MD Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS) JAEB Center for Health Research Duration: 3/6/12–8/31/16

Joseph Caprioli, MD Multicenter Study for Normal Database of Optic Nerve Head, Retinal Nerve Fiber Layer, and Macula Parameters, with the Heidelberg Spectralis Heidelberg Engineering Duration: 9/25/13–9/24/15

Lynn K. Gordon, MD, PhD Novel Therapies to Prevent Blindness Caused by Proliferative Vitreoretinopathy National Eye Institute Duration: 4/1/10–3/31/15

Stacy L. Pineles, MD Pediatric Eye Disease Investigator Group (PEDIG) JAEB Center for Health Research Duration: 2/28/11–12/31/18

James C.H. Tan, MD, PhD, FRCOphth Role of Trabecular Meshwork Contractility in Modulating Outflow Resistance National Eye Institute Duration: 6/16/14–8/31/15

David S. Williams, PhD RPE Cell Biology of Myosin VIIa National Eye Institute Duration: 7/1/09–6/30/15

Clinical Trials Robert Alan Goldberg, MD A Multicenter Double-Masked Placebo-Controlled Efficacy and Safety Study of RV001, an Insulin-like Growth Factor-1 Receptor Antagonist Antibody (Fully Human), Administered Every 3 Weeks by Intravenous Infusion in Patients Suffering from Active Thyroid Eye Disease Premier Research International, LLC Duration: 4/16/13–4/16/15

Lynn K. Gordon, MD, PhD A Phase I Open Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I) Quark Pharmaceuticals, Inc. Duration: 3/17/10–3/16/15

Appendices | Stein Eye Institute 113 Gary N. Holland, MD A Phase I/II Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium Cells in Patients with Stargardt Macular Dystrophy (SMD) Advanced Cell Technology Duration: 1/7/14–12/12/16 A Phase I/II Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial Cells in Patients with Advanced Dry Age-Related Macular Degeneration (AMD) Advanced Cell Technology Duration: 5/31/13–12/12/16 A Phase I/II Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary Myopic Macular Degeneration Advanced Cell Technology Duration: 3/31/14–3/31/16

Jean-Pierre Hubschman, MD A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti-PDGF-B Pegylated Aptamer)…ARMD Ophthotech Corporation Duration: 12/4/13–12/3/15

Olivia L. Lee, MD A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Noninfectious Intermediate Posterior or Pan-Uveitis Currently Controlled with Systemic Treatment Xoma (US) LLC Duration: 1/8/13–12/10/15 A Randomized Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Noninfectious Intermediate, Posterior, or Pan-Uveitis Xoma (US) LLC Duration: 1/8/13–12/10/15

Kevin M. Miller, MD Safety and Effectiveness of the Customflex Artificial Iris Prosthesis for the Treatment of Iris Defects Clinical Research Consultants, Inc. Duration: 6/12/14–6/14/16 A Prospective Randomized Controlled Multi-Center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens in Subjects with Pre-Existing Corneal Astigmatism Calhoun Vision, Inc. Duration: 7/26/12–10/21/15 Post Approval Study of the Acrysof IQ Toric High Cylinder Power Intraocular Lens Alcon Laboratories, Inc. Duration: 4/17/12–2/9/16

David Sarraf, MD Intravitreal AflibErcept Injection for the Treatment of Submacular Vascularized PigmEnt Epithelial DetachmeNt (EVEN Study) Southern California Desert Retina Consultants Duration: 2/7/13–7/21/16

114 Stein Eye Institute | Appendices Steven D. Schwartz, MD A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells in Patients with Stargardt Macular Dystrophy Advanced Cell Technology Duration: 3/23/11–2/24/16 A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells in Patients with Advanced Dry AMD Advanced Cell Technology Duration: 4/5/11–2/24/16 A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Subretinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to Myopic Macular Degeneration Advanced Cell Technology Duration: 4/10/14–9/1/16 A National History of Macular (Parafoveal) Telangiectasia Lowy Medical Research Institute Duration: 9/1/05–12/31/15

Faculty, Doheny Eye Center UCLA

Vision Science Grants Alex A. Huang, MD, PhD Anterior Sclera Pathology in Glaucoma American Glaucoma Society Mentoring for Advancement of Physician-Scientists (MAPS) Award Duration: 3/1/14–3/1/15

Deming Sun, MD Core Grant for Vision Research National Eye Institute Duration: 9/30/97–4/30/15 Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis National Eye Institute 09/01/09–08/31/14 Role of Trabecular Meshwork Contractility in Modulating Outflow Resistance National Eye Institute Duration: 9/30/10–8/31/14

Appendices | Stein Eye Institute 115 Identifying Novel Genes Corneal Endothelial Cell Changes Clinical Research Studies for Fuchs Corneal in Children with Uveitis Endothelial Dystrophy This is a prospective study to evaluate In this multicenter study, investi- the cornea, specifically endothelial Cornea and External Eye gators are working to identify the cells, in children with uveitis. Uveitis A Clinical Trial to Evaluate the gene(s) responsible for Fuchs corneal is a general term meaning inflam- Efficacy of an Investigational Drug endothelial dystrophy, an inherited mation inside the eye. Investigators for the Treatment of State 2 and 3 disorder that may result in irreversible will be comparing these changes for Neurotrophic Keratitis corneal swelling and loss of vision. children with anterior uveitis who have The purpose of this study is to find Investigators: Anthony J. Aldave, MD, received a glaucoma drainage tube out the effectiveness of a formulation Gary N. Holland, MD, and Bartly J. and those who have not. Investigators: containing anti-oxidant of recombinant Mondino, MD Joseph Caprioli, MD, JoAnn A. Giaconi, human nerve growth factor (rhNGF) MD, Gary N. Holland, MD, Simon eye drops solution in healing the Keratoprosthesis K. Law, MD, PharmD, and Ralph D. corneal epithelium or corneal ulcers Implantation in Patients with Levinson, MD in patients with neurotrophic keratitis. Corneal Opacification Investigators: Anthony J. Aldave, MD, This study aims to determine the suc- Factors Related to the Severity of and Sophie X. Deng, MD, PhD cess rate of keratoprosthesis (artificial Ocular Toxoplasmosis corneal) transplantation for visual Toxoplasmosis is a common parasitic Analysis of the Corneal and rehabilitation in patients with corneal disease that can cause a vision- Limbal Epithelial Changes in opacification. Investigators: Anthony J. threatening infection of the retina. Limbal Stem Cell Deficiency Using Aldave, MD, and Gary N. Holland, MD Individuals with and without ocular In Vivo Confocal Microscopy toxoplasmosis are being evalu- Investigators are working to establish ated with a blood test to determine a system for diagnosing limbal stem Eye Infections whether (1) people can have a genetic cell deficiency at a cellular level by and Inflammations predisposition to severe disease when correlating the information from impres- infected with the parasite, or (2) there A Comprehensive Analysis is a particular strain of parasite that sion cytology tests, confocal micros- of Visual Function in copy pictures, and medical records. causes more severe disease than Patients Diagnosed with others. Investigators: Gary N. Holland, Investigators: Anthony J. Aldave, MD, Birdshot Chorioretinopathy and Sophie X. Deng, MD, PhD MD, and Ralph D. Levinson, MD The main goal in this study is to investigate the relationship between vision Effect of Corneal Preservation Multicenter Uveitis Steroid dysfunction (eg, symptoms, visual Treatment (MUST) Time on Long-Term Graft Success field changes, contrast sensitivity, and The purpose of this study is to evalu- Investigators are comparing two color vision changes) experienced currently available treatments for ate the effect of preservation time on by patients diagnosed with birdshot corneal transplants. It will compare the uveitis. Systemic treatment utilizing chorioretinopathy and the location medications taken orally, by injec- preservation time up to the FDA limit of defects in the retina as identi- of 14 days and hopes to determine tion, or by intravenous infusion is fied by electrophysiological testing. being compared to treatment with an that longer preservation time does not Investigators: Gary N. Holland, MD, adversely impact graft success and intraocular implant containing cortico- Ralph D. Levinson, MD, and Steven steroid. Investigators: Gary N. Holland, endothelial cell density. Investigators: Nusinowitz, PhD Anthony J. Aldave, MD, and Sophie X. MD, Jean-Pierre Hubschman, MD, and Ralph D. Levinson, MD Deng, MD, PhD A Comprehensive Analysis of Visual Function in Patients Natural Killer Cell Receptor Genes Genetic Basis of Posterior Diagnosed with HIV Polymorphous Corneal Dystrophy and AIDS-Related CMV Retinitis The main goal of this study is to deter- Institute faculty members are studying Funded by the National Eye Institute, mine the sequence of events that lead this study seeks to identify the gene(s) why some people with AIDS develop to visual disturbances in HIV-infected CMV retinitis, an infection of the retina, responsible for posterior polymor- patients. Investigators will obtain phous dystrophy, an inherited corneal while others do not. This study aims measures of visual function with a to determine whether KIR genes, endothelial disorder that may result in series of established clinical electro- irreversible corneal swelling and loss which control natural killer cell activi- physiological and psychophysical tests ties and other immune functions, differ of vision. Investigators: Anthony J. commonly used to evaluate the func- Aldave, MD, and Gary N. Holland, MD between HIV-infected individuals who tion at different sites within the retina. develop CMV retinitis and those who Results of this study may enable bet- do not, despite similar risk factors. ter understanding and measurements Investigators: Gary N. Holland, MD, of how vision is affected in subjects and Ralph D. Levinson, MD diagnosed with HIV. Investigators: Gary N. Holland, MD, and Steven Nusinowitz, PhD

116 Stein Eye Institute | Appendices Studies Evaluating a New Drug Clinical Measurements of the Glaucoma Imaging Study in the Treatment of Patients Optic Nerve in Glaucoma This study is evaluating different imag- with Uveitis The goal of this study is to develop ing techniques and their use in improv- Uveitis is caused by inflammation of novel structural measures of the optic ing open-angle glaucoma detection. the middle layer of the eye. The pur- nerve and nerve fiber layer, which are Investigators: Joseph Caprioli, MD, pose of this study is to find out more sensitive and specific for early and and Kouros Nouri-Mahdavi, MD about how the drug works, and if it is progressive glaucomatous optic nerve effective for treating uveitis by limiting damage. Investigators: Joseph Caprioli, Glaucomatous Cupping and one of the proteins that causes inflam- MD, Anne L. Coleman, MD, PhD, and Visual Field Abnormalities in mation. Investigators: Gary N. Holland, Simon K. Law, MD, PharmD Chinese Young Adults MD, and Ralph D. Levinson, MD The glaucoma-like syndrome is a con- Earlier Intraocular Pressure dition where patients appear to have Control after Ahmed Glaucoma signs of glaucoma but are actually Glaucoma Valve Implantation normal. This glaucoma-like syndrome A Clinical Trial to Evaluate an The purpose of this study is to evalu- is unusually common in young adult Investigational Injection for ate the occurrence rate of the high Chinese patients who normally would Patients with Acute Primary pressure phase and the final pressure not be expected to show signs of Angle-Closure Glaucoma outcomes between subjects treated eye disease. The purpose of the with glaucoma medications prior to study is to determine the prevalence This study will evaluate an investi- the onset of the high pressure phase and characteristics of the glaucoma- gational medication in patients with and subjects who start glaucoma like syndrome in Chinese young an attack of primary angle-closure medications at the onset of the high adults. Investigator: Simon K. Law, glaucoma. Acute primary angle- pressure phase. Investigators: Joseph MD, PharmD closure glaucoma represents an ocular Caprioli, MD, Anne L. Coleman, MD, emergency in which the outflow of PhD, JoAnn A. Giaconi, MD, and Ocular Biometric Measurements in aqueous humor through the anterior Simon K. Law, MD, PharmD Angle-Closure Glaucoma chamber angle is blocked. As a result, intraocular pressure (IOP) rises to The purpose of this study is to deter- Effect of Yoga on Glaucoma levels high above normal, causing mine the potential contributing factors pain, edema, iris ischemia, and ocular The purpose of this study is to in angle-closure patients of different tissue damage. Ocular damage can examine the practice of yoga and its ethnicities and to determine predic- involve damage to the lens, increased ability to improve a patient’s vision by tive factors for this type of glaucoma. risk of ischemic damage to the retina relieving stress and reducing eye pres- Investigators: Joseph Caprioli, MD, and the optic nerve, and increased risk sure. Investigator: Anne L. Coleman, Anne L. Coleman, MD, PhD, Simon of reduced blood flow to the retina. MD, PhD K. Law, MD, PharmD, and Kouros Investigators: Brian Francis, MD, Gad Nouri-Mahdavi, MD Heilweil, MD, Alex Huang, MD, PhD, Eye Health Imaging Study and SriniVas Sadda, MD The purpose of this study is to expand Ocular Hypertension the normative database for the Heidel Treatment Study A Clinical Trial to Evaluate berg Spectarlis OCT by collecting Since topical hypotensive medica- the Efficacy and Safety of an ophthalmic data from healthy eyes of tions are safe and effective in delay- Investigational Eye Drop in people of Hispanic/Latino, Asian, and ing or preventing primary open angle Patients with Open-Angle African American descent. Investiga- glaucoma, this study is examining Glaucoma or Ocular Hypertension tors: Joseph Caprioli, MD, and Kouros whether other forms of treatment The study objective is to evaluate the Nouri-Mahdavi, MD can be deferred with little or no pen- intraocular pressure-lowering efficacy alty. Investigator: Anne L. Coleman, and safety of two dose strengths of Glaucoma Drainage Devices MD, PhD an investigational eye drop in patients and Filtering Surgery with open-angle glaucoma or ocular with Antimetabolites Optic Nerve Appearance in hypertension after initial and repeated This study looks at the effect of two Age-Related Macular Degeneration administrations. Investigators: Joseph surgical procedures—glaucoma In order to evaluate the relationship Caprioli, MD, Anne L. Coleman, MD, implant surgery and filtering surgery between macular degeneration and PhD, JoAnn A. Giaconi, MD, Simon with antimetabolites—on the corneal optic nerve change, digital imaging K. Law, MD, PharmD, and Kouros endothelium. It evaluates the possibil- technology and photography are being Nouri-Mahdavi, MD ity of surgical damage to the corneal used to assess the structural appear- endothelium, which may result in ance of the optic nerve in patients loss of corneal clarity. Investigators: with age-related macular degen- Joseph Caprioli, MD, Anne L. Coleman, eration. Investigator: Simon K. Law, MD, PhD, JoAnn A. Giaconi, MD, and MD, PharmD Simon K. Law, MD, PharmD

Appendices | Stein Eye Institute 117 Role of Pattern Electroretinogram Safety and Effectiveness of A Study to Assess the Efficacy (PERG) in Glaucoma the CustomFlex Artificial Iris and Safety of Lampalizumab This study is researching an elec- Prosthesis for the Treatment of Administered Intravitreally to trophysiological test called pattern Iris Defects Patients with Geographic Atrophy electroretinogram (PERG). The goal This study is being conducted to evalu- Secondary to Age-Related is to determine the role of PERG in ate the safety and effectiveness of an Macular Degeneration estimating the risk of future glaucoma artificial iris prosthesis for the treat- This study is a Phase III, double- progression and the reversibility of ment of full or partial aniridia resulting masked, multicenter, randomized, glaucomatous damage after treatment. from congenital aniridia, acquired sham injection-controlled study evalu- The latter could help clinicians better iris defects (including traumatic iris ating the efficacy and safety of lampali- determine to what extent eye pres- defects and mydriasis), or conditions zumab administered every four weeks sure needs to be lowered to prevent associated with full or partial aniridia, or every six weeks by intravitreal disease progression. Investigators: such as ocular or oculocutaneous injections for approximately a two- Joseph Caprioli, MD, Anne L. Cole- albinism and iridocorneal endothelial year (96-week) treatment period in man, MD, PhD, JoAnn A. Giaconi, (ICE) syndrome, and iris coloboma. patients with geographic atrophy of MD, Simon K. Law, MD, PharmD, Investigators: Anthony J. Aldave, MD, the retina resulting from age-related and Kouros Nouri-Mahdavi, MD and Kevin M. Miller, MD macular degeneration. Investigators: David Sarraf, MD, and Steven D. Vision-Related Quality of Life and Schwartz, MD Ocular Dominance Macula, Retina, and Vitreous This study is designed to evaluate how A Study to Evaluate the Treatment Air, Perfluoropropane, and of Subfoveal Pigment Epithelial quality of life is impacted by glaucoma Sulfur Hexafluoride Gas in relation to eye dominance. It aims Detachment Associated with Disappearance Variability Choroidal Neovascularization to determine whether quality of life is after Vitrectomy affected more by glaucoma if it primar- The aim of this study is to see if the The purpose of this study is to evalu- ily affects the dominant eye. Investi- treatment of pigment epithelial detach- ate different gases used in vitrectomy gators: Joseph Caprioli, MD, Anne L. ment is safe and effective with the surgeries and to understand why Coleman, MD, PhD, JoAnn A. Giaconi, regular dose of intravitreal aflibercept there is variability in the time that MD, and Simon K. Law, MD, PharmD injection. This study is being per- the different gases remain in the eye formed in collaboration with Southern after vitrectomy surgery. Investiga- California Desert Retina Consultants. tors: Jean-Pierre Hubschman, MD, and Lens and Cataract Investigator: David Sarraf, MD Steven D. Schwartz, MD ® Post-Approval Study of ACRYSOF Clinical Characterization, Genetic IQ Toric High Cylinder Power A Phase 2 Clinical Trial to Assess Testing, and Visual Function in Intraocular Lens the Efficacy and Safety of an Patients with Stargardt Disease This is a post-approval study of an Investigational Drug for Patients with Geographic Atrophy Investigators are doing a compre- intraocular lens. The primary objective hensive analysis of visual function in of this study is to evaluate an FDA- Secondary to Age-Related patients diagnosed with Stargardt dis- approved intraocular lens ( Macular Degeneration Models ease, an early onset form of macular ) for patients with Investigators are currently evaluat- SN6AT6–SN6AT9 degeneration caused by a number of corneal astigmatism. Investigators: ing intravitreal injection for patients mutations in the ABCR gene. They are D. Rex Hamilton, MD, and Kevin M. with geographic atrophy secondary performing molecular genetic testing Miller, MD to age-related macular degeneration to confirm the Stargardt diagnosis and Investigators: Michael Gorin, MD, PhD, better understand the diversity of the Jean-Pierre Hubschman, MD, Colin Safety and Effectiveness of the condition. Investigators: Debora B. McCannel, MD, David Sarraf, MD, and Calhoun Vision Light Adjustable Farber, PhD, DPhhc, Michael B. Gorin, Steven D. Schwartz, MD Lens for Treating Postoperative MD, PhD, Steven Nusinowitz, PhD, Sphere and Cylinder and Maria Carolina Ortube, MD This is a prospective, randomized A Safety and Tolerability controlled multicenter clinical study to Trial of CNTF in Patients with Dexamethasone Injections evaluate the safety and effectiveness MacTel Type 2 in the Treatment of Diabetic of Light Adjustable Lens in subjects This study is assessing the safety of Macular Edema with preoperative corneal astigmatism. the NT-501 implant in patients with Faculty members are participating in a Investigators: Anthony J. Aldave, MD, macular telangiectasia type 2. The study to assess the safety and efficacy D. Rex Hamilton, MD, and Kevin M. device, an implant, is a small capsule of 70 mg and 350 mg dexametha- Miller, MD of cells that is placed inside the eye. sone posterior segment drug delivery This allows a controlled, sustained systems in the treatment of patients release of CNTF directly to the retina. with diabetic macular edema. Inves- Investigators: Jean-Pierre Hubschman, tigators: Allan E. Kreiger, MD, Tara A. MD, Allan E. Kreiger, MD, and Steven McCannel, MD, PhD, and Steven D. D. Schwartz, MD Schwartz, MD

118 Stein Eye Institute | Appendices Heavy Metals in Surgically Modified Retinal Fundus Camera P200CAF Autofluorescence Removed Human Ocular Tissue This study evaluates a modified retinal Ultra-Widefield Scanning Laser Faculty members are examining the fundus camera to see if significant Ophthalmoscope in Subjects concentration of heavy metals in differences can be found in patients with Vitreoretinal Disease ocular tissue compared to blood con- with choroidal melanoma, age-related This study utilizes an ultra-widefield centrations. High volumes of specific macular degeneration, or diabetic reti- scanning laser ophthalmoscope with heavy metals in the vitreous have nopathy. Investigator: Irena Tsui, MD autofluorescence (SLO-AF) to take been found to cause toxicity in the pictures of the retina in a noninva- retina. Information about the concen- Mobile Application to Enhance sive way. Images acquired with the trations of heavy metals in common Diabetic Care SLO‑AF are compared with those from vitreoretinal diseases could lead to This study is being conducted to other currently available instruments a new physiopathological approach. determine whether use of an Internet to evaluate the potentially improved Investigators: Jean-Pierre Hubschman, application to record and coordinate resolution for diagnosis of retinal eye MD, and Steven D. Schwartz, MD diabetes management by the diabetic diseases. Investigators: Jean-Pierre patient, diabetes medical care team, Hubschman, MD, Allan E. Kreiger, MD, Incidence of Late Macular and ophthalmology vision care team Tara A. McCannel, MD, PhD, and Degeneration in Older Women results in improved control of dia- Steven D. Schwartz, MD The goal of this research is to deter- betes and decreased risk of eye mine the incidence of late age-related complications. Investigators: Bradley Pars Plana Vitrectomy macular degeneration (AMD), the R. Straatsma, MD, JD, and Irena with and Without ILM Peel rate of progression of AMD, and the Tsui, MD This study is evaluating and comparing association of specific risk factors possible differences in the vision, as such as diabetes mellitus and prior Natural History Study of well as the thickness and shape of the cataract surgery with late AMD and its Macular Telangiectasia back of the eye, following pars plana progression in older women. Investiga- Investigators are collecting data about vitrectomy surgery with and without tor: Anne L. Coleman, MD, PhD macular telangiectasia with the goal internal limiting membrane peeling in of acquiring more knowledge of and patients with complications of diabetic Lucentis and Fovista Combination developing a treatment for this rare retinopathy. Investigator: Jean-Pierre Therapy for Wet AMD Compared retinal disease. Investigators: Michael Hubschman, MD to Lucentis Only B. Gorin, MD, PhD, Jean-Pierre The purpose of this study is to Hubschman, MD, Allan E. Kreiger, Rapid, Noninvasive, Regional evaluate the safety and efficacy of MD, Tara A. McCannel, MD, PhD, Functional Imaging of the Retina Fovista™ intravitreous administration David Sarraf, MD, and Steven D. In this study funded by the NIH, when administered in combination Schwartz, MD Institute investigators are monitoring with Lucentis® compared to Lucentis the responses of the pupil to light as a monotherapy in subjects with sub- Natural History of the method for detecting regional losses foveal choroidal neovascularization Progression of Choroideremia of function of the retina. The ultimate secondary to age-related macular This is a one-year natural history, goal of this research is to develop a degeneration. Investigator: Jean-Pierre observational study to characterize the simple, noninvasive, rapid method Hubschman, MD visual function and retinal structural for widespread screening of diabet- changes associated with X-linked cho- ics in order to identify those who Microcystic Maculopathy roideremia with the intention of deter- may require medical attention and/or Associated with Tamoxifen, mining the best means of measuring therapy for diabetic retinopathy. Inves- Paclitaxel, and Docetaxel Therapy disease progression and the rate of tigators: Michael B. Gorin, MD, PhD, Using Spectral-Domain Optical natural progression for this condition. and Maria Carolina Ortube, MD Coherence Tomography Imaging Investigators: Michael B. Gorin, MD, This study evaluates chemotherapeu- PhD, and Steven Nusinowitz, PhD Research with Retinal Cells tics used in the treatment of breast, Derived from Stem Cells lung, stomach, and prostate cancer Ocular Hazards from Currently for Dry Age-Related for eye complications. They are given Available Light Curing Units Macular Degeneration (AMD) via injection and work by preventing The purpose of this study is to assess This study is evaluating the safety of microtubule function thus arresting the potential of currently available surgical procedures used to implant mitotic division. These drugs have curing lights to cause retinal damage MA09-hRPE cells, assessing the num- been associated with microcystic to dental personnel, to evaluate the ber of cells to be transplanted in future maculopathy. These findings have only amount of exposure to curing lights studies, and evaluating measures been noted in sporadic case reports by dental personnel, and to assess for determining the effectiveness and this will be a prospective cohort current levels of retinal degenera- of future stem cell therapy for AMD. study to define this complication. tive changes in dental workers that Investigators: Jean-Pierre Hubschman, Investigator: David Sarraf, MD are possibly induced by curing lights. MD, Allan E. Kreiger, MD, and Steven Investigators: Jean-Pierre Hubschman, D. Schwartz, MD MD, and Steven D. Schwartz, MD

Appendices | Stein Eye Institute 119 Research with Retinal Cells Study of Macular Disease A Protocol to Follow-up Derived from Stem Cells for Using Spectral Domain Optical with Patients on Emergency Myopic Macular Degeneration Coherence Tomography Administration of EPI-743 The aim of this study is to determine Angiography (SD-OCTA) with Leber Hereditary the safety and tolerability of subretinal The RTVue XR 100 Avanti with SSADA Optic Neuropathy [LHON] transplantation of human embryonic will be used to screen patients with EPI-743 is a new experimental drug stem cell derived retinal pigmented macular disease (eg, vitreomacular that may improve mitochondrial func- epithelial (MA09-hRPE) cells in disorders, diabetic retinopathy, retinal tion. EPI-743 is a form of vitamin E patients with geographic atrophy vascular disease, retinal toxicity, age- that has been changed to a new com- secondary to myopic macular degen- related macular degeneration, or any pound in the laboratory. The experi- eration. Investigators: Jean-Pierre other retinal or macular disorder) as mental drug EPI-743 was selected Hubschman, MD, Allan E. Kreiger, MD, detected with clinical examination or because the mitochondrial disease and Steven D. Schwartz, MD ancillary testing, such as with standard manifestations appeared to improve OCT or with color fundus photography when the drug was given to cells from Research with Retinal Cells or fluorescein angiography (FA) or fun- a patient with LHON, which were Derived from Stem Cells for dus autofluorescence. Investigators: grown in the laboratory. Investigator: Stargardt Macular Dystrophy Michael B. Gorin, MD, PhD, Colin A. Alfredo Sadun, MD, PhD This study is evaluating the safety of McCannel, MD, David Sarraf, MD, and surgical procedures used to implant Steven D. Schwartz, MD MA09-hRPE cells, assessing the Ocular Melanoma number of cells to be transplanted in Understanding the Genetics of Inherited Eye Disorders Molecular and Cytogenetic future studies, and evaluating mea- Studies of Ocular Melanoma sures for determining the effective- The Institute is participating in a study The goal of this research is to study ness of future stem cell therapy for to search for the gene(s) respon- ocular melanoma tumor tissue and Stargardt macular dystrophy. Investi- sible for inherited disorders that are to identify key molecular and genetic gators: Jean-Pierre Hubschman, MD, either specific to the eye or have features that could help predict those Allan E. Kreiger, MD, and Steven D. eye findings as part of the medical patients who may be at high risk for Schwartz, MD condition. This study provides for the metastasis. Investigators: Lynn K. clinical characterization of affected Gordon, MD, PhD, Tara A. McCannel, Resolution of Vitreomacular individuals and at-risk family members, MD, PhD, and Bradley R. Straatsma, Adhesion Associated with in conjunction with molecular genetic MD, JD Neovascular Age-Related testing, to identify the causative genes Macular Degeneration with and mutations. Investigators: Anthony Intravitreal Microplasmin J. Aldave, MD, Michael B. Gorin, MD, Optical Coherence Tomography PhD, and Maria Carolina Ortube, MD of Regional Abnormalities Faculty members are evaluating the Associated with Choroidal safety and efficacy of intravitreal injec- Nevus, Choroidal Melanoma, and tion of microplasmin on age-related Neuro-Ophthalmology Choroidal Melanoma Treated with macular degeneration (AMD) with Iodine-125 Brachytherapy focal vitreomacular adhesion (VMA). Analysis of Samples from Patients In this study, optical coherence ther- Previous research has shown that with Rhegmatogenous Retinal apy (OCT) imaging is performed during intravitreal microplasmin may offer Detachment (RRD) to Identify regularly scheduled visits on patients physicians a safe agent for resolution Potential Biochemical Markers of with choroidal nevus, choroidal of focal VMA in AMD patients without Retinal Stress melanoma, and choroidal melanoma surgery. Investigators: Jean-Pierre Vision loss from a retinal detachment treated with iodine-125 brachytherapy. Hubschman, MD, and Steven D. is due in part to ischemia that occurs The purpose is threefold: to study the Schwartz, MD when the retina moves away from the structure and function of the retina choroidal vessels that supply oxygen overlying the tumor and the macula, to and nutrition to the outer two-thirds evaluate the effects of radiation on the of the retina. Studying the biochemi- retina, and to compare OCT imaging to cal mechanisms of retinal stress and other imaging procedures. Investiga- death can be useful in understanding tors: Tara A. McCannel, MD, PhD, and the cellular mechanisms and timeline Bradley R. Straatsma, MD, JD of vision loss, leading to new ways to improve vision. The aim of the study is to identify biomarkers for rhegmatogenous retinal detachment in aqueous (the fluid in the front of the eye), vitreous (the gel filling the center of the eye), and blood. Investigators: Brian Francis, MD, and Alfredo Sadun, MD, PhD

120 Stein Eye Institute | Appendices PET/CT Imaging for Early Pro-Inflammatory Cytokines, Volumetric Analysis of Detection of Ocular Melanoma Dry Eye, and Thyroid Eye Disease Orbital Images (CT and MRI This research involves the use of The purpose of this study is to Sequences) with Mimics combined positron emission tomog- determine whether there are specific Image Processing Software raphy (PET)/computed tomography inflammatory proteins in tears of This study is evaluating the volumet- (CT) scans in subjects with ocular patients with active stage thyroid eye ric changes of orbital tissues using melanoma. It may ultimately provide disease (TED). If these inflammatory a validated 3D image processing new knowledge that will be used to proteins exist, the study aims to deter- software. Orbital diseases such as develop better ways of monitoring for mine whether they can be used to thyroid eye disease, myositis, inflam- tumor spread and allow for early treat- predict dry eye symptomatology and if matory and neoplastic conditions are ment if metastasis is found. Investiga- they can be used to predict TED activ- characterized by significant soft tissue tors: Tara A. McCannel, MD, PhD, and ity. Investigators: Robert Alan Gold- changes. Their assessment with Bradley R. Straatsma, MD, JD berg, MD, and Daniel Rootman, MD Mimics software is helpful in understanding the clinical course of these Quality of Life Study in diseases, as well as defining the etio- Orbital and Ophthalmic Patients with Graves Disease logic and pathogenetic mechanisms Plastic Surgery This study is assessing the quality involved. Investigator: Robert Alan Goldberg, MD A Research Study Evaluating a of life in patients with Graves dis- New Drug for the Treatment of ease orbitopathy before and after Thyroid Eye Disease medical treatment or medical procedures. Investigator: Robert Alan Pediatrics and Strabismus The purpose of this study is to obtain Goldberg, MD information on the safety and effec- A Randomized Clinical Trial of tiveness of an investigational drug to Observation Versus Occlusion Studies on Tissue in Therapy for Intermittent Exotropia treat thyroid eye disease (TED). People Autoimmune Diseases with TED experience eye problems Although occlusion treatment, or often due to an overactive thyroid This study aims to determine the patching of the eye, is a widely used caused by Graves disease. Investiga- cause of eye problems in Graves dis- treatment for intermittent exotropia tor: Robert Alan Goldberg, MD ease and other autoimmune diseases. (IXT), there have been no randomized Examination is being done of material clinical trials evaluating its effective- Characteristics of the Brow–Eyelid removed from orbits during surgical ness. This study is being conducted to Margin Relationship therapy for Graves disease or other assess the natural history of IXT and problems requiring surgery on the The purpose of this study is to deter- to establish the effectiveness of patch- tissue surrounding the eyes, of thyroid ing in its treatment. Investigators: mine if changing the effect of gravity tissue removed during the course of has an effect on eyelid position. Inves- Stacey L. Pineles, MD, and Federico G. surgical therapy, or of blood drawn for Velez, MD tigator: Robert Alan Goldberg, MD laboratory tests. Investigator: Robert Alan Goldberg, MD Hyaluronic Acid Gels for A Randomized Trial of Upper Lid Retraction in Levodopa as Treatment for Ultrasound Study of Residual Amblyopia (ATS17) Active State Thyroid Eye Disease Eyelid Mobility Before and The objective of this study is to The purpose of this study is to After Blepharoplasty and compare the efficacy and safety of determine if hyaluronic acid gel (HAG) Injectable Fillers oral levodopa and patching versus can be used reliably and reproduc- This study uses a high-resolution ibly to correct upper eyelid retraction, oral placebo and patching in children ultrasound machine to capture real- 7 to <13 years for residual amblyopia. improve dry eye related symptoms, time films of the tissues immediately aesthetic appearance, and quality of Investigators: Stacy L. Pineles, MD, surrounding the eye. Patients in each and Federico G. Velez, MD life in active stage thyroid eye dis- of the following three arms are being ease (TED). The study also aims to studied: pre/post botulinum toxin determine the long-term outcome of injection, pre/post synthetic filler injec- TED and how long the effects of HAG tion, and pre/post periocular cosmetic can last. Investigator: Catherine J. surgery, including fat repositioning or Hwang, MD fat transfer. Data gathered is being used to study the dispersion of filler injections, to gain more detailed and accurate insight into this cosmetic field. Investigator: Robert Alan Goldberg, MD

Appendices | Stein Eye Institute 121 Biomechanical Analysis in Optical Coherence Tomography Prospective Study to Determine Strabismus Surgery in the Newborn Eye the Proportion of Patients with This study aims to develop new The purpose of this study is to bet- Isolated Third, Fourth, and Sixth diagnostic tests and computer models ter characterize the retina and optic Nerve Palsies of Microvascular that will lead to improvements in nerve in newborns using spectral- Versus Nonmicrovascular Etiology strabismus surgery. Tests of binocular domain optical coherence tomography Currently, magnetic resonance imag- alignment and eye movements, as (SD-OCT). SD-OCT has been used ing scanning is only recommended well as magnetic resonance imaging for many years to help diagnose and in atypical cases (ie, young age, no of the extraocular muscles, are being treat adults with eye diseases, but vascular risk factors). The purpose of performed in the Institute’s Clinical it has never been studied in new- this multicenter study is to determine and Basic Science Ocular Motility borns, where it could potentially help whether central nervous system Laboratory before and after strabis- in the diagnoses of glaucoma, optic abnormalities are detected in patients mus surgery. To date, this research nerve hypoplasia, foveal hypoplasia, who otherwise would not have has fundamentally contributed to the and colobomata, among many other neuroimaging. Investigator: Stacey L. knowledge of the functional anatomy disorders. Investigator: Sherwin J. Pineles, MD of the extraocular muscles and con- Isenberg, MD nective tissues, and allowed discovery Sensory Processing and Learning of causes of common strabismus and Optic Nerve in Amblyopia This study evaluates amblyopic development of new types of surger- Amblyopia is a major cause of child- patients, who are traditionally thought ies. Investigator: Joseph L. Demer, hood visual loss. This study uses high to be beyond the critical period for MD, PhD resolution, surface-coil magnetic reso- treatment. Those subjects will be nance imaging to study optic nerve enrolled and randomized to one of Genetic and Anatomic Studies size in amblyopia. It tests the theory the two amblyopia therapies using a of Eye Movement Disorders that the optic nerve is smaller than perceptual learning technique. Investi- This collaborative National Eye normal in amblyopia and that optic gator: Stacey L. Pineles, MD Institute-funded study is conducting nerve size may be a limiting factor magnetic resonance imaging of the in restoration of vision by amblyopia Sweep Visual Evoked Potential extraocular muscles. This procedure treatment. Investigator: Joseph L. for Use in Amblyopia and Pediatric clarifies the phenotypes and mecha- Demer, MD, PhD Optic Nerve Disorders nisms of congenital cranial dysinner- Using a new technique, investiga- vation syndromes whose hereditary Prevention of Visual Impairment tors are measuring vision in preverbal properties have been characterized in School-Age Children children to diagnose and follow optic using modern molecular genetics. In this community-based participa- nerve diseases. Currently, treatment Patients with these syndromes have tory intervention to promote the use decisions are based on clinical exami- severe forms of strabismus. Investi of eyeglasses in schools, first- and nations that are insensitive and reveal gator: Joseph L. Demer, MD, PhD second-grade students with refractive vision loss well after permanent dam- errors receive two pairs of eyeglasses, age has taken place. This technique with one pair staying at home and the allows more accurate examinations, other in the classroom. School nurses leading to provision of treatments at collaborate with teachers in moni- the first signs of vision loss, thereby toring the use of eyeglasses in the decreasing the risk of permanent dam- classroom, and parents receive eye age. Investigators: Joseph L. Demer, care education. Investigator: Anne L. MD, PhD, Sherwin J. Isenberg, MD, Coleman, MD, PhD Stacey L. Pineles, MD, and Federico G. Velez, MD

122 Stein Eye Institute | Appendices Kwong JM, Hoang C, Dukes RT, Yee McCannel TA, Chmielowski B, Finn RS, RW, Gray BD, Pak KY, Caprioli J. Goldman J, Ribas A, Wainberg ZA, Publications of the Bis(zinc-dipicolylamine), Zn-DPA, a new McCannel CA. Bilateral subfoveal Full-Time Faculty marker for apoptosis. Invest Ophthal- neurosensory retinal detachment mol Vis Sci. 2014 Jul 17;55(8):4913–21. associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. Publications are ordered chronologically Yang Y, Hong J, , Xu J. Age- Deng SX 2014 Aug;132(8):1005–9. July 1, 2014–June 30, 2015 related changes in human corneal epithelial thickness measured with anterior Hong J, Yang Y, Wei A, Deng SX, Kong July 2014 segment optical coherence tomography. X, Chen J, Girard MJ, Mari JM, Xu J, Jang MS, Roldan AN, Frausto RF, Invest Ophthalmol Vis Sci. 2014 Jul 22; Sun X. Schlemm’s canal expands after Aldave AJ. Posterior polymorphous 55(8):5032–8. trabeculectomy in patients with primary corneal dystrophy 3 is associated angle-closure glaucoma. Invest Ophthal- Jing Z, Gangalum RK, Bhat AM, Naga- with agenesis and hypoplasia of the mol Vis Sci. 2014 Aug 12;55(9):5637–42. corpus callosum. Vision Res. 2014 Jul; oka Y, Jiang M, Bhat SP. HSF4 muta- 100:88–92. tion p.Arg116His found in age-related Shaikh Y, Yu F, Coleman AL. Burden cataracts and in normal populations of undetected and untreated glaucoma Miller KM. July consultation #6. produces childhood lamellar cataract in the United States. Am J Ophthalmol. J Cataract Refract Surg. 2014 Jul;40(7): in transgenic mice. Hum Mutat. 2014 2014 Dec;158(6):1121–29.e1. Epub 1243–4; discussion 1245. Sep;35(9):1068–71. Epub 2014 Jul 23. 2014 Aug 22. Nouri-Mahdavi K, Nowroozizadeh Lim MC, Chiang MF, Boland MV, Hwang CJ, Morgan PV, Pimentel A, S, Nassiri N, Cirineo N, Knipping S, McCannel CA, Wedemeyer L, Epley Sayre JW, Goldberg RA, Duckwiler G. Giaconi J, Caprioli J. Reply: To PMID KD, Silverstone DE, Saini A, Lum F. Localization and retrieval of an eyelid 24075422. Am J Ophthalmol. 2014 Jul; Meaningful use: how did we do, where metallic foreign body with an oscillating 158(1):211–2. are we now, where do we go from magnet and high-resolution ultrasonog here? Ophthalmology. 2014 Sep;121(9): raphy. Ophthal Plast Reconstr Surg. Rahimy E, Freund KB, Larsen M, Spaide 1667–9. Epub 2014 Jul 25. 2014 Aug 26. RF, Costa RA, Hoang Q, Christakopou- los C, Munch IC, Sarraf D. Multilayered Vo RC, Stafeeva K, Aldave AJ, Stulting Gangalum RK, Jing Z, Bhat AM, Lee J, pigment epithelial detachment in neo- RD, Moore Q, Pflugfelder SC, Chungfat Nagaoka Y, Deng SX, Jiang M, Bhat vascular age-related macular degenera- NC, Holsclaw DS, Margolis TP, Deng SP. Expression of the HSF4 DNA bind- tion. Retina. 2014 Jul;34(7):1289–95. SX. Complications related to a cos- ing domain-EGFP hybrid gene recreates metic eye-whitening procedure. Am J early childhood lamellar cataract in Sarraf D, Joseph A, Rahimy E. Retinal Ophthalmol. 2014 Nov;158(5):967–73. transgenic mice. Invest Ophthalmol Vis pigment epithelial tears in the era of Epub 2014 Jul 27. Sci. 2014 Aug 28;55(11):7227–40. intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treat- Zernant J, Xie YA, Ayuso C, Riveiro- Lee JM, Nouri-Mahdavi K, Morales E, ment (an American Ophthalmological Alvarez R, Lopez-Martinez MA, Afifi A, Yu F,Caprioli J. Comparison of Society thesis). Trans Am Ophthalmol Simonelli F, Testa F, Gorin MB, Strom regression models for serial visual field Soc. 2014 Jul;112:142–59. SP, Bertelsen M, Rosenberg T, Boone analysis. Jpn J Ophthalmol. 2014 Nov; PM, Yuan B, Ayyagari R, Nagy PL, 58(6):504–14. Epub 2014 Aug 28. Kim JM, Kyung H, Azarbod P, Lee JM, Tsang SH, Gouras P, Collison FT, Lupski Caprioli J. Disc haemorrhage is associ- JR, Fishman GA, Allikmets R. Analysis Vanarotti MS, Miller DJ, Guibao CD, ated with the fast component, but not of the ABCA4 genomic locus in Star- Nourse A, and Zheng JJ. Structural and the slow component, of visual field gardt disease. Hum Mol Genet. 2014 mechanistic insights into the interaction decay rate in glaucoma. Br J Ophthal- Dec 20;23(25):6797–806. Epub 2014 between Pyk2 and Paxillin LD motifs. mol. 2014 Nov;98(11):1555–9. Epub Jul 31. J Mol Biol. 2014 Dec 12;426(24):3985– 2014 Jul 2. 4001. Epub 2014 Aug 29. Nilforushan N, Parsamanesh M, Yu F, Chang MY, McCannel TA. Comparison Nassiri N, Miraftabi A, Coleman AL. of uveal melanoma cytopathologic September 2014 Effect of yellow-tinted intraocular lens sample retrieval in trans-scleral versus Gelman SK, Gorin MB. Significant on standard automated perimetry and vitrectomy-assisted transvitreal fine macular edema in a patient with cone short wavelength automated perim- needle aspiration biopsy. Br J Ophthal- dystrophy and improvement with etry in patients with glaucoma. Middle mol. 2014 Dec;98(12):1654–8. Epub acetazolamide treatment. Retin Cases East Afr J Ophthalmol. 2014 Jul–Sep; 2014 Jul 4. Brief Rep. 2014 Fall;8(4):300–5. 21(3):216–9. Miller NR, Arnold AC. Current con- Lin CF, Sarraf D. Best disease present- cepts in the diagnosis, pathogenesis, August 2014 ing as a giant serous pigment epithelial detachment. Retin Cases Brief Rep. and management of nonarteritic Demer JL. The Apt Lecture. Connec- anterior ischemic optic neuropathy. Eye tive tissues reflect different mecha- 2014 Fall;8(4):247–50. (Lond). 2015 Jan;29(1):65–79. Epub nisms of strabismus over the life span. McDonald HR, Sadda S, Sarraf D. 2014 Jul 4. J AAPOS. 2014 Aug;18(4):309–15. Retinal Cases & Brief Reports. Edito- rial. Retin Cases Brief Rep. 2014 Fall; Iragavarapu S, Gorin MB. Gender Kekunnaya R, Velez FG, Pineles SL. specific issues in hereditary ocular dis- Authors’ Reply. Indian J Ophthalmol. 8(4):235. orders. Curr Eye Res. 2015 Feb;40(2): 2014 Aug;62(8):895–6. 128–45. Epub 2014 Jul 14.

Appendices | Stein Eye Institute 123 Reed DC, Sarraf D. Multiple bilateral Vendome J, Felsovalyi K, Song H, Yang Joseph A, Rahimy E, Sarraf D. Periph- branch retinal artery occlusions in a Z, Jin X, Brasch J, Harrison OJ, Ahlsen eral retinal ischemia after intravenous patient with sickle cell disease with G, Bahna F, Kaczynska A, Katsamba tissue plasminogen activator for central vancomycin red man syndrome. Retin PS, Edmond D, Hubbell WL, Shapiro L, retinal artery occlusion. Can J Ophthal- Cases Brief Rep. 2014 Fall;8(4):251–3. Honig B. Structural and energetic deter- mol. 2014 Oct;49(5):e127–9. minants of adhesive binding specificity Bitrian E, Song BJ, Caprioli J. Bleb in type I cadherins. Proc Natl Acad Sci Kozak I, Mansour A, Diaz RI, Calzada revision for resolution of hypotony U S A. 2014 Oct 7;111(40):E4175–84. JI, Pichi F, Cruz-Villegas V, Diaz-Llopis maculopathy following primary trabec Epub 2014 Sep 24. M, Gallego-Pinazo R, Chhablani J, ulectomy. Am J Ophthalmol. 2014 Martinez-Cartier M, Meerhoff M, Sep;158(3):597–604. Law SK, Kornmann HL, Giaconi JA, Mieler WF, Arevalo JF; King Khaled Eye Kwong A, Tran E, Caprioli J. Early Specialist Hospital International Col- Smith RJ, , , McCannel CA Gordon LK aqueous suppressant therapy on hyper- laborative Retina Study Group (Sarraf Hollander DA, , Stelzner SK, Giaconi JA tensive phase following glaucoma D). Outcomes of treatment of pediat- Devgan U, Bartlett JD, Mondino BJ. drainage device procedure: a random- ric choroidal neovascularization with Evaluating teaching methods: validation ized prospective trial. J Glaucoma. 2014 intravitreal antiangiogenic agents: the of an evaluation tool for hydrodissec- Sep 26. results of the KKESH International Col- tion and phacoemulsification portions laborative Retina Study Group. Retina. Tandon AK, , , of cataract surgery. J Cataract Refract Velez FG Isenberg SJ 2014 Oct;34(10):2044–52. Surg. 2014 Sep;40(9):1506–13.e4. Demer JL, Pineles SL. Binocular inhibi- tion in strabismic patients is associated Yoo SH, Rootman DB, Goh A, Savar A, Yen M, Ausayakhun S, Chen J, with diminished quality of life. J AAPOS. Goldberg RA. Transorbital approach Ausayakhun S, Jirawison C, Heiden D, 2014 Oct;18(5):423–6. Epub 2014 without craniotomy to orbital tumors Holland GN, Margolis TP, Keenan JD. Sep 27. with extradural intracranial extension. Telemedicine diagnosis of cytomega- Orbit. 2014 Oct;33(5):343–51. lovirus retinitis by nonophthalmolo- Velez FG, Oltra E, Isenberg SJ, gists. JAMA Ophthalmol. 2014 Sep; Pineles SL. Assessment of torsion Nakatsu MN, González S, Mei H, Deng 132(9):1052–8. after superior rectus transposition with SX. Human limbal mesenchymal cells or without medial rectus recession for support the growth of human cor- Chung DW, Frausto RF, Ann LB, Jang Duane syndrome and abducens nerve neal epithelial stem/progenitor cells. MS, Aldave AJ. Functional impact palsy. J AAPOS. 2014 Oct;18(5):457–60. Invest Ophthalmol Vis Sci. 2014 Oct 2; of ZEB1 mutations associated with Epub 2014 Sep 27. 55(10):6953–9. posterior polymorphous and Fuchs’ endothelial corneal dystrophies. Invest Han J, Young JW, Frausto RF, Isenberg Chan CK, Abraham P, Sarraf D, Nuthi Ophthalmol Vis Sci. 2014 Sep 4;55(10): SJ, Aldave AJ. X-linked megalocornea AS, Lin SG, McCannel CA. Earlier 6159–66. associated with the novel CHRDL1 therapeutic effects associated with gene mutation p.(Pro56Leu*8). Oph- high dose (2.0 mg) Ranibizumab for Lee AG, Arnold AC. The Next Accredi- thalmic Genet. 2015 Jun;36(2):145–8. treatment of vascularized pigment tation System in ophthalmology. Surv Epub 2013 Sep 27. epithelial detachments in age-related Ophthalmol 2015;60:82–5. Epub 2014 macular degeneration. Eye (Lond). 2015 Hong J, Yu Z, Cui X, Qian T, Le Q, Wei Sep 4. Jan;29(1):80–7. Epub 2014 Oct 3. A, Liu Z, Sun X, Deng SX, Xu J. Meibo- Savatovsky E, Mwanza JC, Budenz DL, mian gland alteration in patients with Nouri-Mahdavi K, Caprioli J. Measur- Feuer WJ, Vandenbroucke R, Schiffman primary chronic dacryocystitis: an ing rates of structural and functional JC, Anderson DR; Ocular Hypertension in vivo confocal microscopy study. Curr change in glaucoma. Br J Ophthalmol. Treatment Study (Baker RS). Longitu- Eye Res. 2014 Sep 30:1–8. 2015 Jul;99(7):893–8. Epub 2014 dinal changes in peripapillary atrophy Oct 6. Review. in the ocular hypertension treatment Lin W, Pan CK, Tsui I. Spontaneous study: a case-control assessment. resolution of clinically apparent submac- Pineles SL, Velez FG, Yu F, Demer JL, Ophthalmology. 2015 Jan;122(1):79–86. ular fluid after scleral buckling surgery. Birch E. Normative reference ranges for Epub 2014 Sep 7. Ophthalmic Surg Lasers Imaging Retina. binocular summation as a function of 2014 Sep–Oct;45(5):474–7. age for low contrast letter charts. Stra- Gasymov OK, Abduragimov AR, bismus. 2014 Dec;22(4):167–75. Epub Glasgow BJ. Restoration of struc- October 2014 2014 Oct 6. tural stability and ligand binding after removal of the conserved disulfide Amouyal F, Shah SU, Pan CK, Schwartz Sy ME, Zhang L, Yeroushalmi A, Huang bond in tear lipocalin. Biochem Biophys SD, Hubschman JP. Morphologic fea- D, Hamilton DR. Effect of mitomycin-C Res Commun. 2014 Oct 3;452(4): tures and evolution of inner retinal dim- on the variance in refractive outcomes 1004–8. Epub 2014 Sep 16. ples on optical coherence tomography after photorefractive keratectomy. after internal limiting membrane peel- J Cataract Refract Surg. 2014 Dec; Yu S, Pang CE, Gong Y, Freund KB, ing. Retina. 2014 Oct;34(10):2096–102. 40(12):1980–4. Epub 2014 Oct 8. Yannuzzi LA, Rahimy E, Lujan BJ, Tabandeh H, Cooney MJ, Sarraf D. The Gelman SK, Freund KB, Shah VP, Amini N, Nowroozizadeh S, Cirineo N, spectrum of superficial and deep capil- Sarraf D. The pearl necklace sign: a Henry S, Chang T, Chou T, Coleman AL, lary ischemia in retinal artery occlusion. novel spectral domain optical coher- Caprioli J, Nouri-Mahdavi K. Influ- Am J Ophthalmol. 2015 Jan;159(1): ence tomography finding in exudative ence of the disc-fovea angle on limits of 53–63.e1–2. Epub 2014 Sep 22. macular disease. Retina. 2014 Oct; RNFL variability and glaucoma discrimi- 34(10):2088–95. nation. Invest Ophthalmol Vis Sci. 2014 Oct 9;55(11):7332–42.

124 Stein Eye Institute | Appendices Brown NG, Watson ER, Weissmann Oltra EZ, Pineles SL, Demer JL, Quan Bilgin G and Al-Obailan M, Bonelli F, Jarvis MA, Van der Linden R, Grace AV, Velez FG. The effect of rectus mus- L, Glasgow BJ, Vinters HV, Arnold CR, Frye JJ, Qiao R, Dube P, Petzold G, cle recession, resection and plication on AC. Aggressive low grade optic nerve Cho SE, Alsharif O, Bao J, Davidson IF, anterior segment circulation in humans. glioma in adults. Neuro-Ophthalmology. Zheng JJ, Nourse A, Kurinov I, Peters Br J Ophthalmol. 2015 Apr;99(4):556– 2014;38:297–309. Epub 2014 Nov 12. JM, Stark H, and Schulman BA. Mecha- 60. Epub 2014 Oct 23. Gesite-de Leon B, . Consecu- nism of polyubiquitination by human Demer JL , Huang JS, Nassiri N, Moghimi tive exotropia: why does it happen, and anaphase-promoting complex: RING Law SK S, Nilforushan N, Parham A, Moossai can medial rectus advancement correct repurposing for ubiquitin chain assem- J, Kim M, , . it? J AAPOS. 2014 Dec;18(6):554–8. bly. Mol Cell. 2014 Oct 23;56(2):246–60. Caprioli J Aldave AJ Technique of combined glaucoma tube Epub 2014 Nov 12. Epub 2014 Oct 9. shunt and keratoprosthesis implan- Manchandia AM, Demer JL. Sensitivity Jones JL, Bonetti V, Holland GN, Press tation. J Glaucoma. 2014 Oct–Nov; of the three-step test in diagnosis of C, Sanislo SR, Khurana RN, Montoya 23(8):501–7. superior oblique palsy. J AAPOS. 2014 JG. Ocular toxoplasmosis in the United Zarei-Ghanavati S, Alizadeh R, Dec;18(6):567–71. Epub 2014 Nov 12. States: recent and remote infections. Deng . Topical interferon alpha-2b for Clin Infect Dis. 2015 Jan 15;60(2): SX treatment of noninvasive ocular surface Eblimit A, Nguyen TM, Chen Y, Esteve- 271–3. Epub 2014 Oct 9. squamous neoplasia with 360° limbal Rudd J, Zhong H, Letteboer S, Van Reeuwijk J, Simons DL, Ding Q, Wu Frost LS, Lopes VS, Bragin A, Reyes- involvement. J Ophthalmic Vis Res. KM, Li Y, Van Beersum S, Moayedi Y, Reveles J, Brancato J, Cohen A, Mitch- 2014 Oct–Dec;9(4):423–6. Xu H, Pickard P, Wang K, Gan L, Wu ell CH, Williams DS, Boesze-Battaglia SM, Williams DS, Mardon G, Roepman K. The contribution of melanoregulin to November 2014 R, Chen R. Spata7 is a retinal ciliopa- microtubule-associated protein 1 light Lee JW, Morales E, Yu F, Afifi AA, Kim thy gene critical for correct RPGRIP1 chain 3 (LC3) associated phagocytosis EA, Abdollahi N, Nouri-Mahdavi K, localization and protein trafficking in in retinal pigment epithelium. Mol Caprioli J. Effect of cataract extraction the retina. Hum Mol Genet. 2015 Mar Neurobiol. 2014 Oct 10. on the visual field decay rate in patients 15;24(6):1584–601. Epub 2014 Nov 14. Shin J, Lee JW, Kim EA, Caprioli J. The with glaucoma. JAMA Ophthalmol. Xie BB, Zhang XM, Hashimoto T, Tien effect of corneal biomechanical proper- 2014 Nov;132(11):1296–302. AH, Chen A, Ge J, . Differ- ties on rebound tonometer in patients Yang XJ Srikumaran D, Munoz B, Aldave AJ, entiation of retinal ganglion cells and with normal-tension glaucoma. Am J Aquavella JV, Hannush SB, Schultze photoreceptor precursors from mouse Ophthalmol. 2015 Jan;159(1):144–54. R, Belin M, Akpek EK. Long-term induced pluripotent stem cells carrying Epub 2014 Oct 13. outcomes of Boston type 1 keratopros- an Atoh7/Math5 lineage reporter. PLoS Schwartz SD, Regillo CD, Lam BL, thesis implantation: a retrospective One. 2014 Nov 17;9(11):e112175. Eliott D, Rosenfeld PJ, Gregori NZ, multicenter cohort. Ophthalmology. Schlötzer-Schrehardt U, Bachmann Hubschman JP, Davis JL, Heilwell 2014 Nov;121(11):2159–64. BO, Tourtas T, Torricelli AA, Singh A, G, Spirn M, Maguire J, Gay R, Bate- Vo RC, Stafeeva K, Aldave AJ, Stulting González S, Mei H, , Wilson man J, Ostrick RM, Morris D, Vincent Deng SX RD, Moore Q, Pflugfelder SC, Chungfat SE, Kruse FE. Ultrastructure of the M, Anglade E, Del Priore LV, Lanza R. NC, Holsclaw DS, Margolis TP, Deng posterior corneal stroma. Ophthalmol- Human embryonic stem cell-derived ret- SX. Complications related to a cos- ogy. 2015 Apr;122(4):693–9. Epub 2014 inal pigment epithelium in patients with metic eye-whitening procedure. Am J Nov 18. age-related macular degeneration and Ophthalmol. 2014 Nov;158(5):967–73. Stargardt’s macular dystrophy: follow- Kim MK, Lee JM, Morales E, Caprioli up of two open-label phase 1/2 studies. López CJ, Fleissner MR, Brooks EK, J. Prevalence and spatial concordance Lancet. 2015 Feb 7;385(9967):509–16. Hubbell WL. Stationary-phase EPR of visual field deterioration in fellow Epub 2014 Oct 15. for exploring protein structure, confor- eyes of glaucoma patients. Korean J mation, and dynamics in spin-labeled Ophthalmol. 2014 Dec;28(6):436–43. Yang Z, Jiménez-Osés G, López CJ, proteins. Biochemistry. 2014 Nov 18; Epub 2014 Nov 19. Bridges MD, Houk KN, Hubbell WL. 53(45):7067–75. Epub 2014 Nov 5. Long-range distance measurements in Law SK, Giaconi JA. Re: Pakravan proteins at physiological temperatures Chen A, Nouri-Mahdavi K, Otarola FJ, et al.: Effect of early treatment with using saturation recovery EPR spectros- Yu F, Afifi AA,Caprioli J. Models of aqueous suppressants on Ahmed copy. J Am Chem Soc. 2014 Oct 29; glaucomatous visual field loss. Invest glaucoma valve implantation outcomes 136(43):15356–65. Epub 2014 Oct 17. Ophthalmol Vis Sci. 2014 Nov 6;55(12): (Ophthalmology 2014;121:1693–8). 7881–7. Ophthalmology. 2014 Dec;121(12): Yen M, Chen J, Ausayakhun S, e68–9. Epub 2014 Nov 24. Kunavisarut P, Vichitvejpaisal P, Frausto RF, Wang C, Aldave AJ. Ausayakhun S, Jirawison C, Shantha Transcriptome analysis of the human Kwong JM, Gu L, Nassiri N, Bekerman J, Holland GN, Heiden D, Margolis TP, corneal endothelium. Invest Ophthal- V, Kumar-Singh R, Rhee KD, Yang XJ, Keenan JD. Retinal detachment associ- mol Vis Sci. 2014 Nov 6;55(12):7821–30. Hauswirth WW, Caprioli J, Piri N. ated with AIDS-related cytomegalo- Dutta A, Altenbach C, Mangahas AAV-mediated and pharmacological virus retinitis: risk factors in a resource- S, Yanamala N, Gardner E, Hubbell induction of Hsp70 expression stimu- limited setting. Am J Ophthalmol. 2015 WL, Klein-Seetharaman J. Differential lates survival of retinal ganglion cells Jan;159(1):185–92. Epub 2014 Oct 22. dynamics of extracellular and cyto- following axonal injury. Gene Ther. 2014 Nov 27. Miller KM. November consultation #4. plasmic domains in denatured states J Cataract Refract Surg. 2014 Nov; of rhodopsin. Biochemistry. 2014 Nov 40(11):1932. Epub 2014 Oct 23. 25;53(46):7160–9. Epub 2014 Nov 10.

Appendices | Stein Eye Institute 125 Gorin MB, Weeks DE, Baron RV, Shin A, Yoo L, Demer JL. Independent Zhang L, Sy ME, Mai H, Yu F, Hamilton Conley YP, Ortube MC, Nusinowitz S. active contraction of extraocular muscle DR. Effect of posterior corneal astigma- Endophenotypes for age-related macu- compartments. Invest Ophthalmol Vis tism on refractive outcomes after toric lar degeneration: extending our reach Sci. 2014 Dec 11;56(1):199–206. intraocular lens implantation. J Cataract into the preclinical stages of disease. Refract Surg. 2015 Jan;41(1):84–9. Hong J, Le Q, , Cao W, Xu J. J Clin Med. 2014 Nov 28;3(4):1335–56. Deng SX Pseudomonas aeruginosa keratitis Wang Q, Tuten WS, Lujan BJ, Holland Mrejen S, Pang CE, Sarraf D, Goldberg misdiagnosed as fungal keratitis by in J, Bernstein PS, Schwartz SD, Duncan NR, Gallego-Pinazo R, Klancnik JM, vivo confocal microscopy: a case report. JL, Roorda A. Adaptive optics micro Sorenson JA, Yannuzzi LA, Freund BMC Res Notes. 2014 Dec 13;7(1):907. perimetry and OCT images show pre- KB. Adaptive optics imaging of cone served function and recovery of cone , Sanchez PJ, Chen L. Clinical mosaic abnormalities in acute macular Deng SX visibility in macular telangiectasia type outcomes of Descemet membrane neuroretinopathy. Ophthalmic Surg 2 retinal lesions. Invest Ophthalmol Vis endothelial keratoplasty using eye bank- Lasers Imaging Retina. 2014 Nov–Dec; Sci. 2015 Jan 13;56(2):778–86. prepared tissues. Am J Ophthalmol. 45(6):562–9. 2015 Mar;159(3):590–6. Epub 2014 Demer JL, Clark RA. Magnetic reso- Dec 17. nance imaging demonstrates compart- December 2014 mental muscle mechanisms of human Avery RL, Bakri SJ, Blumenkranz Chew EY, Clemons TE, Peto T, Sallo vertical fusional vergence. J Neuro- MS, Brucker AJ, Cunningham ET Jr, FB, Ingerman A, Tao W, Singerman L, physiol. 2015 Apr 1;113(7):2150–63. D’Amico DJ, Dugel PU, Flynn HW Schwartz SD, Peachey NS, Bird AC; Epub 2015 Jan 14. Jr, Freund KB, Haller JA, Jumper JM, MacTel-CNTF Research Group. Ciliary Liebmann JM, McCannel CA, Mieler neurotrophic factor for macular telangi- Meredith TA, McCannel CA, Barr C, WF, Ta CN, Williams GA. Intravitreal ectasia type 2: results from a phase 1 Doft BH, Peskin E, Maguire MG, injection technique and monitoring: safety trial. Am J Ophthalmol. 2015 Apr; Martin DF, Prenner JL; Comparison updated guidelines of an expert panel. 159(4):659–66.e1. Epub 2014 Dec 19. of Age-Related Macular Degenera- Retina. 2014 Dec;34 Suppl 12:S1–S18. tion Treatments Trials Research Group. Cheng G, Zhong M, Kawaguchi R, Postinjection endophthalmitis in the Cui X, Hong J, Wang F, Deng SX, Yang Kassai M, Al-Ubaidi M, Deng J, Ter- comparison of age-related macular Y, Zhu X, Wu D, Zhao Y, Xu J. Assess- Stepanian M, Sun H. Identification of degeneration treatments trials (CATT). ment of corneal epithelial thickness in PLXDC1 and PLXDC2 as the trans- Ophthalmology. 2015 Apr;122(4):817– dry eye patients. Optom Vis Sci. 2014 membrane receptors for the multi 21. Epub 2015 Jan 15. Dec;91(12):1446–54. functional factor PEDF. Elife. 2014 Dec 23;3:e05401. Jabs DA, Drye L, Van Natta ML, Thorne Hong J, Qian T, Yang Y, Jiang C, Liu JE, Holland GN; Studies of the Ocular Z, Sun X, Deng SX, Xu J. Corneal epi- Amesbury EC, Miller KM. When should Complications of AIDS Research Group. thelial thickness map in long-term soft I use a toric intraocular lens versus Incidence and long-term outcomes contact lenses wearers. Optom Vis Sci. astigmatic keratotomy or peripheral of the human immunodefıciency 2014 Dec;91(12):1455–61. corneal relaxing incisions? In Kim T. virus neuroretinal disorder in patients Curbside Consultation in Cataract Sur- Nouri-Mahdavi K. Selecting visual field with AIDS. Ophthalmology. 2015 gery, 49 Clinical Questions, 2nd Edition. Apr;122(4):760–8. Epub 2015 Jan 16. tests and assessing visual field deterio- Thorofare, NJ: SLACK Inc, 2014. ration in glaucoma. Can J Ophthalmol. Woodruff ML, Rajala A, Fain GL, Rajala 2014 Dec;49(6):497–505. Review. Miller KM. Capsulorrhexis. In Hen- RV. Effect of knocking down the insulin derson BA (ed). Essentials of Cataract Rao NM, Prasad PS, Flippen CC receptor on mouse rod responses.Sci Surgery, 2nd Edition. Thorofare, NJ: Rep. 2015 Jan 19;5:7858. 2nd, Wagner AS, Yim CM, Salamon SLACK Inc, 2014. N, Vinters HV. Primary angiitis of the Van Eps N, Thomas CJ, Hubbell WL, central nervous system presenting as Miller KM. What is the best way Sprang SR. The guanine nucleotide unilateral optic neuritis. J Neuroophthal- to mark the eye for a toric IOL? In exchange factor Ric-8A induces domain mol. 2014 Dec;34(4):380–5. Henderson BA, Yoo S (ed). Curbside separation and Ras domain plasticity in Consultation in Refractive and Lens- Shin J, Lee JW, Choi BS, Yun EY, Jung Gαi1. Proc Natl Acad Sci U S A. 2015 Based Surgery, 49 Clinical Questions. Feb 3;112(5):1404–9. Epub 2015 Jan 20. JH, Kim EA, Caprioli J. The circadian Thorofare, NJ: SLACK Inc, 2014. changes of intraocular pressure and Errera MH, Levinson RD, Fardeau ocular perfusion pressure after taflu- Quan AV, Pineles SL, Tsui I, Velez FG. C, Thomas D, Cohen D, Navarro A, prost compared with travoprost in Phthisis bulbi after lensectomy in reti- Héron E, Paques M, Pavesio C, Sahel normal tension glaucoma. J Ocul Phar- nopathy of prematurity eyes previously JA, Westcott MC, Gaudric A, LeHoang macol Ther. 2014 Dec;30(10):803–9. treated with laser photocoagulation. P, Bodaghi B. Late posterior segment Retin Cases Brief Rep. 2015 Winter; relapses in a series of Vogt-Koyanagi- Shin A, Yoo L, Demer JL. Visco- 9(1):67–71. elastic characterization of extraocular Harada disease. Acta Ophthalmol. 2015 Jan 21. Z-myotomy. Invest Ophthalmol Vis Sci. January 2015 2014 Dec 4;56(1):243–51. Pineles SL, Repka MX, Yu F, Lum F, Rootman DB, Kim MJ, Aldave AJ, Chang MY, Velez FG, Demer JL, Isen- Coleman AL. Risk of musculoskeletal Douglas R, Hwang C, Goldberg R. berg SJ, Coleman AL, Pineles SL. injuries, fractures, and falls in Medicare Ocular surface, fornix, and eyelid reha- Quality of life in adults with strabismus. beneficiaries with disorders of binocular bilitation in Boston type I keratopros- Am J Ophthalmol. 2015 Mar;159(3): vision. JAMA Ophthalmol. 2015 Jan; thesis patients with mucous membrane 539–44.e2. Epub 2014 Dec 9. 133(1):60–5. disease. Ophthal Plast Reconstr Surg. 2015 Jan–Feb;31(1):43–9.

126 Stein Eye Institute | Appendices February 2015 Pappas D, Hollenbach J, Pineles SL, Z, Frezzotti P, Kinoshita S, Fingert JH, Bitrian E, Song BJ, Caprioli J. Gorin MB, Yu F, Williams K, Noble J, Inatani M, Tashiro K, Reis A, Edward Reply. Am J Ophthalmol. 2015 Tranah GJ; Study of Osteoporotic Frac- DP, Pasquale LR, Kubota T, Wiggs JL, Feb;159(2):410–1. tures (SOF) Research Group. HLA class Pasutto F, Topouzis F, Dubina M, Craig II genotypes are not associated with JE, Yoshimura N, Sundaresan P, John Chaudhuri Z, Demer JL. Character- age related macular degeneration in a SW, Ritch R, Hauser MA, Khor CC. A istics and surgical results in patients case-control, population-based study. common variant mapping to CACNA1A with age-related divergence insuf- Hum Immunol. 2015 Mar;76(2–3):142– is associated with susceptibility to ficiency esotropia. J AAPOS. 2015 5. Epub 2015 Feb 7. exfoliation syndrome. Nat Genet. 2015 Feb;19(1):98–9. Apr;47(4):387–92. Epub 2015 Feb 23. Chen CK, Woodruff ML, Fain GL. Rho- Demer JL. Compartmentalization of dopsin kinase and recoverin modulate Diouf B, Crews KR, Lew G, Pei D, extraocular muscle function. Eye (Lond). phosphodiesterase during mouse Cheng C, Bao J, Zheng JJ, Yang W, 2015 Feb;29(2):157–62. photoreceptor light adaptation. J Gen Fan Y, Wheeler HE, Wing C, Delaney Physiol. 2015 Mar;145(3):213–24. Epub SD, Komatsu M, Paugh SW, McCorkle De Salvo G, Keane PA, Tufail A, Sarraf 2015 Feb 9. JR, Lu X, Winick, Carroll WL, Loh D. Diagnostic and therapeutic chal- ML, Hunger SP, Devidas M, Pui C-H, lenges. Retina. 2015 Feb;35(2):374–7. Tseng VL, Lee GY, Shaikh Y, Yu F, Cole- Dolan ME, Relling MV, and Evans WE. . The association between Jirawison C, Yen M, Leenasirimakul P, man AL Association of an inherited genetic glaucoma and immunoglobulin E anti- Chen J, Guadanant S, Kunavisarut P, variant with vincristine-related periph- body response to indoor allergens. Am Patikulsila D, Watanachai N, Ausaya eral neuropathy in children with acute J Ophthalmol. 2015 May;159(5):986–93. khun S, Heiden D, Holland GN, lymphoblastic leukemia. JAMA. 2015 e1. Epub 2015 Feb 19. Margolis TP, Keenan JD. Telemedicine Feb 24;313(8):815–23. screening for cytomegalovirus retinitis Aung T, Ozaki M, Mizoguchi T, Alling- at the point of care for human immu- ham RR, Li Z, Haripriya A, Nakano S, March 2015 nodeficiency virus infection. JAMA Uebe S, Harder JM, Chan AS, Lee MC, Chang MY, Velez FG, Demer JL, Ophthalmol. 2015 Feb;133(2):198–205. Burdon KP, Astakhov YS, Abu-Amero Isenberg SJ, Coleman AL, Pineles KK, Zenteno JC, Nilgün Y, Zarnowski T, Kekunnaya R, Kraft S, Rao VB, Velez SL. Quality of life in adults with stra- Pakravan M, Safieh LA, Jia L, Wang YX, FG, Sachdeva V, Hunter DG. Surgical bismus. Am J Ophthalmol. 2015 Mar; Williams S, Paoli D, Schlottmann PG, management of strabismus in Duane 159(3):539–44.e2. Epub 2014 Dec 9. Huang L, Sim KS, Foo JN, Nakano M, retraction syndrome. J AAPOS. 2015 Ikeda Y, Kumar RS, Ueno M, Manabe Franco-Cardenas V, Rosenberg J, Feb;19(1):63–9. S, Hayashi K, Kazama S, Ideta R, Mori Ramirez A, Lin J, Tsui I. Decade- Pediatric Eye Disease Investigator Y, Miyata K, Sugiyama K, Higashide T, long profile of women in ophthalmic Group (Pineles SL), Wallace DK, Lazar Chihara E, Inoue K, Ishiko S, Yoshida publications. JAMA Ophthalmol. 2015 EL, Repka MX, Holmes JM, Kraker A, Yanagi M, Kiuchi Y, Aihara M, Ohashi Mar;133(3):255–9. RT, Hoover DL, Weise KK, Waters AL, T, Sakurai T, Sugimoto T, Chuman Pang CE, Sarraf D, Freund KB. Extreme Rice ML, Peters RJ. A randomized H, Matsuda F, Yamashiro K, Gotoh N, choroidal thinning in high myopia. trial of adding a plano lens to atro- Miyake M, Astakhov SY, Osman EA, Retina. 2015 Mar;35(3):407–15. pine for amblyopia. J AAPOS. 2015 Al-Obeidan SA, Owaidhah O, Al-Jasim Feb;19(1):42–8. L, Al Shahwan S, Fogarty RA, Leo P, Pineles SL, Demer JL, Isenberg SJ, Yetkin Y, Og˘uz Ç, Kanavi MR, Beni AN, Birch EE, Velez FG. Improvement in Rahimy E, Pitcher JD 3rd, Gee CJ, Yazdani S, Akopov EL, Toh KY, Howell binocular summation after strabismus Kreiger AE, Schwartz SD, Hubschman GR, Orr AC, Goh Y, Meah WY, Peh SQ, surgery. JAMA Ophthalmol. 2015 JP. Diabetic tractional retinal detach- Kosior-Jarecka E, Lukasik U, Krumbiegel Mar;133(3):326–32. ment repair by vitreoretinal fellows in M, Vithana EN, Wong TY, Liu Y, Koch Gasymov OK, Abduragimov AR, a county health system. Retina. 2015 AE, Challa P, Rautenbach RM, Mackey Glasgow BJ. Double tryptophan Feb;35(2):303–9. DA, Hewitt AW, Mitchell P, Wang JJ, exciton probe to gauge proximal side Ziskind A, Carmichael T, Ramakrishnan Weiss JS, Møller HU, Aldave AJ, chains in proteins: augmentation at low R, Narendran K, Venkatesh R, Vijayan Seitz B, Bredrup C, Kivelä T, Munier temperature. J Phys Chem B. 2015 Mar S, Zhao P, Chen X, Guadarrama-Vallejo FL, Rapuano CJ, Nischal KK, Kim EK, 12;119(10):3962–8. Epub 2015 Mar 2. Sutphin J, Busin M, Labbé A, Kenyon D, Cheng CY, Perera SA, Husain R, KR, Kinoshita S, Lisch W. IC3D classifi- Ho SL, Welge-Luessen UC, Mardin Silveira C, Muccioli C, Holland GN, cation of corneal dystrophies—edition 2. C, Schloetzer-Schrehardt U, Hillmer Jones JL, Yu F, de Paulo A, Belfort Cornea. 2015 Feb;34(2):117–59. AM, Herms S, Moebus S, Nöthen R Jr. Ocular involvement following an MM, Weisschuh N, Shetty R, Ghosh A, epidemic of toxoplasma gondii infec- Yoo SH, Pineles SL, Jarrahy R, Velez Teo YY, Brown MA, Lischinsky I; Blue tion in Santa Isabel do Ivaí, Brazil. Am J FG. Ophthalmic manifestations of Mountains Eye Study GWAS Team; Ophthalmol. 2015 Jun;159(6):1013–21. cherubism. J AAPOS. 2015 Feb; Wellcome Trust Case Control Consor- e3. Epub 2015 Mar 2. 19(1):70–2. tium 2, Crowston JG, Coote M, Zhao B, Sang J, Zhang N, You Q, Vysochin- Arantes TE, Silveira C, Holland GN, Morshedian A, Fain GL. Single-photon Muccioli C, Yu F, Jones JL, Goldhardt R, sensitivity of lamprey rods with cone- skaya V, Founti P, Chatzikyriakidou A, Lambropoulos A, Anastasopoulos E, Lewis KG, Belfort R Jr. Ocular involve- like outer segments. Curr Biol. 2015 ment following postnatally acquired Feb 16;25(4):484–7. Epub 2015 Feb 5. Coleman AL, Wilson MR, Rhee DJ, Kang JH, May-Bolchakova I, Heegaard toxoplasma gondii infection in South- S, Mori K, Alward WL, Jonas JB, Xu L, ern Brazil: a 28-year experience. Am J Liebmann JM, Chowbay B, Schaeffeler Ophthalmol. 2015 Jun;159(6):1002–12. E, Schwab M, Lerner F, Wang N, Yang e2. Epub 2015 Mar 3.

Appendices | Stein Eye Institute 127 Shin SY, Demer JL. Superior oblique Chen X, Rahimy E, Sergott RC, Nunes Lerch MT, López CJ, Yang Z, Kreitman extraocular muscle shape in superior RP, Souza EC, Choudhry N, Cutler MJ, Horwitz J, Hubbell WL. Structure- oblique palsy. Am J Ophthalmol. 2015 NE, Houston SK, Munk MR, Fawzi relaxation mechanism for the response Jun;159(6):1169–79.e2. Epub 2015 AA, Mehta S, Hubschman JP, Ho AC, of T4 lysozyme cavity mutants to hydro- Mar 4. Sarraf D. Spectrum of retinal vascular static pressure. Proc Natl Acad Sci diseases associated with paracentral U S A. 2015 May 12;112(19):E2437–46. Kim EA, Law SK, Coleman AL, Nouri- acute middle maculopathy. Am J Epub 2015 Apr 27. Mahdavi K, Giaconi JA, Yu F, Lee Ophthalmol. 2015 Jul;160(1):26–34.e1. Chen JJ, Wendel LJ, Birkholz ES, JW, Caprioli J. Long-term bleb-related Epub 2015 Apr 4. infections after trabeculectomy: inci- Vallone JG, Coleman AL, Yu F, Mahajan dence, risk factors, and influence of Caprioli J, Kim JH, Friedman DS, Kiang VB. The metabolic syndrome and sever- bleb revision. Am J Ophthalmol. 2015 T, Moster MR, Parrish RK 2nd, Rorer ity of diabetic retinopathy. Clin Ophthal- Jun;159(6):1082–91. Epub 2015 Mar 5. EM, Samuelson T, Tarver ME, Singh K, mol. 2015 Apr 28;9:757–64. Eydelman MB. Special commentary: Lee WB, Shtein RM, Kaufman SC, Baron RV, Conley YP, Gorin MB, supporting innovation for safe and , Rosenblatt MI. Boston Weeks DE. dbVOR: a database system effective minimally invasive glaucoma Deng SX keratoprosthesis: outcomes and for importing pedigree, phenotype and surgery: summary of a joint meeting complications: a report by the American genotype data and exporting selected of the American Glaucoma Society Academy of Ophthalmology. Ophthal- subsets. BMC Bioinformatics. 2015 and the Food and Drug Administration, mology. 2015 Jul;122(7):1504–11. Epub Mar 18;16:91. Washington, DC, February 26, 2014. 2015 Apr 28. Hwang CJ, Morgan PV, Pimentel A, Ophthalmology. 2015 Apr 13. Sy ME, Kovoor TA, Tannan A, Choi D, Sayre JW, Goldberg RA, Duckwiler G. Dmuchowska DA, Zalewska R, Jasie- , Danesh J, . Rethinking the role of nitroglycerin oint- wicz M, Krasnicki P, Mikita A, Sobko- Deng SX Hamilton DR Combined astigmatic keratotomy ment in ischemic vascular filler com- wicz B, Mariak Z, Sarraf D. Diagnostic and conductive keratoplasty to correct plications: an animal model with ICG and therapeutic challenges. Retina. high corneal astigmatism. J Cataract imaging. Ophthal Plast Reconstr Surg. 2015 Apr 13. 2015 Mar 18. Refract Surg. 2015 May;41(5):1050–6. Miller KM, Amesbury AC. F1000Prime Epub 2015 Apr 29. Kyung H, Kwong JM, Bekerman V, Gu Recommendation of Hengerer FH, Dick Volland S, Esteve-Rudd J, Hoo J, Yee C, L, Yadegari D, Caprioli J, Piri N. Celas- HB, Kohnen T, Conrad-Hengerer I. . A comparison of some trol supports survival of retinal ganglion Assessment of intraoperative complica- Williams DS organizational characteristics of the cells injured by optic nerve crush. Brain tions in intumescent cataract surgery mouse central retina and the human Res. 2015 Jun 3;1609:21–30. Epub using 2 ophthalmic viscosurgical macula. PLoS One. 2015 Apr 29;10(4): 2015 Mar 24. devices and trypan blue staining. J e0125631. de Miranda AP, Nassiri N, Goldberg Cataract Refract Surg 2015; 41:714–8. RA. Engorgement of the angular and In F1000Prime, 14 Apr 2015. Law SK, Lowe S, Law SM, Giaconi JA, Pineles SL, Caprioli J. Prospective temporal veins following periorbital Tsui I, Drexler A, Stanton AL, evaluation of acupuncture as treatment hyaluronic acid gel injection. Ophthal Kageyama J, Ngo E, Straatsma BR. for glaucoma. Am J Ophthalmol. 2015 Plast Reconstr Surg. 2015 Mar 25. Pilot study using mobile health to coor- Apr 30. Nassiri N, Rootman J, Rootman DB, dinate the diabetic patient, diabetolo- Goldberg RA. Orbital lymphatico gist, and ophthalmologist. J Diabetes May 2015 venous malformations: current and Sci Technol. 2014 Jul;8(4):845–9. Epub future treatments. Surv Ophthalmol. 2014 Apr 14. Kim HY, Hodapp E, Grajewski AL, Sarraf D, John VJ, Hess DJ, Berrocal 2015 Sep–Oct;60(5):383–405. Epub Pan X, Schwartz SD. Free energy sur- 2015 Mar 26. AM. Peripheral retinal vasculopathy face of the Michaelis complex of lactate in childhood glaucoma. Retina. 2015 dehydrogenase: a network analysis of May;35(5):1028–35. April 2015 microsecond simulations. J Phys Chem Nagiel A, Sarraf D, Sadda SR, Spaide B. 2015 Apr 30;119(17):5430–6. Epub Tsui I, Rosenberg JB, Franco-Cardenas RF, Jung JJ, Bhavsar KV, Ameri H, 2015 Apr 15. V. Women in print—reply. JAMA Querques G, Freund KB. Type 3 neo- Ophthalmol. 2015 May 1;133(5):621. vascularization: evolution, association Lum F, Tarver ME, Kahook MY, Oetting with pigment epithelial detachment, TA, Hilmantel G, Calogero D, Kiang T, Christenbury JG, Klufas MA, Sauer TC, and treatment response as revealed Berdahl JP, Coleman AL, Eydelman Sarraf D. OCT angiography of paracen- by spectral domain optical coher- MB. Special commentary: Food and tral acute middle maculopathy associ- ence tomography. Retina. 2015 Apr; Drug Administration and American ated with central retinal artery occlusion 35(4):638–47. Academy of Ophthalmology spon- and deep capillary ischemia. Ophthal- sored: Developing novel end points for mic Surg Lasers Imaging Retina. 2015 Wong RK, Hubschman S, Tsui I. Reac- premium intraocular lenses workshop. May 1;46(5):579–81. tivation of retinopathy of prematurity Ophthalmology. 2015 Jul;122(7): Kimbrel EA, Kouris NA, Yavanian after ranibizumab treatment. Retina. 1522–31. Epub 2015 Apr 18. 2015 Apr;35(4):675–80. GJ, Chu J, Qin Y, Chan A, Singh RP, Zhong M, Sun H. A genetic clog in the McCurdy D, Gordon L, Levinson RD, Shin SY, Demer JL. Location and gaze- Vitamin A transport machinery. Cell. Lanza R. Mesenchymal stem cell popu- dependent shift of inferior oblique 2015 Apr 23;161(3):435–7. lation derived from human pluripotent muscle position: anatomic contributors stem cells displays potent immuno- to vertical strabismus following lower modulatory and therapeutic properties. lid blepharoplasty? Invest Ophthalmol Stem Cells Dev. 2014 Jul 15;23(14): Vis Sci. 2015 Apr 1;56(4):2408–15. 1611–24. Epub 2014 May 2.

128 Stein Eye Institute | Appendices Quan AV, Moore GH, Tsui I. Retinal June 2015 Dror RO, Mildorf TJ, Hilger D, Manglik vein-to-vein anastomoses in Sturge- Lass JH, Szczotka-Flynn LB, Ayala AR, A, Borhani DW, Arlow DH, Philippsen Weber syndrome documented by Benetz BA, Gal RL, Aldave AJ, Corri- A, Villanueva N, Yang Z, Lerch MT, ultra-widefield fluorescein angiography. gan MM, Dunn SP, McCall TL, Pramanik Hubbell WL, Kobilka BK, Sunahara RK, J AAPOS. 2015 Jun;19(3):270–2. Epub S, Rosenwasser GO, Ross KW, Terry Shaw DE. Signal transduction. Struc- 2015 May 2. MA, Verdier DD; Writing Committee tural basis for nucleotide exchange for the Cornea Preservation Time Study in heterotrimeric G proteins. Science. Pedula KL, Coleman AL, Yu F, Cauley 2015 Jun 19;348(6241):1361–5. JA, Ensrud KE, Hochberg MC, Fink Group. Cornea preservation time study: HA, Hillier TA. Study of osteoporotic methods and potential impact on the Gasymov OK, Abduragimov AR, fractures research group: age-related cornea donor pool in the United States. Glasgow BJ. Exploring protein solution macular degeneration and mortality in Cornea. 2015 Jun;34(6):601–8. structure: second moments of fluo- older women: the study of osteoporotic Peragallo JH, Pineles SL, Demer JL. rescent spectra report heterogeneity fractures. J Am Geriatr Soc. 2015 Recent advances clarifying the etiolo- of tryptophan rotamers. Spectrochim May;63(5):910–7. Epub 2015 May 4. gies of strabismus. J Neuroophthalmol. Acta A Mol Biomol Spectrosc. 2015 Jun 19;150:909–920. Kim EA, Law SK, Pineles SL, Nouri- 2015 Jun;35(2):185–93. Mahdavi K, Giaconi JA, Yu F, Lee Nagiel A, Sadda SR, Sarraf D. A Zhao B, Chen W, Jiang R, Zhang R, JW, Caprioli J. Long-term bleb-related Promising future for optical coherence Wang Y, Wang L, Gordon L, Chen infections after trabeculectomy: inci- tomography angiography. JAMA Oph- L. Expression profile of IL-1 family dence, risk factors, and influence of thalmol. 2015 Jun 1;133(6):629–30. cytokines in aqueous humor and sera bleb revision. Am J Ophthalmol. 2015 of patients with HLA-B27 associated Jun;159(6):1082–91. Epub 2015 Mar 5. Tsui I, Williams BK Jr, Kok YO, Heilweil anterior uveitis and idiopathic anterior G, Schwartz SD. Reliability of ische uveitis. Exp Eye Res. 2015 Jun 24; Kaylor JJ, Radu RA, Bischoff N, mic index grading in common retinal 138:80–86. Makshanoff J, Hu J, Lloyd M, Edding- vascular diseases. Ophthalmic Surg ton S, Bianconi T, Bok D, Travis GH. Lasers Imaging Retina. 2015 Jun 1; Milman T, Kao AA, Chu D, Gorski M, Diacylglycerol O-acyltransferase type-1 46(6):618–25. Steiner A, Simon CZ, Shih C, Aldave synthesizes retinyl esters in the retina AJ, Eagle RC Jr, Jakobiec FA, Udell I. and retinal pigment epithelium. PLoS Matynia A, Parikh S, Deot N, Wong Paraproteinemic keratopathy: the One. 2015 May 14;10(5):e0125921. A, Kim P, Nusinowitz S, Gorin MB. expanding diversity of clinical and Light aversion and corneal mechanical pathologic manifestations. Ophthalmol- Manglik A, Kim TH, Masureel M, sensitivity are altered by intrinscally ogy. 2015 Jun 25. Altenbach C, Yang Z, Hilger D, Lerch photosensitive retinal ganglion cells MT, Kobilka TS, Thian FS, Hubbell in a mouse model of corneal surface Pang CE, Sarraf D, Freund KB. Reply. WL, Prosser RS, Kobilka BK. Structural damage. Exp Eye Res. 2015 Jun 9; Retina. 2015 Jun 30. insights into the dynamic process of 137:57–62. β2-adrenergic receptor signaling. Cell. 2015 May 21;161(5):1101–11. Epub Bui DK, Jiang Y, Wei X, Ortube MC, 2015 May 14. Weeks DE, Conley YP, Gorin MB. Genetic ME-a visualization application Kuehlewein L, Sadda SR, Sarraf D. for merging and editing pedigrees for OCT angiography and sequential genetic studies. BMC Res Notes. 2015 quantitative analysis of type 2 neovas- Jun 16;8:241. cularization after ranibizumab therapy. Eye (Lond). 2015 Jul;29(7):932–5. Epub Majumder A, Pahlberg J, Muradov H, 2015 May 15. Boyd KK, Sampath AP, Artemyev NO. Exchange of cone for rod phospho- Chen A, Kim EA, Aigner DJ, Afifi A, diesterase 6 catalytic subunits in rod Caprioli J. Index to estimate the effi- photoreceptors mimics in part features ciency of an ophthalmic practice. JAMA of light adaptation. J Neurosci. 2015 Ophthalmol. 2015 May 28. Jun 17;35(24):9225–35. Marcet MM, Shtein RM, Bradley EA, Chen A, Yu F, Law SK, Giaconi JA, Deng SX, Meyer DR, Bilyk JR, Yen MT, Coleman AL, Caprioli J. Valved Lee WB, Mawn LA. Safety and efficacy glaucoma drainage devices in pediatric of lacrimal drainage system plugs for glaucoma: retrospective long-term out- dry eye syndrome: a report by the comes. JAMA Opthalmol, 2015 Jun 18. American Academy of Ophthalmology. Ophthalmology. 2015 May 30. Klufas MA, Itty S, McCannel CA, Glasgow BJ, Moreno C, McCannel TA. Kodjebacheva GD, Maliski S, Coleman Variable results for uveal melanoma- AL. Use of eyeglasses among children specific gene expression profile prog- in elementary school: perceptions, nostic test in choroidal metastasis. behaviors, and interventions discussed JAMA Ophthalmol. 2015 Jun 18. by parents, school nurses, and teachers during focus groups. Am J Health Promot. 2015 May–Jun;29(5):324–31.

Appendices | Stein Eye Institute 129 Giving Opportunities

UCLA Stein Eye Institute is dedicated to the preservation of sight and the prevention of blindness. Today, UCLA’s vision scientists are extending the boundaries of current knowledge and approaching the goal for a lifetime of good vision for everyone, due in large part to a strong tradition of philanthropy from private sources.

Contributions from individuals, foundations, and corporations, help underwrite exemplary patient-care programs, innovative scientific advances, key community engagement, and the highest-quality training and education. The Institute offers a variety of giving options to those who wish to contribute to this tradition of excellence.

How to Support UCLA Stein Eye Institute

Direct Gifts Real Estate Endowments Direct gifts of cash, securities, or other When you give a gift of your home or A gift of an endowment demonstrates property provide the Institute with real property to the Institute, you may a long-term commitment to the much-needed financial assistance. Out- claim an income-tax charitable deduc- Institute, since the fund is maintained right gifts have an immediate impact on tion based on the full market value of in perpetuity. A portion of the annual faculty research, education, and patient the gift, avoid capital gains taxes, and investment income is used to sup- care programs because they are used eliminate certain costs associated with port clinical, educational, and scientific to support a variety of current needs. the transfer of real property. Gifts of real initiatives and the remaining invest- estate can also provide income to you. ment yield is returned to principal, thus, Gift Pledges over the years, the fund can grow and A pledge is a formal statement of inten- Bequests provide continuous support. tion to make a gift to the Institute. It In writing a will or living trust, donors An endowment serves as an endur- may be followed by an immediate gift, can specify that they would like their ing legacy as it can bear the donor’s or may simply confirm your intention to estate or various assets to benefit the name, or can honor a loved one. These make a gift in the future. Many donors Institute, thereby building a legacy at funds can be made payable for up to choose to complete their gift pledge by the UCLA Stein Eye Institute. five years. Giving opportunities exist making regular payments over a five- for endowed chairs, endowed fellow- year period. This method often allows Charitable Gift Annuity ships, and endowed funds for research, donors to give more generously than Donors can transfer money, securities, education, and patient care. they may have originally considered. or real estate in trust to the Institute Whenever possible, full payment of and receive income for themselves Qualified Retirement Plans pledges is encouraged within five years or a loved one for life. Donors may Naming The UCLA Foundation as a of the original commitment. receive immediate tax benefits, and beneficiary of your qualified retirement the Institute ultimately receives the plan (eg, IRA, 401(k), 403(b), or KEOGH) Securities trust property. may be particularly advantageous. A gift of long-term appreciated market- Doing so may result in more assets able securities helps you save taxes Tribute Gifts being passed on to your heirs than if twice. Such a gift will provide an Contributions may be made in memory, you make a bequest from other funds income-tax charitable deduction and honor, or celebration of a loved one, or in your estate. capital gains tax savings. to commemorate a special occasion. Donations can be used for unrestricted Matching Gifts program support or be directed to any Many corporations have demonstrated area of the Institute. their support by matching or multiplying their employees’ gifts to the Institute up to a set amount. Before making a gift, you may want to ask whether your Your Gift Can Make a Difference employer participates in a matching However you choose to support the Institute, you will be embarking on a partnership gift program. Certain restrictions apply with one of the world’s preeminent eye research centers. Such an investment will to matching gifts. Please consult your greatly expand our understanding of the causes of eye diseases, expose alternative company’s personnel office. treatment options, and ultimately prevent blindness. For information on how to incorporate the UCLA Stein Eye Institute into your estate and retirement planning, or to make a gift of any kind, please contact: Stein Eye Institute Development Office 100 Stein Plaza, Room 1-124 University of California, Los Angeles Los Angeles, California 90095-7000 Phone: (310) 206-6035 Fax: (310) 794-1665 [email protected] 130 Stein Eye Institute | Appendices

David Geffen School of Medicine at UCLA University of California, Los Angeles